[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Gf Health Products\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":411},{"warningLetters":4,"total":410},[5,30,52,76,98,119,139,160,178,197,217,236,257,273,297,315,335,353,369,392],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},894,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-24T04:00:00Z\">03\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-health-products-inc-697777-03242025\">United Health Products, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Bioresearch Monitoring Program\u002FInstitutional Review Board (IRB)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Thom\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>United Health Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>520 Fellowship Road, Suite #D-406\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mt. Laurel\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@uhpcorp.com\"> (b)(6)@uhpcorp.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 24, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Thom:\u003C\u002Fp>\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at United Health Products, Inc. from September 23, 2024, to October 4, 2024, by an investigator from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting,” for CelluSTAT Absorbable HemoStat, Premarket Approval (PMA) Application, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, complied with applicable federal regulations. The CelluSTAT Absorbable Hemostat is a device as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited and discusses your written response, dated October 25, 2024, to the noted violations.\u003C\u002Fp>\u003Cp>The inspection was conducted under the Bioresearch Monitoring (BIMO) Program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDEs), PMA applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\u003Cp>Our review of the inspection report prepared by OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions and 21 CFR Part 50 - Protection of Human Subjects, which concern requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you. The deviations noted on Form FDA-483, your written response, and our subsequent review of the inspection report are discussed below:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to submit an IDE application to FDA and failure to obtain FDA approval prior to beginning an investigation for which FDA’s approval is required [21 CFR 812.20(a)(1) and (2).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sponsors must submit an IDE application to the FDA if the sponsor intends to use a significant risk device in a clinical investigation. In addition, a sponsor may not begin an investigation for which FDA’s approval of an application is required until FDA has approved the application. You did not submit an IDE application to FDA or obtain FDA approval prior to beginning such an investigation.\u003C\u002Fp>\u003Cp>You conducted your study, UHP001, without submission and approval of an IDE application to FDA. The Western Copernicus Group (WCG) Institutional Review Board (IRB) determined that the procedures in the research posed a potential significant risk to subjects and requested documentation of the FDA’s non-significant risk (NSR) determination in multiple communications. You provided to the IRB FDA written feedback for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and FDA meeting minutes for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which had been modified from the FDA official correspondence by removal of references to future IDE submission and by addition of language that purported to indicate FDA agreement that the study was non-significant risk (NSR). In particular, you provided the transmittal email from FDA along with these meeting minutes, which imply that the meeting minutes that you submitted to the IRB were those provided by FDA to you as the official record. The IRB used this documentation, which misrepresented the FDA risk determination for this study, to support their determination of the regulatory status of the study, and to review and approve this study without FDA oversight.\u003C\u002Fp>\u003Cp>FDA maintains that the study UHP0001 that you have conducted to support \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a Class III device is considered a significant risk device clinical investigation for which you should have submitted an IDE application to FDA and obtained FDA approval prior to initiation. Your device is an absorbable hemostat intended to be used as an adjunct to primary hemostasis in surgical procedures to assist in controlling capillary, venous and small arterial hemorrhage when other conventional methods are ineffective or impractical. Absorbable hemostatic agents are intended to be absorbed into the body and are Class III devices per 21 CFR 878.4490. The agency considers such devices to be significant risk devices because they are absorbed internally and present “a potential for serious risk to the health, safety, or welfare of a subject” per 21 CFR 812.3(m). 21 CFR 812.20(a) requires any sponsor who intends to use a significant risk device in an investigation to submit an application to FDA, and to wait to begin the investigation until FDA has approved the application. FDA approval of an IDE application helps to ensure subject safety and that the risks associated with the device and study procedures are minimized.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your response dated October 25, 2024 is inadequate. Your written response includes a discussion of the interactions with FDA regarding this study and describes your misunderstanding of those interactions and of NSR\u002Fsignificant risk studies. It indicates that the meeting minutes for \u003Cstrong>(b)(4)\u003C\u002Fstrong> that you had provided to the IRB were your modifications to the minutes received from FDA and that you had informally emailed them to FDA. However, there is no record of your submission of these revised meeting minutes to FDA either by email or with a Meeting Minutes Disagreement amendment, the procedure outlined in FDA’s transmittal email for handling changes to meeting minutes. Importantly, there is also no agreement by FDA on these meeting minutes that you had revised. Your response also does not speak to the modifications that were made to the official FDA correspondence for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, where you inserted the word “NSR” in describing the name of the study and removed references to a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA is greatly concerned about your misrepresentation of the FDA’s stance regarding the risk determination of the study to the IRB, which resulted in you inappropriately conducting this study without submitting and obtaining approval of an IDE application from FDA prior to initiation.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to ensure proper monitoring of the investigation [21 CFR 812.40].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sponsors are responsible for ensuring that a clinical investigation is properly monitored. However, you failed to properly monitor your clinical investigation. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. Although you had described in the study protocol, UHP001, sections 10 and 14.9, that details regarding monitoring would be provided in the study specific Monitoring Plan and clinical site monitoring would be documented in a Clinical Monitoring Plan (CMP), respectively, you did not have an effective and implemented CMP during study conduct.\u003C\u002Fp>\u003Cp>b. You did not maintain adequate documentation regarding those monitoring activities that did occur:\u003C\u002Fp>\u003Cp>i. You failed to maintain adequate site initiation visit (SIV) documentation for the two clinical investigation sites. There were several discrepancies in documentation of SIV Monitoring Visit Reports, investigator site’s personnel training logs (SIV Training Logs), and Site Visit Logs. For example, the SIV Monitoring Visit Report for site 01 documented the visit was held on-site on December 17, 2018, with the clinical investigator and research coordinator. However, the SIV Training Log for site 01 documented the clinical investigator received SIV training on December 10, 2018, and the research coordinator received SIV training on March 19, 2019. The Site Visit Log for site 01 documented a single SIV date as December 19, 2018.\u003C\u002Fp>\u003Cp>ii. You failed to maintain adequate interim monitoring documentation for the two clinical investigation sites. For example, the Site Visit Log for site 01 documented the interim monitoring visit was held on-site on July 9, 2019, but there was no interim monitoring report for this visit. In addition, the site visit log for site 02 documented the interim monitoring visit was held on-site on September 10, 2019, but there was no interim monitoring report for this visit.\u003C\u002Fp>\u003Cp>Proper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a retrospectively-created CMP, new Standard Operating Procedures (SOPs) for clinical monitoring, clinical site selection, and site initiation, and revised Site Visit Logs for both clinical investigation sites. Your response indicates that the retrospectively-created CMP reflects the monitoring practices that were followed during the study conduct and indicates that the updated Site Visit Log added visits that occurred for SIV training for both clinical investigation sites, but were not present on the initial Site Visit Log. You did not provide SIV Monitoring Visit Reports for the additional SIV training conducted for both clinical investigation sites that were added to the Site Visit Logs. You also did not provide the interim monitoring reports for both clinical investigation sites that document the activities that occurred during the interim monitoring visits, nor did you provide the follow-up communication to the investigator\u002Fstudy personnel that discusses visit findings, outstanding action items, and requests for additional information. These items are needed to assess the adequacy of the monitoring conducted for this study.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to secure clinical investigator’s compliance with the signed agreement, the investigational plan, applicable FDA regulations, and any other conditions of approval imposed by the reviewing IRB or FDA, or if compliance could not be obtained, failure to discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation [21 CFR 812.46(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As part of monitoring responsibilities, a sponsor is responsible for securing the investigator’s compliance with the investigational plan to ensure adherence with the study protocol and other regulatory requirements. You failed to obtain and secure the clinical investigator’s compliance with the investigational plan and applicable FDA regulations. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. Forty (40) subjects had baseline laboratory results indicating thrombocytopenia or no baseline platelet laboratory results. As a result, these subjects met exclusion criterion # 9, which lists subjects with a coagulation disorder, thrombocytopenia, liver disease and anti-thrombin therapy as not eligible for study. You did not ensure that investigators properly enrolled subjects according to the investigational plan.\u003C\u002Fp>\u003Cp>b. According to your Protocol Deviation Log, there were three (3) subjects whose informed consent forms were not signed by the subject, which violates inclusion criterion # 4, as well as 21 CFR 812.100, which requires that investigators obtain informed consent in accordance with 21 CFR Part 50. You did not ensure that investigators obtained informed consent according to the investigational plan and applicable FDA regulations.\u003C\u002Fp>\u003Cp>Securing clinical investigator compliance is a critical component of monitoring and is critical for ensuring the safety and welfare of study subjects. Failure to secure compliance impacts the reliability and quality of the data resulting from the study and in turn adversely impacts FDA’s ability to assess the overall safety and effectiveness of the device. As you failed to conduct proper monitoring, you did not identify that enrollment criteria were violated or that informed consent was not properly obtained, and also did not take steps to secure compliance with these requirements. Having failed to secure the investigator’s compliance, you also did not discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. While your response acknowledged the issue of enrolling subjects that did not meet the eligibility criteria related to thrombocytopenia and provided a comprehensive corrective action and preventative action plan, you have not addressed the issue of failing to obtain informed consent. Specifically, you did not provide any root cause analysis regarding the informed consent protocol deviations. You also did not identify any corrective or preventative actions taken to ensure that informed consent is properly obtained by investigators such that human subjects are adequately protected.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to immediately conduct an evaluation of any unanticipated adverse device effects and failure to report results of such an evaluation to FDA and to all reviewing IRB’s and participating investigators within 10 working days [21 CFR 812.46(b)(1) and 21 CFR 812.150(b)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for conducting an evaluation of any adverse device effects that are reported as serious and unanticipated to ensure adverse events are adequately recorded and reported, and that appropriate follow-up occurs. You failed to conduct these evaluations. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. You failed to evaluate the unanticipated adverse device effect (UADE) for subject 02-0074 that occurred on April 30, 2019. Information for this UADE was recorded in an Adverse Event (AE) Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\u003C\u002Fp>\u003Cp>b. You failed to evaluate the UADE for subject 02-0074 that occurred on May 12, 2019. Information for this UADE was recorded in an AE Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\u003C\u002Fp>\u003Cp>Proper evaluation of UADEs, as required by 812.46(b)(1), is a critical step in ensuring the safety and welfare of study subjects. Appropriate review and evaluation of UADEs and their resolution allows for any necessary changes to be made to the investigational plan to protect study participants. Furthermore, the regulations under 812.150(b)(1) require that a sponsor who conducts an evaluation of an unanticipated adverse device effect under 812.46(b) report the results of such evaluation to FDA. Proper evaluation and timely reporting to FDA of the result of any evaluation of a UADE is important for FDA’s assessment of the overall safety profile of the device.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a description that the clinical site did not report these AEs to the sponsor as UADEs, and that they therefore were not handled as UADEs. In addition, you provided an updated SOP (CLN-06 Adverse Event Monitoring) to include UADE reporting requirements. However, these documents do not describe how an AE designated as a UADE by an investigator on the AE paper form is reported to the sponsor. It appears that the designation of an AE as a UADE is not captured in the electronic case report form (eCRF) and therefore these two AEs were not reported to the sponsor as UADEs, despite being identified by the investigator as such. As a result, these two AEs were not properly evaluated to determine whether they met the definition of a UADE, as required by the study protocol, UHP001, sections 9.1 and 9.8. Neither the updated SOP nor the protocol provide adequate detail to prevent a recurrence of this scenario in future studies. In addition, you did not provide source documentation for subject 02-0074 that was obtained according to Section 9.4 of the study protocol, UHP001, to assess the causal relationship between the AE and the investigational device. This documentation is needed to ensure that you have adequately conducted an evaluation of reported AEs as expected in the UHP001 study protocol. Although in this case, these two AEs were ultimately determined not to be UADEs through your postinspection activities, timely investigation of UADEs identified by study investigators while the study is ongoing is required by 21 CFR 812.46(b)(1) and a critical element of good clinical practices and does not appear to be assured by your corrective actions.\u003C\u002Fp>\u003Cp>Finally, section 7.6.1 of your updated SOP provides UADE reporting requirements and suggests that the requirement only applies to IDE studies. The evaluation requirement under 812.46 and reporting requirement under 812.150(b)(1) for UADEs also apply to non-significant risk studies subject to abbreviated requirements per 812.2(b), not just studies being conducted under an IDE. The regulatory requirements should be clarified and corrected in the SOP.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to maintain accurate, complete, and current device shipment and disposition records [21 CFR 812.140(b)(2)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for maintaining accurate, complete, and current records relating to an investigation. Specifically, records of shipment must include the name and address of the consignee, type and quantity of device, date of shipment, and batch number or code mark, and records of disposition must describe the batch number or code marks of any devices returned to the sponsor, repaired, or disposed of in other ways by the investigator or another person, and the reasons for and method of disposal. You failed to maintain the necessary records. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. You failed to maintain records of investigational devices received by a sponsor employee, investigational devices returned to the sponsor, or unused investigational devices disposed of for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigational device units packaged.\u003C\u002Fp>\u003Cp>b. You failed to maintain accurate device accountability records for both clinical investigation sites. For example, your Master Device Accountability Log documented that there were 230 subjects who received the investigational device in site # 01 and 4 subjects who received the investigational device in site # 02, with zero returned devices. However, there were only a total of 118 subjects randomized to receive the investigational device and the other subjects were assigned to the control group. In addition, the UHP001 Inventory Log for Site # 02 indicated that only 1 device was used, but the Master Device Accountability Log documented that there were 4 devices used.\u003C\u002Fp>\u003Cp>Proper records of device shipment and disposition are necessary for control of devices and to confirm that the investigational device is used only by qualified investigators on subjects appropriately enrolled in the study. If the devices were used by unqualified individuals on patients not enrolled in the study, there would be an increased risk of harm to both the user and patient.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response provided a SOP for investigational device management and a corrected Master Accountability Log. However, you did not provide source documentation of study subjects’ randomization assignment to verify the changes made to the Master Accountability Log and to demonstrate that device usage was appropriate.\u003C\u002Fp>\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the additional corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\u003C\u002Fp>\u003Cp>Your response should reference “CTS# \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and be sent via email to: Irfan.Khan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>A copy of this letter has been sent to FDA’s OII BIMO Division 1 via email OIIBIMODivision1Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\u003Cp>The Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn\u002F.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Soma Kalb, PhD\u003Cbr>Director\u003Cbr>Division of Clinical Policy and Quality\u003Cbr>Office of Clinical Evidence &amp; Analysis\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nBiologics\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nBrian Thom\n\nRecipient Title\n\nCEO\n\nUnited Health Products, Inc.\n\n520 Fellowship Road, Suite #D-406\n\nMt. Laurel, NJ 08054\n\nUnited States\n\n(b)(6)@uhpcorp.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWarning Letter\nMarch 24, 2025\nDear Mr. Thom:\nThis Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at United Health Products, Inc. from September 23, 2024, to October 4, 2024, by an investigator from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting,” for CelluSTAT Absorbable HemoStat, Premarket Approval (PMA) Application, (b)(4), complied with applicable federal regulations. The CelluSTAT Absorbable Hemostat is a device as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited and discusses your written response, dated October 25, 2024, to the noted violations.\nThe inspection was conducted under the Bioresearch Monitoring (BIMO) Program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDEs), PMA applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\nOur review of the inspection report prepared by OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions and 21 CFR Part 50 - Protection of Human Subjects, which concern requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you. The deviations noted on Form FDA-483, your written response, and our subsequent review of the inspection report are discussed below:\n1. Failure to submit an IDE application to FDA and failure to obtain FDA approval prior to beginning an investigation for which FDA’s approval is required [21 CFR 812.20(a)(1) and (2).\nSponsors must submit an IDE application to the FDA if the sponsor intends to use a significant risk device in a clinical investigation. In addition, a sponsor may not begin an investigation for which FDA’s approval of an application is required until FDA has approved the application. You did not submit an IDE application to FDA or obtain FDA approval prior to beginning such an investigation.\nYou conducted your study, UHP001, without submission and approval of an IDE application to FDA. The Western Copernicus Group (WCG) Institutional Review Board (IRB) determined that the procedures in the research posed a potential significant risk to subjects and requested documentation of the FDA’s non-significant risk (NSR) determination in multiple communications. You provided to the IRB FDA written feedback for (b)(4) and FDA meeting minutes for (b)(4), which had been modified from the FDA official correspondence by removal of references to future IDE submission and by addition of language that purported to indicate FDA agreement that the study was non-significant risk (NSR). In particular, you provided the transmittal email from FDA along with these meeting minutes, which imply that the meeting minutes that you submitted to the IRB were those provided by FDA to you as the official record. The IRB used this documentation, which misrepresented the FDA risk determination for this study, to support their determination of the regulatory status of the study, and to review and approve this study without FDA oversight.\nFDA maintains that the study UHP0001 that you have conducted to support (b)(4) as a Class III device is considered a significant risk device clinical investigation for which you should have submitted an IDE application to FDA and obtained FDA approval prior to initiation. Your device is an absorbable hemostat intended to be used as an adjunct to primary hemostasis in surgical procedures to assist in controlling capillary, venous and small arterial hemorrhage when other conventional methods are ineffective or impractical. Absorbable hemostatic agents are intended to be absorbed into the body and are Class III devices per 21 CFR 878.4490. The agency considers such devices to be significant risk devices because they are absorbed internally and present “a potential for serious risk to the health, safety, or welfare of a subject” per 21 CFR 812.3(m). 21 CFR 812.20(a) requires any sponsor who intends to use a significant risk device in an investigation to submit an application to FDA, and to wait to begin the investigation until FDA has approved the application. FDA approval of an IDE application helps to ensure subject safety and that the risks associated with the device and study procedures are minimized.\nThis was conveyed to you in the Form FDA-483, and your response dated October 25, 2024 is inadequate. Your written response includes a discussion of the interactions with FDA regarding this study and describes your misunderstanding of those interactions and of NSR\u002Fsignificant risk studies. It indicates that the meeting minutes for (b)(4) that you had provided to the IRB were your modifications to the minutes received from FDA and that you had informally emailed them to FDA. However, there is no record of your submission of these revised meeting minutes to FDA either by email or with a Meeting Minutes Disagreement amendment, the procedure outlined in FDA’s transmittal email for handling changes to meeting minutes. Importantly, there is also no agreement by FDA on these meeting minutes that you had revised. Your response also does not speak to the modifications that were made to the official FDA correspondence for (b)(4), where you inserted the word “NSR” in describing the name of the study and removed references to a (b)(4). FDA is greatly concerned about your misrepresentation of the FDA’s stance regarding the risk determination of the study to the IRB, which resulted in you inappropriately conducting this study without submitting and obtaining approval of an IDE application from FDA prior to initiation.\n2. Failure to ensure proper monitoring of the investigation [21 CFR 812.40].\nSponsors are responsible for ensuring that a clinical investigation is properly monitored. However, you failed to properly monitor your clinical investigation. Examples include, but are not limited to, the following:\na. Although you had described in the study protocol, UHP001, sections 10 and 14.9, that details regarding monitoring would be provided in the study specific Monitoring Plan and clinical site monitoring would be documented in a Clinical Monitoring Plan (CMP), respectively, you did not have an effective and implemented CMP during study conduct.\nb. You did not maintain adequate documentation regarding those monitoring activities that did occur:\ni. You failed to maintain adequate site initiation visit (SIV) documentation for the two clinical investigation sites. There were several discrepancies in documentation of SIV Monitoring Visit Reports, investigator site’s personnel training logs (SIV Training Logs), and Site Visit Logs. For example, the SIV Monitoring Visit Report for site 01 documented the visit was held on-site on December 17, 2018, with the clinical investigator and research coordinator. However, the SIV Training Log for site 01 documented the clinical investigator received SIV training on December 10, 2018, and the research coordinator received SIV training on March 19, 2019. The Site Visit Log for site 01 documented a single SIV date as December 19, 2018.\nii. You failed to maintain adequate interim monitoring documentation for the two clinical investigation sites. For example, the Site Visit Log for site 01 documented the interim monitoring visit was held on-site on July 9, 2019, but there was no interim monitoring report for this visit. In addition, the site visit log for site 02 documented the interim monitoring visit was held on-site on September 10, 2019, but there was no interim monitoring report for this visit.\nProper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a retrospectively-created CMP, new Standard Operating Procedures (SOPs) for clinical monitoring, clinical site selection, and site initiation, and revised Site Visit Logs for both clinical investigation sites. Your response indicates that the retrospectively-created CMP reflects the monitoring practices that were followed during the study conduct and indicates that the updated Site Visit Log added visits that occurred for SIV training for both clinical investigation sites, but were not present on the initial Site Visit Log. You did not provide SIV Monitoring Visit Reports for the additional SIV training conducted for both clinical investigation sites that were added to the Site Visit Logs. You also did not provide the interim monitoring reports for both clinical investigation sites that document the activities that occurred during the interim monitoring visits, nor did you provide the follow-up communication to the investigator\u002Fstudy personnel that discusses visit findings, outstanding action items, and requests for additional information. These items are needed to assess the adequacy of the monitoring conducted for this study.\n3. Failure to secure clinical investigator’s compliance with the signed agreement, the investigational plan, applicable FDA regulations, and any other conditions of approval imposed by the reviewing IRB or FDA, or if compliance could not be obtained, failure to discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation [21 CFR 812.46(a)].\nAs part of monitoring responsibilities, a sponsor is responsible for securing the investigator’s compliance with the investigational plan to ensure adherence with the study protocol and other regulatory requirements. You failed to obtain and secure the clinical investigator’s compliance with the investigational plan and applicable FDA regulations. Examples include, but are not limited to, the following:\na. Forty (40) subjects had baseline laboratory results indicating thrombocytopenia or no baseline platelet laboratory results. As a result, these subjects met exclusion criterion # 9, which lists subjects with a coagulation disorder, thrombocytopenia, liver disease and anti-thrombin therapy as not eligible for study. You did not ensure that investigators properly enrolled subjects according to the investigational plan.\nb. According to your Protocol Deviation Log, there were three (3) subjects whose informed consent forms were not signed by the subject, which violates inclusion criterion # 4, as well as 21 CFR 812.100, which requires that investigators obtain informed consent in accordance with 21 CFR Part 50. You did not ensure that investigators obtained informed consent according to the investigational plan and applicable FDA regulations.\nSecuring clinical investigator compliance is a critical component of monitoring and is critical for ensuring the safety and welfare of study subjects. Failure to secure compliance impacts the reliability and quality of the data resulting from the study and in turn adversely impacts FDA’s ability to assess the overall safety and effectiveness of the device. As you failed to conduct proper monitoring, you did not identify that enrollment criteria were violated or that informed consent was not properly obtained, and also did not take steps to secure compliance with these requirements. Having failed to secure the investigator’s compliance, you also did not discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. While your response acknowledged the issue of enrolling subjects that did not meet the eligibility criteria related to thrombocytopenia and provided a comprehensive corrective action and preventative action plan, you have not addressed the issue of failing to obtain informed consent. Specifically, you did not provide any root cause analysis regarding the informed consent protocol deviations. You also did not identify any corrective or preventative actions taken to ensure that informed consent is properly obtained by investigators such that human subjects are adequately protected.\n4. Failure to immediately conduct an evaluation of any unanticipated adverse device effects and failure to report results of such an evaluation to FDA and to all reviewing IRB’s and participating investigators within 10 working days [21 CFR 812.46(b)(1) and 21 CFR 812.150(b)(1)].\nAs a sponsor, you are responsible for conducting an evaluation of any adverse device effects that are reported as serious and unanticipated to ensure adverse events are adequately recorded and reported, and that appropriate follow-up occurs. You failed to conduct these evaluations. Examples include, but are not limited to, the following:\na. You failed to evaluate the unanticipated adverse device effect (UADE) for subject 02-0074 that occurred on April 30, 2019. Information for this UADE was recorded in an Adverse Event (AE) Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\nb. You failed to evaluate the UADE for subject 02-0074 that occurred on May 12, 2019. Information for this UADE was recorded in an AE Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\nProper evaluation of UADEs, as required by 812.46(b)(1), is a critical step in ensuring the safety and welfare of study subjects. Appropriate review and evaluation of UADEs and their resolution allows for any necessary changes to be made to the investigational plan to protect study participants. Furthermore, the regulations under 812.150(b)(1) require that a sponsor who conducts an evaluation of an unanticipated adverse device effect under 812.46(b) report the results of such evaluation to FDA. Proper evaluation and timely reporting to FDA of the result of any evaluation of a UADE is important for FDA’s assessment of the overall safety profile of the device.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a description that the clinical site did not report these AEs to the sponsor as UADEs, and that they therefore were not handled as UADEs. In addition, you provided an updated SOP (CLN-06 Adverse Event Monitoring) to include UADE reporting requirements. However, these documents do not describe how an AE designated as a UADE by an investigator on the AE paper form is reported to the sponsor. It appears that the designation of an AE as a UADE is not captured in the electronic case report form (eCRF) and therefore these two AEs were not reported to the sponsor as UADEs, despite being identified by the investigator as such. As a result, these two AEs were not properly evaluated to determine whether they met the definition of a UADE, as required by the study protocol, UHP001, sections 9.1 and 9.8. Neither the updated SOP nor the protocol provide adequate detail to prevent a recurrence of this scenario in future studies. In addition, you did not provide source documentation for subject 02-0074 that was obtained according to Section 9.4 of the study protocol, UHP001, to assess the causal relationship between the AE and the investigational device. This documentation is needed to ensure that you have adequately conducted an evaluation of reported AEs as expected in the UHP001 study protocol. Although in this case, these two AEs were ultimately determined not to be UADEs through your postinspection activities, timely investigation of UADEs identified by study investigators while the study is ongoing is required by 21 CFR 812.46(b)(1) and a critical element of good clinical practices and does not appear to be assured by your corrective actions.\nFinally, section 7.6.1 of your updated SOP provides UADE reporting requirements and suggests that the requirement only applies to IDE studies. The evaluation requirement under 812.46 and reporting requirement under 812.150(b)(1) for UADEs also apply to non-significant risk studies subject to abbreviated requirements per 812.2(b), not just studies being conducted under an IDE. The regulatory requirements should be clarified and corrected in the SOP.\n5. Failure to maintain accurate, complete, and current device shipment and disposition records [21 CFR 812.140(b)(2)].\nAs a sponsor, you are responsible for maintaining accurate, complete, and current records relating to an investigation. Specifically, records of shipment must include the name and address of the consignee, type and quantity of device, date of shipment, and batch number or code mark, and records of disposition must describe the batch number or code marks of any devices returned to the sponsor, repaired, or disposed of in other ways by the investigator or another person, and the reasons for and method of disposal. You failed to maintain the necessary records. Examples include, but are not limited to, the following:\na. You failed to maintain records of investigational devices received by a sponsor employee, investigational devices returned to the sponsor, or unused investigational devices disposed of for the (b)(4) investigational device units packaged.\nb. You failed to maintain accurate device accountability records for both clinical investigation sites. For example, your Master Device Accountability Log documented that there were 230 subjects who received the investigational device in site # 01 and 4 subjects who received the investigational device in site # 02, with zero returned devices. However, there were only a total of 118 subjects randomized to receive the investigational device and the other subjects were assigned to the control group. In addition, the UHP001 Inventory Log for Site # 02 indicated that only 1 device was used, but the Master Device Accountability Log documented that there were 4 devices used.\nProper records of device shipment and disposition are necessary for control of devices and to confirm that the investigational device is used only by qualified investigators on subjects appropriately enrolled in the study. If the devices were used by unqualified individuals on patients not enrolled in the study, there would be an increased risk of harm to both the user and patient.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response provided a SOP for investigational device management and a corrected Master Accountability Log. However, you did not provide source documentation of study subjects’ randomization assignment to verify the changes made to the Master Accountability Log and to demonstrate that device usage was appropriate.\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\nWithin 15 working days of receiving this letter, please provide documentation of the additional corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\nYour response should reference “CTS# (b)(4)” and be sent via email to: Irfan.Khan@fda.hhs.gov.\nA copy of this letter has been sent to FDA’s OII BIMO Division 1 via email OIIBIMODivision1Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\nThe Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn\u002F.\nIf you have any questions, please contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\nSincerely yours,\n\u002FS\u002F\nSoma Kalb, PhD\nDirector\nDivision of Clinical Policy and Quality\nOffice of Clinical Evidence & Analysis\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","United Health Products, Inc.","united-health-products-inc-697777-03242025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-health-products-inc-697777-03242025","2026-10-26T08:10:17.734231+00:00","Warning Letter","Issued","2025-05-20","697777","BiologicsMedical Devices","Brian Thom","2026-08-19T16:46:50.292+00:00","2025-03-24",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":11,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},21731,[33,34,35,11,36,13,13,13],"\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-07T04:00:00Z\">07\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspecialty-health-products-co-llc-726564-07072026\">Specialty Health Products CO, LLC\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John C. Kavanagh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>QA\u002FRA Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Specialty Health Products CO, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2514 E Mohawk Ln, Suite 111\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 726564\u003C\u002Fp>\u003Cp>July 7, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Kavanagh:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Phoenix, AZ, from December 1, 2025, through December 11, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit), the Aqua Cleanse Colonic Irrigation System, and Speculum Kits. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that the Hydro-San Plus, Aqua Cleanse, and Speculum Kits are adulterated under section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) Regulation found at 21 CFR Part 820. We received your firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026. These responses are not adequate for the reasons described below.\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>Specifically, your firm has not conducted design validation for your biocompatibility or shelf life requirements of the Class II colonic irrigation devices (Hydro-San Plus and Aqua Cleanse).\u003C\u002Fp>\u003Cp>a. Your firm does not have evidence that biocompatibility testing per ISO 10993 standards was conducted for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> material used in patient-contacting speculums despite your specifications requiring compliance to ISO 10993: Biological Evaluation of Medical Devices. Your QA\u002FRA Manager stated that no such records exist.\u003C\u002Fp>\u003Cp>b. Your firm does not have shelf-life validation studies or accelerated aging data to support the claimed 7-year shelf life for the Hydro-San Plus, despite your own risk analysis document explicitly acknowledging a 7-year shelf life due to possible deterioration of components.\u003C\u002Fp>\u003Cp>c. Your firm’s risk analysis documents are inadequate and do not address risk associated with biocompatibility of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> material. Your risk analysis documents do not reference the specific material (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), specific test reports or laboratory names, or ISO 10993 biocompatibility testing standards. Your firm’s risk analysis for the Hydro-San Plus does not evaluate risks from oxygen administration or materials incompatible with high-oxygen environments. The only documentation provided for the oxygen hose does not indicate that the tubing is rated, tested, or approved for medical oxygen delivery applications. Your firm’s risk analysis identified disinfection as a control measure but failed to ensure the control measure was adequately established. The Hydro-San Plus User Guide specifies only 15 seconds of contact time for the Cetylcide disinfectant, which is non-compliant with the manufacturer’s required 1-minute contact time for sanitizing and 10-minute contact time for virucidal activity.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-009 response proposes reviewing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Safety Data Sheet (SDS) and conducting a single cytotoxicity test. An SDS is not a substitute for biocompatibility testing per ISO 10993 standards, and a single cytotoxicity test does not constitute adequate biocompatibility assessment for a device that contacts mucous membranes. Regarding shelf life, your firm produced a report concluding the device does not have a shelf life, which directly contradicts your own risk analysis document that stated a 7-year shelf life. Your firm has not adequately explained this discrepancy or provided evidence that components do not degrade over time. Your firm’s progress reports contain no mention of risk analysis, design validation, biocompatibility testing, or shelf-life studies.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain design change procedures as required by 21 CFR 820.30(i).\u003C\u002Fp>\u003Cp>Specifically, your firm’s Design Controls procedure (Rev B, dated 7\u002F14\u002F2023) requires design changes to be documented in Engineering Change Orders (ECOs). However, your firm could not provide ECOs or design change input approval for multiple changes to the Hydro-San Plus device, including: \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> different valves used in various device models at unknown times with no ECO documentation); and addition of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> (implemented at an unknown point in time with no ECO or approval documentation), despite the fact that the work instruction for the Hydro-San Plus Light Unit, Document 020-0003, Rev A, dated 2\u002F5\u002F2024) demonstrates that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> strip (part \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is a component of the Model A design.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-010 response reveals a gap in understanding what constitutes a design change requiring formal control. The planned assessment of the UV light was scheduled for completion by February 27, 2026, but documentation of the assessment has not been provided. Your firm’s progress reports make no specific reference to establishing or improving design change control procedures, and your firm has not explained how it will identify all previously undocumented design changes, retrospectively review, verify, validate as appropriate, and approve those changes, or prevent future unauthorized design modifications.\u003C\u002Fp>\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\u003C\u002Fp>\u003Cp>Specifically,\u003C\u002Fp>\u003Cp>a. Your firm’s Aqua Cleanse Work Instruction, which documents your assembly instructions for the Aqua Cleanse device, contains no testing procedures, parameters, or acceptance criteria, and no mention of \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing procedures or duration, \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing steps or acceptable ranges, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing protocols.\u003C\u002Fp>\u003Cp>b. Your firm’s disinfection procedures, for the use of Cetylcide disinfectant for disinfecting colonic irrigation devices returned from the field, do not incorporate manufacturer requirements. Your firm’s disinfection procedure, Rev B, dated 6\u002F5\u002F2024 states only “Apply the Cetylcide disinfectant as instructed by the manufacturer” without incorporating specific steps for contact time requirements, dilution ratios, application methods, or verification of disinfection effectiveness.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-017 response does not address whether current process parameters are adequate to ensure device safety and effectiveness in that in-process testing instructions are incomplete (missing test durations, steps, and parameters). Your firm’s corrective action regarding contamination control — installing a barrier around the sink while disinfecting field service returns — does not constitute proper contamination control for potentially biohazardous materials, and your firm has not addressed air handling, surface disinfection protocols, or personal protective equipment requirements. Your firm’s progress reports state only that it has “enhanced our processes and practices from receiving to customer service,” which provides no specific information about how process control procedures have been corrected.\u003C\u002Fp>\u003Cp>4. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically,\u003C\u002Fp>\u003Cp>a. Your firm did not document formal evaluation, review, or investigation of eight complaints. RGA #411 (dated 8\u002F25\u002F2025), which involved a mislabeled speculum shipment, was closed on the same day it was opened without reference to any investigation or evaluation documentation, and no cause analysis was documented.\u003C\u002Fp>\u003Cp>b. Your firm was not consistently documenting all complaints in the RGA Log or on RGA Forms as required by your “\u003Cem>Complaint Handling, Rev. B, 6\u002F11\u002F2024\u003C\u002Fem>”. A Corrective Action Record (CAR #005, dated 1\u002F27\u002F2025) references three customer complaints from January 2025 (customers DM, AD, and SE), but no corresponding RGA numbers or RGA forms exist for these complaints.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-008 proposes updating the complaint log and establishing formal complaint meetings but fails to address the fundamental breakdown in complaint investigation methodology. Your firm’s corrective actions focus primarily on documentation updates and form creation but do not establish clear criteria for determining when formal investigations are required, what constitutes an adequate investigation, or how to ensure complaints are properly evaluated for reportability under Medical Device Reporting (MDR) requirements. Your firm’s April 2026 progress report states only that it “started to hold formal CAPA and complaints review meetings,” but provides no evidence that the missing Complaint Report Log has been created, or that a system has been implemented to ensure complaints receive proper evaluation and investigation.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures to control all documents that are required by this part, as required by 21 CFR 820.40.\u003C\u002Fp>\u003Cp>Specifically,\u003C\u002Fp>\u003Cp>a. Your firm’s current Servicing procedure (Rev B, dated 6\u002F5\u002F2024) contains no servicing steps or requirements. Instead, the body of the Environmental Controls procedure was inadvertently saved under the Servicing procedure title, and this error was not detected before the procedure was released as a controlled document.\u003C\u002Fp>\u003Cp>b. Multiple controlled documents, including the Device Master Record for the Hydro-San Plus and the Aqua Cleanse Work Instruction, were provided as editable MS Word files without password protection, electronic signatures, or any controls preventing unauthorized modification. The Aqua Cleanse work instruction was also undated and unsigned.\u003C\u002Fp>\u003Cp>Your firm’s responses are not adequate. Your firm’s CAPA-020 addresses individual instances of document control failures but does not demonstrate understanding of the systemic breakdown in your firm’s document control system. Your firm has not explained how the body of one procedure was saved under the title of another and has not addressed the need for a comprehensive overhaul of its electronic document management system, including access controls, audit trails, and version control. Your firm’s progress reports make no mention of document control improvements.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed the Specialty Health Products website, user’s guide, product catalog, and written orders, and determined that the Hydro-San Plus is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Hydro-San Plus is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\u003Cp>Specifically, the Hydro-San Colonic Irrigation System was cleared under K891585 with the following indications: The Hydro-San Colonic irrigation system is to be used when colonic irrigation is indicated. However, your firm’s promotion of the device provides evidence that the device is distributed with an intended use for colon hydrotherapy, which is an alternative practice that flushes the large intestine with warm, filtered water to remove waste typically marketed for general wellbeing, including to boost energy and detoxify the body, rather than for medical indications. This would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval. Examples include:\u003C\u002Fp>\u003Cul>\u003Cli>Product catalog for the Hydro-San Plus indicates the firm Specialty Health Products is a leading manufacturer of professional colon hydro-therapy systems.\u003C\u002Fli>\u003Cli>Product webpage states the mission is to “be the premier service provider of professional Colon Hydrotherapy devices and integrated serves [sic].”\u003C\u002Fli>\u003Cli>Product webpage asserts several benefits of professional colon hydrotherapy, including improved digesting health, alleviating constipation and promoting bowel movements, lower risk of cancer, and boosting the body’s retention of vitamins and nutrients.\u003C\u002Fli>\u003Cli>Written orders indicate that the device was approved for sale for colon hydrotherapy to wellness centers.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Colonic irrigation systems are classified as Class II if the intended use is “for colon cleansing when medically indicated, such as before radiological or endoscopic examinations” per 21 CFR 876.5220(b)(1). However, per 21 CFR 876.5220(b) (2), a colonic irrigation system is classified as Class III “when the device is intended for other uses, including colon cleansing routinely for general well-being.”\u003C\u002Fp>\u003Cp>Additionally, since the Hydro-San Colonic Irrigation System was cleared under K891585, substantial technological changes were made that significantly affect the safety and effectiveness of the device. Examples include:\u003C\u002Fp>\u003Cul>\u003Cli>The Hydro-San Plus System includes the ultra-filtration collection, which are separate filtration canisters for the hot and cold-water filtration (https:\u002F\u002Fshpllc.net\u002Ffiltration\u002F). Performance and biocompatibility testing is needed to support the safety and efficacy of the filters with the system.\u003C\u002Fli>\u003Cli>The Hydro-San Plus System includes an optional Ultraviolet (UV) Light Unit. Additional performance and electrical safety testing is needed to support the safety and effectiveness of the UV Light Unit.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The distribution of colonic irrigation systems with these major changes and without the required premarket authorization may raise serious public health concerns, as colonic irrigation can lead to perforation of the rectum and\u002For colon, infection, imbalance of electrolytes, dehydration, and microbial dysbiosis.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency, per 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed\u003C\u002Fp>\u003Cp>Our office requests that Specialty Health Products cease any activities that result in the misbranding or adulteration of the Hydro-San Plus, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identifier (UDI)\u002FGUDID Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The device cleared with K891585, Hydro-San Colonic Irrigation System, is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the device. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI.\u003C\u002Fp>\u003Cp>FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Specialty Health Products is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting this device.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>Based on a review of the GUDID on June 30, 2026, there are no entries for Hydro-San Colonic Irrigation System under “Specialty Health Products Inc.” or under “Quality Medical Supply.”\u003C\u002Fp>\u003Cp>Your firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026, are not adequate. Your firm’s responses do not address GUDID reporting.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Registration and Listing Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During an inspection of your firm, located in Phoenix, AZ, on December 01, 2025, through December 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit) and the Aqua Cleanse Colonic Irrigation System. In addition to this, you also develop specifications for packaging and labeling of enema (speculum) kits to be sold with these irrigation devices. Specialty Health Products also imports enema (speculum) kits that are already packaged and labeled to distribute in the U.S.\u003C\u002Fp>\u003Cp>Your firm has registered for Fiscal Year 2026, but you have not identified your establishment as an initial importer. You also have not listed the following devices:\u003C\u002Fp>\u003Cul>\u003Cli>The modified Hydro-San Plus, using a new premarket submission number\u003C\u002Fli>\u003Cli>Aqua Cleanse enema (speculum) kits\u003C\u002Fli>\u003Cli>Hydro-San Plus enema (speculum) kits\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, the devices are misbranded in that they were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>If you are not manufacturing and marketing the device cleared under K891585, you must deactivate that listing. Specialty Health Products must submit a new premarket submission for the Hydro-San Plus device. This device and the Hydro-San Plus enema (speculum) kits cannot be listed until the new premarket submission has been authorized. After the authorization, your firm must list the devices using the new premarket submission number. You must also list the Aqua Cleanse enema (speculum) kits using K150381.\u003C\u002Fp>\u003Cp>In addition to updating your listing information, you must also update the registration information. The owner\u002Foperator contact person must log in and change the owner\u002Foperator contact person and official correspondent’s email address and add initial importer to Specialty Health Products’ registration.\u003C\u002Fp>\u003Cp>Instructions explaining how to list exempt and non-exempt devices, update the owner\u002Foperator contact person and official correspondent information and add initial importer can be found on our website at: \u003Cu>How to Register and List | FDA\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such device will not be approved until the violations have been addressed. Should FDA determine your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The recent inspection from December 1, 2025 through December 11, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at - CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 726564” when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CAPT Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJohn C. Kavanagh\n\nRecipient Title\n\nQA\u002FRA Manager\n\nSpecialty Health Products CO, LLC\n\n2514 E Mohawk Ln, Suite 111\n\nPhoenix, AZ 85050\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 726564\nJuly 7, 2026\nDear Mr. Kavanagh:\nDuring an inspection of your firm located in Phoenix, AZ, from December 1, 2025, through December 11, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit), the Aqua Cleanse Colonic Irrigation System, and Speculum Kits. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nOur inspection revealed that the Hydro-San Plus, Aqua Cleanse, and Speculum Kits are adulterated under section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) Regulation found at 21 CFR Part 820. We received your firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026. These responses are not adequate for the reasons described below.\n1. Failure to establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\nSpecifically, your firm has not conducted design validation for your biocompatibility or shelf life requirements of the Class II colonic irrigation devices (Hydro-San Plus and Aqua Cleanse).\na. Your firm does not have evidence that biocompatibility testing per ISO 10993 standards was conducted for the (b)(4) material used in patient-contacting speculums despite your specifications requiring compliance to ISO 10993: Biological Evaluation of Medical Devices. Your QA\u002FRA Manager stated that no such records exist.\nb. Your firm does not have shelf-life validation studies or accelerated aging data to support the claimed 7-year shelf life for the Hydro-San Plus, despite your own risk analysis document explicitly acknowledging a 7-year shelf life due to possible deterioration of components.\nc. Your firm’s risk analysis documents are inadequate and do not address risk associated with biocompatibility of your (b)(4) material. Your risk analysis documents do not reference the specific material ((b)(4)), specific test reports or laboratory names, or ISO 10993 biocompatibility testing standards. Your firm’s risk analysis for the Hydro-San Plus does not evaluate risks from oxygen administration or materials incompatible with high-oxygen environments. The only documentation provided for the oxygen hose does not indicate that the tubing is rated, tested, or approved for medical oxygen delivery applications. Your firm’s risk analysis identified disinfection as a control measure but failed to ensure the control measure was adequately established. The Hydro-San Plus User Guide specifies only 15 seconds of contact time for the Cetylcide disinfectant, which is non-compliant with the manufacturer’s required 1-minute contact time for sanitizing and 10-minute contact time for virucidal activity.\nYour firm’s responses are not adequate. Your firm’s CAPA-009 response proposes reviewing the (b)(4) Safety Data Sheet (SDS) and conducting a single cytotoxicity test. An SDS is not a substitute for biocompatibility testing per ISO 10993 standards, and a single cytotoxicity test does not constitute adequate biocompatibility assessment for a device that contacts mucous membranes. Regarding shelf life, your firm produced a report concluding the device does not have a shelf life, which directly contradicts your own risk analysis document that stated a 7-year shelf life. Your firm has not adequately explained this discrepancy or provided evidence that components do not degrade over time. Your firm’s progress reports contain no mention of risk analysis, design validation, biocompatibility testing, or shelf-life studies.\n2. Failure to establish and maintain design change procedures as required by 21 CFR 820.30(i).\nSpecifically, your firm’s Design Controls procedure (Rev B, dated 7\u002F14\u002F2023) requires design changes to be documented in Engineering Change Orders (ECOs). However, your firm could not provide ECOs or design change input approval for multiple changes to the Hydro-San Plus device, including: (b)(4) changes ((b)(4) different valves used in various device models at unknown times with no ECO documentation); and addition of a (b)(4) (implemented at an unknown point in time with no ECO or approval documentation), despite the fact that the work instruction for the Hydro-San Plus Light Unit, Document 020-0003, Rev A, dated 2\u002F5\u002F2024) demonstrates that the (b)(4) strip (part (b)(4)) is a component of the Model A design.\nYour firm’s responses are not adequate. Your firm’s CAPA-010 response reveals a gap in understanding what constitutes a design change requiring formal control. The planned assessment of the UV light was scheduled for completion by February 27, 2026, but documentation of the assessment has not been provided. Your firm’s progress reports make no specific reference to establishing or improving design change control procedures, and your firm has not explained how it will identify all previously undocumented design changes, retrospectively review, verify, validate as appropriate, and approve those changes, or prevent future unauthorized design modifications.\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\nSpecifically,\na. Your firm’s Aqua Cleanse Work Instruction, which documents your assembly instructions for the Aqua Cleanse device, contains no testing procedures, parameters, or acceptance criteria, and no mention of (b)(4) testing procedures or duration, (b)(4) testing steps or acceptable ranges, or (b)(4) testing protocols.\nb. Your firm’s disinfection procedures, for the use of Cetylcide disinfectant for disinfecting colonic irrigation devices returned from the field, do not incorporate manufacturer requirements. Your firm’s disinfection procedure, Rev B, dated 6\u002F5\u002F2024 states only “Apply the Cetylcide disinfectant as instructed by the manufacturer” without incorporating specific steps for contact time requirements, dilution ratios, application methods, or verification of disinfection effectiveness.\nYour firm’s responses are not adequate. Your firm’s CAPA-017 response does not address whether current process parameters are adequate to ensure device safety and effectiveness in that in-process testing instructions are incomplete (missing test durations, steps, and parameters). Your firm’s corrective action regarding contamination control — installing a barrier around the sink while disinfecting field service returns — does not constitute proper contamination control for potentially biohazardous materials, and your firm has not addressed air handling, surface disinfection protocols, or personal protective equipment requirements. Your firm’s progress reports state only that it has “enhanced our processes and practices from receiving to customer service,” which provides no specific information about how process control procedures have been corrected.\n4. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically,\na. Your firm did not document formal evaluation, review, or investigation of eight complaints. RGA #411 (dated 8\u002F25\u002F2025), which involved a mislabeled speculum shipment, was closed on the same day it was opened without reference to any investigation or evaluation documentation, and no cause analysis was documented.\nb. Your firm was not consistently documenting all complaints in the RGA Log or on RGA Forms as required by your “Complaint Handling, Rev. B, 6\u002F11\u002F2024”. A Corrective Action Record (CAR #005, dated 1\u002F27\u002F2025) references three customer complaints from January 2025 (customers DM, AD, and SE), but no corresponding RGA numbers or RGA forms exist for these complaints.\nYour firm’s responses are not adequate. Your firm’s CAPA-008 proposes updating the complaint log and establishing formal complaint meetings but fails to address the fundamental breakdown in complaint investigation methodology. Your firm’s corrective actions focus primarily on documentation updates and form creation but do not establish clear criteria for determining when formal investigations are required, what constitutes an adequate investigation, or how to ensure complaints are properly evaluated for reportability under Medical Device Reporting (MDR) requirements. Your firm’s April 2026 progress report states only that it “started to hold formal CAPA and complaints review meetings,” but provides no evidence that the missing Complaint Report Log has been created, or that a system has been implemented to ensure complaints receive proper evaluation and investigation.\n5. Failure to establish and maintain procedures to control all documents that are required by this part, as required by 21 CFR 820.40.\nSpecifically,\na. Your firm’s current Servicing procedure (Rev B, dated 6\u002F5\u002F2024) contains no servicing steps or requirements. Instead, the body of the Environmental Controls procedure was inadvertently saved under the Servicing procedure title, and this error was not detected before the procedure was released as a controlled document.\nb. Multiple controlled documents, including the Device Master Record for the Hydro-San Plus and the Aqua Cleanse Work Instruction, were provided as editable MS Word files without password protection, electronic signatures, or any controls preventing unauthorized modification. The Aqua Cleanse work instruction was also undated and unsigned.\nYour firm’s responses are not adequate. Your firm’s CAPA-020 addresses individual instances of document control failures but does not demonstrate understanding of the systemic breakdown in your firm’s document control system. Your firm has not explained how the body of one procedure was saved under the title of another and has not addressed the need for a comprehensive overhaul of its electronic document management system, including access controls, audit trails, and version control. Your firm’s progress reports make no mention of document control improvements.\nUnapproved Device Violation(s)\nFDA has reviewed the Specialty Health Products website, user’s guide, product catalog, and written orders, and determined that the Hydro-San Plus is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Hydro-San Plus is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\nSpecifically, the Hydro-San Colonic Irrigation System was cleared under K891585 with the following indications: The Hydro-San Colonic irrigation system is to be used when colonic irrigation is indicated. However, your firm’s promotion of the device provides evidence that the device is distributed with an intended use for colon hydrotherapy, which is an alternative practice that flushes the large intestine with warm, filtered water to remove waste typically marketed for general wellbeing, including to boost energy and detoxify the body, rather than for medical indications. This would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval. Examples include:\nProduct catalog for the Hydro-San Plus indicates the firm Specialty Health Products is a leading manufacturer of professional colon hydro-therapy systems.\nProduct webpage states the mission is to “be the premier service provider of professional Colon Hydrotherapy devices and integrated serves [sic].”\nProduct webpage asserts several benefits of professional colon hydrotherapy, including improved digesting health, alleviating constipation and promoting bowel movements, lower risk of cancer, and boosting the body’s retention of vitamins and nutrients.\nWritten orders indicate that the device was approved for sale for colon hydrotherapy to wellness centers.\nColonic irrigation systems are classified as Class II if the intended use is “for colon cleansing when medically indicated, such as before radiological or endoscopic examinations” per 21 CFR 876.5220(b)(1). However, per 21 CFR 876.5220(b) (2), a colonic irrigation system is classified as Class III “when the device is intended for other uses, including colon cleansing routinely for general well-being.”\nAdditionally, since the Hydro-San Colonic Irrigation System was cleared under K891585, substantial technological changes were made that significantly affect the safety and effectiveness of the device. Examples include:\nThe Hydro-San Plus System includes the ultra-filtration collection, which are separate filtration canisters for the hot and cold-water filtration (https:\u002F\u002Fshpllc.net\u002Ffiltration\u002F). Performance and biocompatibility testing is needed to support the safety and efficacy of the filters with the system.\nThe Hydro-San Plus System includes an optional Ultraviolet (UV) Light Unit. Additional performance and electrical safety testing is needed to support the safety and effectiveness of the UV Light Unit.\nThe distribution of colonic irrigation systems with these major changes and without the required premarket authorization may raise serious public health concerns, as colonic irrigation can lead to perforation of the rectum and\u002For colon, infection, imbalance of electrolytes, dehydration, and microbial dysbiosis.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency, per 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed\nOur office requests that Specialty Health Products cease any activities that result in the misbranding or adulteration of the Hydro-San Plus, such as the commercial distribution of the device for the uses discussed above.\nUnique Device Identifier (UDI)\u002FGUDID Violation\nThe device cleared with K891585, Hydro-San Colonic Irrigation System, is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the device. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI.\nFDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Specialty Health Products is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting this device.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nBased on a review of the GUDID on June 30, 2026, there are no entries for Hydro-San Colonic Irrigation System under “Specialty Health Products Inc.” or under “Quality Medical Supply.”\nYour firm’s responses dated January 5, 2026, February 6, 2026, March 5, 2026, April 10, 2026, May 6, 2026, and June 10, 2026, are not adequate. Your firm’s responses do not address GUDID reporting.\nRegistration and Listing Violation\nDuring an inspection of your firm, located in Phoenix, AZ, on December 01, 2025, through December 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the Hydro-San Colonic Irrigation System (also known as Hydro-San Plus, Hydro-San, and Hydro-San Plus A Base Unit) and the Aqua Cleanse Colonic Irrigation System. In addition to this, you also develop specifications for packaging and labeling of enema (speculum) kits to be sold with these irrigation devices. Specialty Health Products also imports enema (speculum) kits that are already packaged and labeled to distribute in the U.S.\nYour firm has registered for Fiscal Year 2026, but you have not identified your establishment as an initial importer. You also have not listed the following devices:\nThe modified Hydro-San Plus, using a new premarket submission number\nAqua Cleanse enema (speculum) kits\nHydro-San Plus enema (speculum) kits\nTherefore, the devices are misbranded in that they were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nIf you are not manufacturing and marketing the device cleared under K891585, you must deactivate that listing. Specialty Health Products must submit a new premarket submission for the Hydro-San Plus device. This device and the Hydro-San Plus enema (speculum) kits cannot be listed until the new premarket submission has been authorized. After the authorization, your firm must list the devices using the new premarket submission number. You must also list the Aqua Cleanse enema (speculum) kits using K150381.\nIn addition to updating your listing information, you must also update the registration information. The owner\u002Foperator contact person must log in and change the owner\u002Foperator contact person and official correspondent’s email address and add initial importer to Specialty Health Products’ registration.\nInstructions explaining how to list exempt and non-exempt devices, update the owner\u002Foperator contact person and official correspondent information and add initial importer can be found on our website at: How to Register and List | FDA\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such device will not be approved until the violations have been addressed. Should FDA determine your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The recent inspection from December 1, 2025 through December 11, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jeffrey Wooley, Acting Assistant Director, at - CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 726564” when replying. If you have any questions about the contents of this letter, please contact Raymond Brullo at raymond.brullo@fda.hhs.gov\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCAPT Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Specialty Health Products CO, LLC","specialty-health-products-co-llc-726564-07072026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspecialty-health-products-co-llc-726564-07072026","2026-11-03T01:02:17.615107+00:00","2026-09-22","726564","Medical Devices","John C. Kavanagh","2026-10-14T12:37:00.545+00:00","VIA Electronic Mail","2026-07-07",{"id":53,"raw":54,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":71,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},1537,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-05T05:00:00Z\">12\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambaya-gold-health-products-llc-648130-12052023\">Ambaya Gold Health Products, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations West IV","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pilar G. Martin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ambaya Gold Health Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10 Gideon Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sedona\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>86336\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Reference: CMS Case # 648130\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Martin:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U. S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.ambayagold.com in April and November 2023 and has determined that you take orders for the products Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+. We also reviewed your social media website at www.facebook.com\u002FAmbayaGoldHealth, which directs consumers to your website at www.ambayagold.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B)\u002F(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)\u002F(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Brain Balance product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Brain Balance product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fbrain-balance-regeneration):\u003C\u002Fp>\n\n\u003Cp>• “Lithium orotate [an ingredient in Brain Balance] …great natural treatment for a wide range of mental health problems.”\u003Cbr>\n\u003Cbr>\nOn the “What is Ashwagandha?” blog post, dated June 20, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhat_is_ashwagandha), which contains a hyperlink to purchase Brain Balance:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Benefits of Top Rated Ashwagandha Supplements”:\u003Cbr>\n&nbsp; &nbsp; − “1. Powerful anti-inflammatory…”\u003Cbr>\n&nbsp; &nbsp; − “7. Reduce symptoms of depression”\u003Cbr>\n&nbsp; &nbsp; − “8. Lower cholesterol and triglycerides”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 20, 2022:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “HEALTH BENEFITS OF ASHWAGANDHA” [an ingredient in Brain Balance]:\u003Cbr>\n&nbsp; &nbsp; − “REDUCES BLOOD SUGAR LEVELS…helps in [sic] increased insulin secre-tion and improved insu-lin sensitivity.”\u003Cbr>\n&nbsp; &nbsp; − “HELPS FIGHT CANCER…helps in reducing the growth of tumors, prevents cancer cells from growing”\u003Cbr>\n&nbsp; &nbsp; − “IMPROVES THY-ROID FUNCTION…benefits people suffer-ing from hypothyroid-ism…”\u003Cbr>\n&nbsp; &nbsp; − “REDUCES SYMP-TOMS OF DEPRES-SION… plays an essential role in reducing depression”\u003Cbr>\n&nbsp; &nbsp; − “MAY LOWER CHO-LESTEROL AND TRI-GLYCERIDES…helps lower LDL, and VDL cholesterol and triglyceride levels and increase HDL levels.”\u003Cbr>\n&nbsp; &nbsp; − “CAN PREVENT SEI-ZURES…used in traditional ayurvedic medi-cines as a cure for sei-zures and convulsions.”\u003Cbr>\n&nbsp; &nbsp; − “[P]revents loss of bone mineral density and reduces bone reabsorp-tion.”\u003Cbr>\n&nbsp; &nbsp; − “[H]elp prevent chronic eye diseases.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Immune System Boost product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the “Combating Allergies (The Holistic Way)” blog post, dated October 31, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fcombating-allergies-the-holistic-way), which contains a hyperlink to purchase Immune System Boost:\u003Cbr>\n\u003Cbr>\n• “There are natural allergy remedies that have very little to no side effects and can be as effective (if not more) than allergy medications.”\u003Cbr>\n• “If you find yourself constantly effected[sic] by allergies, check out our Immune System Boost.”\u003Cbr>\n• “MSM [an ingredient in Immune System Boost] can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory and antioxidant effects. It binds to the mucosa, blocking host and allergen contact.”\u003Cbr>\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\u003C\u002Fp>\n\n\u003Cp>On the “Keep your Immune System Naturally Strong During Flu Season” blog post, dated October 24, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fkeep-your-immune-system-naturally-strong-during-flu-season), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\u003C\u002Fp>\n\n\u003Cp>On the “Naturally Strengthen Your Immune System” blog post, dated February 3, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnaturally-strengthen-your-immune-system), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Ambaya Gold’s Immune Boost [this phrase hyperlinks to the Immune System Boost product page] is…anti-microbial, anti-viral...”\u003C\u002Fp>\n\n\u003Cp>On the “Top Science-Backed Benefits of MSM” blog post, dated October 10, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Ftop-science-backed-benefits-of-msm), which contains a hyperlink to purchase Immune System Boost:\u003C\u002Fp>\n\n\u003Cp>• “Have you heard about MSM [an ingredient in Immune System Boost] …it can help with a variety of conditions, like arthritis and joint pain.”\u003Cbr>\n• Under the heading “Ten Reasons You Should Consider Taking MSM” [an ingredient in Immune System Boost]:\u003Cbr>\n&nbsp; &nbsp; − “2. MSM May Have Anti-inflammatory Effects…may reduce the release of molecules linked to inflammation…inhibits NF-kB, a protein complex involved in inflammatory responses in the body…reduces production of cytokines such as TNF-a and IL-6, which are signaling proteins linked to systemic inflammation.”\u003Cbr>\n&nbsp; &nbsp; − “3. MSM May Treat Arthritis and Joint Pain…Arthritis is probably the most known condition that MSM is used for, especially osteoarthritis. …MSM might lessen the pain associated with it. One study of 100 people…found that treatment with a supplement containing MSM for 12 weeks lessened pain, stiffness and swelling in the joints, compared to a placebo.”\u003Cbr>\n&nbsp; &nbsp; − “4. MSM May Help with Digestive Problems…may improve symptoms in patients with Leaky Gut Syndrome…One study, however, did show oral intake of MSM assisted in protecting gut damage in rats with colitis. MSM supplements may also reduce swelling and discomfort caused by hemorrhoids.”\u003Cbr>\n&nbsp; &nbsp; − “8. MSM May Relieve Allergies…MSM can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory. …It was found that allergy symptoms and lower respiratory symptoms were reduced in people with seasonal allergic rhinitis after taking MSM supplementation for one month.”\u003Cbr>\n&nbsp; &nbsp; − “9. MSM May Help With Parasites…may be an effective treatment for worms, giardia and trichomonas. …MSM coats the gut lining making it impossible for parasites to attach themselves. They are then naturally flushed out of the body. Candida is when the body experiences an overgrowth in fungus which can cause various health problems. MSM changes the PH in your body where Candida can not [sic] thrive in.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Essensiac product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Essensiac product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fessensiac):\u003C\u002Fp>\n\n\u003Cp>• On the image of your product label:\u003Cbr>\n&nbsp; &nbsp; − “[E]ssiac tea…for…reducing inflammation”\u003Cbr>\n• “Slippery Elm Bark [an ingredient in Essensiac]… can provide anti-inflammatory support.”\u003C\u002Fp>\n\n\u003Cp>On the “Honoring the Benefits of Slippery Elm Tree” blog post, dated November 7, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fhonoring-the-benefits-of-slippery-elm-tree), which contains a hyperlink to purchase Essensiac:\u003C\u002Fp>\n\n\u003Cp>• “[H]ealth benefits of slippery elm bark [an ingredient in Essensiac] come from the biochemical compounds that are extracted from it. They include mucilage…[m]ucilage: Helps to soothe sore throats and suppress coughs…”\u003Cbr>\n• “Tannins [a component of the slippery elm bark ingredient in the Essensiac product]: Contains…anti-inflammatory properties. Helps lower cholesterol, lower blood pressure…It also has antibacterial properties that help fight tooth decay.”\u003Cbr>\n• “Sterols [a component of the slippery elm bark ingredient in the Essensiac product]: Plant sterols can help to lower cholesterol and prevent cardiovascular disease…”\u003Cbr>\n• “[A]nti-inflammatory properties of fatty acids, tannins and plant sterols [components of the slippery elm bark ingredient in the Essensiac product] …may all contribute to Slippery Elm Bark’s use as an alternative anti-inflammation aid for some chronic conditions.”\u003Cbr>\n• “…Slippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…for help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated November 7, 2022:\u003C\u002Fp>\n\n\u003Cp>• “[S]lippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…to help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated February 4, 2022:\u003C\u002Fp>\n\n\u003Cp>• “It assists the body to create an environment that fights against dis-ease…”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 14, 2021:\u003C\u002Fp>\n\n\u003Cp>• “My morning routine includes…Essensiac for its…anti-inflammatory properties....”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dentist In A Bottle product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Dentist In A Bottle product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fdentist-in-a-bottle):\u003C\u002Fp>\n\n\u003Cp>• “Assistance with the prevention of tooth decay”\u003Cbr>\n• “By reducing harmful bacteria growth and replacing essential minerals, Dentist in a Bottle…assists in the prevention and remediation of gum and tooth decay.”\u003Cbr>\n• “I bought Dentist in a Bottle because my dentist told me I needed a root canal…used it twice a day, soaking the area for about two minutes. The pain and infection subsided after one day and disappeared after one week. A new dentist said that I did not need a root canal…”\u003Cbr>\n• “…[A]lways had problems with my teeth and gums…led to lifelong chronic gum and tooth infections . . . has completely removed the plaque buildup and now my teeth and gums feel clean and healthy…my gums have stopped bleeding. …Dentist In A Bottle”\u003C\u002Fp>\n\n\u003Cp>On the “Reasons You Should Switch to a Natural Mouthwash Today” blog post, dated September 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Freasons-you-should-switch-to-a-natural-mouthwash-today), which contains a hyperlink to purchase Dentist In A Bottle:\u003C\u002Fp>\n\n\u003Cp>• “Two main ingredients in our mouthwash, Dentist in a Bottle, are Fulvic and Silver. Both are known for their antibacterial properties and can be very effective at reducing harmful bacteria. Using these two together can help prevent gum disease and tooth decay.”\u003Cbr>\n• “…Effective on Bacteria”\u003Cbr>\n• “Assistance with the prevention of tooth decay”\u003Cbr>\n• “Most natural rinses, like ours, contain popular ingredients like peppermint, rosemary, thyme, cinnamon bark, eucalyptus, wintergreen, lemon, clove and birch oil. Research has proven their anti bacterial [sic], antimicrobial and anti-inflammatory properties’”\u003Cbr>\n• “‘Oral infections can result in inflammation in other parts of the body since our oral mucosa has a direct pathway to the bloodstream.’ …Our Dentist in a Bottle offers overall improvement in oral health...”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated September 5, 2022:\u003C\u002Fp>\n\n\u003Cp>• “Fulvic and Silver [ingredients in Dentist In A Bottle] are known for their antibacterial properties and can be very effective at reducing harmful bacteria.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 8, 2022:\u003C\u002Fp>\n\n\u003Cp>• “By reducing harmful bacteria growth and replacing essential mineral, Dentist in a Bottle, freshens the mouth…while assisting in the prevention and remediation of gum and tooth decay.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated July 12, 2021:\u003C\u002Fp>\n\n\u003Cp>• “Our effective mouthwash is a natural alternative to toxic mouthwashes…reduces harmful bacteria growth and replaces essential minerals!”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Fulvic Green product\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nOn the “The Surprising Benefits of Chlorophyll” blog post, dated August 1, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-surprising-benefits-of-chlorophyll), which contains a hyperlink to purchase Fulvic Green:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “10 Amazing Benefits of Chlorophyll” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “2. [R]epair small gut wounds.”\u003Cbr>\n&nbsp; &nbsp; − “5. It’s also an excellent blood purifier that helps prevent or even reverse dis-ease [sic] in your body.”\u003C\u002Fp>\n\n\u003Cp>On the “Superfood Hawaiian Spirulina” blog post, dated June 27, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fsuperfood_hawaiian_spirulina), which contains a hyperlink to purchase Fulvic Green:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “[R]educes allergy symptoms”\u003Cbr>\n&nbsp; &nbsp; − “[G]reat anti-inflammation”\u003Cbr>\n&nbsp; &nbsp; − “[C]an reduce risk of cancer”\u003Cbr>\n&nbsp; &nbsp; − “[P]revents &amp; helps with cardiovascular disease”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Why Take Hawaiian Spirulina [an ingredient in Fulvic Green] Supplements?”:\u003Cbr>\n&nbsp; &nbsp; − “Lowers Blood Pressure…A great way to lower your blood pressure is to add spirulina to your diet.”\u003Cbr>\n&nbsp; &nbsp; − “[S]pirulina …Foods high in antioxidants have been proven to lower inflammation and eliminate free radicals which can prevent degenerative brain diseases…spirulina helps with ADHD.”\u003Cbr>\n&nbsp; &nbsp; − “Lower Blood Sugar…Spirulina can lower blood sugar levels.”\u003Cbr>\n&nbsp; &nbsp; − “Can Reduce Risk of Cancer…Adding spirulina to your diet can reduce risk of cancer. Testing…showed the spirulina increased the production of antibodies as well as infection-fighting proteins and cells that help to protect against cancer…spirulina could have potential to prevent a number of other diseases”\u003Cbr>\n&nbsp; &nbsp; − “Protect Against Liver Disease…Protection against liver disease”\u003Cbr>\n&nbsp; &nbsp; − “Detox from Heavy Metals…Spirulina acts as a detox for your body, especially from heavy metals, like arsenic. …United States is one of the countries that are most affected by arsenic poisoning. Spirulina is a natural remedy for getting rid of that arsenic and other metals that have accumulated in the body.”\u003Cbr>\n&nbsp; &nbsp; − “Reduce Cholesterol…Spirulina can greatly reduce cholesterol as well. Cholesterol can be a problem that leads to heart disease…Anyone at risk for heart disease…should consider adding spirulina to their diet.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated August 1, 2022:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “CHLOROPHYLL [an ingredient in Fulvic Green] BENEFITS”:\u003Cbr>\n&nbsp; &nbsp; − “ANTI-CARCINOGENIC”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 27, 2022:\u003Cbr>\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\u003Cbr>\n&nbsp; &nbsp; − “[R]educes allergy symptoms”\u003Cbr>\n&nbsp; &nbsp; − “[G]reat anti-inflammation”\u003Cbr>\n&nbsp; &nbsp; − “[C]an reduce risk of cancer”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Silver Solution product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Silver Solution product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-solutions):\u003C\u002Fp>\n\n\u003Cp>• On the image of your product label:\u003Cbr>\n&nbsp; &nbsp; − [W]ide-spectrum antibacterial solution minimizes risk of infections”\u003Cbr>\n• “Silver [an ingredient in Silver Solution] is considered a very powerful antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\u003C\u002Fp>\n\n\u003Cp>On the “The Many Uses of Silver” blog post, dated December 27, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-many-uses-of-silver), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\u003C\u002Fp>\n\n\u003Cp>• “Taking Silver [an ingredient in Silver Solution] orally can assist with symptoms of colds, sinus infections…can lessen the symptoms of allergies and arthritis.”\u003Cbr>\n• “Silver [an ingredient in Silver Solution] can fight hundreds of disease causing [sic] bacteria &amp; viruses...”\u003Cbr>\n• “If you don't like taking antibiotics for urinary tract or bladder infections, silver [an ingredient in Silver Solution], a natural alternative can assist to clear up your system by taking 1\u002F2 teaspoon of our Silver orally…”\u003C\u002Fp>\n\n\u003Cp>On the “What's the Difference Between Silver and Gold?” blog post, dated December 13, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhats-the-difference-between-silver-and-gold), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Silver Solution] ions cause inhibition of bacterial growth. Therefore they are naturally antibacterial. Silver ions, and their interaction with enzymes and proteins play an important role in antibacterial efficacy in the body.”\u003Cbr>\n• “…Silver [an ingredient in Silver Solution] can be used as a non-toxic, safe, and easy to use supplement as a natural antibiotic…”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated December 19, 2021:\u003C\u002Fp>\n\n\u003Cp>• “Silver [an ingredient in Silver Solution] is naturally antibacterial…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Detox Cleanse Renew\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Essentials Kit webpage (https:\u002F\u002Fambayagold.com\u002Fpages\u002Fthe-essentials-kit), which contains a hyperlink to purchase Detox Cleanse Renew:\u003C\u002Fp>\n\n\u003Cp>• “RESTORE FULVIC [an ingredient in Detox Cleanse Renew] RESTORE HEALTH…Toxic build up and mineral deficiencies are two of the biggest health issues that people face today and can lead to symptoms like: …Blood Sugar Imbalances…Insomnia…”\u003Cbr>\n• “BENEFITS OF FULVIC… REDUCES INFLAMMATION …FIGHTS PATHOGENS...”\u003C\u002Fp>\n\n\u003Cp>On the “The Best Detox For Environmental Toxins And Radiation” blog post, dated July 4, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe_best_detox_for_environmental_toxins_and_radiation), which contains a hyperlink to purchase Detox Cleanse Renew:\u003C\u002Fp>\n\n\u003Cp>• “[C]ancers, disease and birth defects are increasing in both humans and animals due to environmental pollutants full of heavy metals and other toxins. …The best way to remove toxic heavy metals from environmental pollution and radiation from the body is by chelating them out with a product…Clinoptilolite Zeolite [an ingredient in Detox Cleanse Renew] is by far the best way to combat these toxins.”\u003Cbr>\n• “The miracle toxin magnet, Zeolite [an ingredient in Detox Cleanse Renew] …draws heavy metals and toxins to the Zeolite…enabling the toxins to be safely eliminated…”\u003Cbr>\n• “As the heavy metals and toxins are eliminated the immune system can grow strong again to better fight off viruses, bacteria and deformed cells...”\u003Cbr>\n• “Routinely detoxifying with zeolite [an ingredient in Detox Cleanse Renew] is necessary because when you’re exposed to toxins, your body stores them in your cells. Over time, toxins and radiation can build up to dangerous levels—leading to disease, chronic fatigue, brain fog and even cancer.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Silver Spray product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Silver Spray product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-spray):\u003C\u002Fp>\n\n\u003Cp>“AMBAYA GOLD . . . SILVER SPRAY . . . wide-spectrum antibacterial solution minimizes risk of infections” [from your product label for SILVER SPRAY]\u003C\u002Fp>\n\n\u003Cp>“Silver Spray . . . Natural antibacterial . . . Disinfects like hydrogen peroxide without the burn . . .” [https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmSADzUva93\u002F and https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002Fposts\u002Fpfbid02Hkd21pHbyrU5TL1MaAgRh1E9CJWtbKVenM5kyQaRtKtC4G9XL2ZMZZ58u7LApMGQl]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Magnesium Oil Spray product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Our fast acting topical Magnesium Oil Spray offers the benefits of pure Magnesium Oil in a proprietary Fulvic base. . . .This convenient spray is designed is designed to provide relief from body tension and soreness quickly and effectively. . . .For muscle cramps or pains, spray directly on problem area.” [from your product website, https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fmagnesium-oil-spray]\u003C\u002Fp>\n\n\u003Cp>Specifically, these products are intended for use as a first aid antiseptic, and an external analgesic, respectively\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, and Detox Cleanse Renew products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>Further, your “Silver Spray” product, containing silver, is a first aid antiseptic subject to section 505G of the FD&amp;C Act, which governs nonprescription drugs marketed without an approved application. Specifically, your silver-containing product falls under section 505G(a)(5) of the FD&amp;C Act, because FDA has determined that no silver containing OTC drugs are generally recognized as safe and effective under a final determination issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>2, 3&nbsp;&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>Therefore, Silver Spray is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for this drug product. Accordingly, “Silver Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Your “Magnesium Oil Spray” is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>However, “Magnesium Oil Spray” does not conform to the conditions specified in the final administrative order for the reasons described below. Your “Magnesium Oil Spray” is not formulated and labeled as an external analgesic counterirritant drug product that is consistent with the final administrative order. Specifically, your product is labeled to contain the ingredients magnesium chloride, fulvic, indium, aloe vera, pyridoxine HCl (B6), MSM, and plant based phytonutrients, all of which are outside of the final applicable administrative order. According to 21 CFR 201.66(b)(2), an “active ingredient” means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans. Although your firm does not specifically list these ingredients as active ingredients, your product website includes statements that claim this combination of ingredients is “designed to provide relief from body tension and soreness” as a treatment for symptoms related to magnesium deficiency that include “leg cramps and muscle soreness,” along with “migraines, insomnia, [and] fatigue.” Such statements demonstrate that those ingredients are considered “active ingredients” as defined by 21 CFR 201.66(b)(2) because this combination of ingredients is intended to furnish pharmacological activity. However, this combination of active ingredients is not permitted under the applicable final order nor are any of these ingredients permitted as a single active ingredient in an external analgesic product under the final administrative order.\u003C\u002Fp>\n\n\u003Cp>Thus, as formulated and labeled, “Magnesium Oil Spray” does not comply with the final administrative order described above or any applicable proposed or final rule. FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Magnesium Oil Spray” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Therefore, “Magnesium Oil Spray” is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, “Magnesium Oil Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>In addition, “Silver Spray” and “Magnesium Oil Spray” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on our review of your website www.ambayagold.com and your social media website www.facebook.com\u002FAmbayaGoldHealth, your Pet Health+ product is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website and social media website that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pet Health+ product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the Pet Health+ product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fpet-health):\u003C\u002Fp>\n\n\u003Cp>• “Detox of heavy metals, chemicals and other toxins* Protection from worms, parasites, and fungus* Natural anti-inflammatory agents*…Protection from infection*…Accelerated wound recovery*”\u003Cbr>\n• “In our Pet Health +, our clean sourced Clinoptilolite Zeolite is formulated and suspended in a freshwater Humic and Fulvic liquid solution. The Humic helps to penetrate deep into the cells, providing a cleansing action by safely binding harmful toxins.”\u003Cbr>\n• “Why Silver and Gold? Monatomic Silver is considered a powerful natural antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\u003Cbr>\n• A customer testimonial from 2\u002F18\u002F2022 states, “This product has help [sic] to support for our new dog’s… anxiety issues…”\u003Cbr>\n\u003Cbr>\nOn the “Natural Remedies for Pain Relief in Dogs” blog post, dated December 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnatural-remedies-for-pain-relief-in-dogs), which contains a hyperlink to purchase Pet Health+:\u003C\u002Fp>\n\n\u003Cp>• “Holistic pet supplements and pain relievers can have a wide range of benefits like: …Assistance with detox of heavy metals, chemicals, and other toxins…Protection from worms, parasites, fungus, and infection…Natural anti-inflammatory agents…Accelerated wound recovery…All of the above benefits have been reported by users of our pet multivitamin, Pet Health+ [hyperlinks to the Pet Health+ product page].\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 15, 2022:\u003C\u002Fp>\n\n\u003Cp>• “Pet Health+ helps…Assist with detox of heavy metals, chemicals, and other toxins…Protect from worms, parasites, fungus, and infection”\u003C\u002Fp>\n\n\u003Cp>On your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated October 8, 2021, with three photos of a cat:\u003C\u002Fp>\n\n\u003Cp>• “…[H]er cat’s obsessive grooming…This caused her to form “hot spots” where the skin had become inflamed and formed open wounds. …When modern medicine didn’t help, she tried Pet Health+ and here are her results after ONLY a week and a half!”\u003C\u002Fp>\n\n\u003Cp>Your Pet Health+ product is a \"new animal drug\" under section 201(v) of the Act [21 U.S.C. § 321(v)] because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Pet Health+ is not approved, conditionally approved, or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the Act [21 U.S.C. § 360b(a)] and adulterated under section 501(a)(5) of the Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Carrie Jolly, Compliance Officer, via email at carrie.jolly@fda.hhs.gov or at 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado. You may reach Ms. Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –\u003Cbr>\nWest Division 4\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> It is not clear whether you intend your “Silver Spray” and “Magnesium Oil Spray” products to be marketed as dietary supplements. Your firm lists these two products on your website under the heading “Supplements.” Under section 201(ff)(2)(A)(i) of the FD&amp;C Act [21 U.S.C. § 321(ff)(2)(A)(i)], a dietary supplement is defined, among other things, as a product intended for ingestion. Topical products and other products that are not intended for ingestion cannot be dietary supplements.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the Act) for which an approved application or abbreviated application under section 505 of the Act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the Act.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(8)(i). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) are deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC000007, available at OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR. part 330 prior to enactment of the CARES Act. In the case of OTC anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPilar G. Martin\n\nRecipient Title\n\nOwner\n\nAmbaya Gold Health Products, LLC\n\n10 Gideon Rd\n\nSedona, AZ 86336\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West IV\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 5, 2023\n\nWARNING LETTER\n\nReference: CMS Case # 648130\n\nDear Ms. Martin:\n\nThis is to advise you that the U. S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.ambayagold.com in April and November 2023 and has determined that you take orders for the products Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, Detox Cleanse Renew, Magnesium Oil Spray, Silver Spray, and Pet Health+. We also reviewed your social media website at www.facebook.com\u002FAmbayaGoldHealth, which directs consumers to your website at www.ambayagold.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B)\u002F(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)\u002F(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nBrain Balance product\n\nOn the Brain Balance product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fbrain-balance-regeneration):\n\n• “Lithium orotate [an ingredient in Brain Balance] …great natural treatment for a wide range of mental health problems.”\n\nOn the “What is Ashwagandha?” blog post, dated June 20, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhat_is_ashwagandha), which contains a hyperlink to purchase Brain Balance:\n\n• Under the heading “Benefits of Top Rated Ashwagandha Supplements”:\n\n− “1. Powerful anti-inflammatory…”\n\n− “7. Reduce symptoms of depression”\n\n− “8. Lower cholesterol and triglycerides”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 20, 2022:\n\n• Under the heading “HEALTH BENEFITS OF ASHWAGANDHA” [an ingredient in Brain Balance]:\n\n− “REDUCES BLOOD SUGAR LEVELS…helps in [sic] increased insulin secre-tion and improved insu-lin sensitivity.”\n\n− “HELPS FIGHT CANCER…helps in reducing the growth of tumors, prevents cancer cells from growing”\n\n− “IMPROVES THY-ROID FUNCTION…benefits people suffer-ing from hypothyroid-ism…”\n\n− “REDUCES SYMP-TOMS OF DEPRES-SION… plays an essential role in reducing depression”\n\n− “MAY LOWER CHO-LESTEROL AND TRI-GLYCERIDES…helps lower LDL, and VDL cholesterol and triglyceride levels and increase HDL levels.”\n\n− “CAN PREVENT SEI-ZURES…used in traditional ayurvedic medi-cines as a cure for sei-zures and convulsions.”\n\n− “[P]revents loss of bone mineral density and reduces bone reabsorp-tion.”\n\n− “[H]elp prevent chronic eye diseases.”\n\nImmune System Boost product\n\nOn the “Combating Allergies (The Holistic Way)” blog post, dated October 31, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fcombating-allergies-the-holistic-way), which contains a hyperlink to purchase Immune System Boost:\n\n• “There are natural allergy remedies that have very little to no side effects and can be as effective (if not more) than allergy medications.”\n\n• “If you find yourself constantly effected[sic] by allergies, check out our Immune System Boost.”\n\n• “MSM [an ingredient in Immune System Boost] can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory and antioxidant effects. It binds to the mucosa, blocking host and allergen contact.”\n\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\n\nOn the “Keep your Immune System Naturally Strong During Flu Season” blog post, dated October 24, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fkeep-your-immune-system-naturally-strong-during-flu-season), which contains a hyperlink to purchase Immune System Boost:\n\n• “Silver [an ingredient in Immune System Boost] …well documented natural antibacterial.”\n\nOn the “Naturally Strengthen Your Immune System” blog post, dated February 3, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnaturally-strengthen-your-immune-system), which contains a hyperlink to purchase Immune System Boost:\n\n• “Ambaya Gold’s Immune Boost [this phrase hyperlinks to the Immune System Boost product page] is…anti-microbial, anti-viral...”\n\nOn the “Top Science-Backed Benefits of MSM” blog post, dated October 10, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Ftop-science-backed-benefits-of-msm), which contains a hyperlink to purchase Immune System Boost:\n\n• “Have you heard about MSM [an ingredient in Immune System Boost] …it can help with a variety of conditions, like arthritis and joint pain.”\n\n• Under the heading “Ten Reasons You Should Consider Taking MSM” [an ingredient in Immune System Boost]:\n\n− “2. MSM May Have Anti-inflammatory Effects…may reduce the release of molecules linked to inflammation…inhibits NF-kB, a protein complex involved in inflammatory responses in the body…reduces production of cytokines such as TNF-a and IL-6, which are signaling proteins linked to systemic inflammation.”\n\n− “3. MSM May Treat Arthritis and Joint Pain…Arthritis is probably the most known condition that MSM is used for, especially osteoarthritis. …MSM might lessen the pain associated with it. One study of 100 people…found that treatment with a supplement containing MSM for 12 weeks lessened pain, stiffness and swelling in the joints, compared to a placebo.”\n\n− “4. MSM May Help with Digestive Problems…may improve symptoms in patients with Leaky Gut Syndrome…One study, however, did show oral intake of MSM assisted in protecting gut damage in rats with colitis. MSM supplements may also reduce swelling and discomfort caused by hemorrhoids.”\n\n− “8. MSM May Relieve Allergies…MSM can decrease allergic reactions by lowering inflammation and inhibiting the release of cytokines and prostaglandins thanks to its anti-inflammatory. …It was found that allergy symptoms and lower respiratory symptoms were reduced in people with seasonal allergic rhinitis after taking MSM supplementation for one month.”\n\n− “9. MSM May Help With Parasites…may be an effective treatment for worms, giardia and trichomonas. …MSM coats the gut lining making it impossible for parasites to attach themselves. They are then naturally flushed out of the body. Candida is when the body experiences an overgrowth in fungus which can cause various health problems. MSM changes the PH in your body where Candida can not [sic] thrive in.”\n\nEssensiac product\n\nOn the Essensiac product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fessensiac):\n\n• On the image of your product label:\n\n− “[E]ssiac tea…for…reducing inflammation”\n\n• “Slippery Elm Bark [an ingredient in Essensiac]… can provide anti-inflammatory support.”\n\nOn the “Honoring the Benefits of Slippery Elm Tree” blog post, dated November 7, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fhonoring-the-benefits-of-slippery-elm-tree), which contains a hyperlink to purchase Essensiac:\n\n• “[H]ealth benefits of slippery elm bark [an ingredient in Essensiac] come from the biochemical compounds that are extracted from it. They include mucilage…[m]ucilage: Helps to soothe sore throats and suppress coughs…”\n\n• “Tannins [a component of the slippery elm bark ingredient in the Essensiac product]: Contains…anti-inflammatory properties. Helps lower cholesterol, lower blood pressure…It also has antibacterial properties that help fight tooth decay.”\n\n• “Sterols [a component of the slippery elm bark ingredient in the Essensiac product]: Plant sterols can help to lower cholesterol and prevent cardiovascular disease…”\n\n• “[A]nti-inflammatory properties of fatty acids, tannins and plant sterols [components of the slippery elm bark ingredient in the Essensiac product] …may all contribute to Slippery Elm Bark’s use as an alternative anti-inflammation aid for some chronic conditions.”\n\n• “…Slippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…for help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated November 7, 2022:\n\n• “[S]lippery Elm (Ulmus fulva) [an ingredient in Essensiac] has been used…to help with a variety of health conditions, including: …Sore throat…Cough…Other chronic conditions that develop from inflammation”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated February 4, 2022:\n\n• “It assists the body to create an environment that fights against dis-ease…”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 14, 2021:\n\n• “My morning routine includes…Essensiac for its…anti-inflammatory properties....”\n\nDentist In A Bottle product\n\nOn the Dentist In A Bottle product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fdentist-in-a-bottle):\n\n• “Assistance with the prevention of tooth decay”\n\n• “By reducing harmful bacteria growth and replacing essential minerals, Dentist in a Bottle…assists in the prevention and remediation of gum and tooth decay.”\n\n• “I bought Dentist in a Bottle because my dentist told me I needed a root canal…used it twice a day, soaking the area for about two minutes. The pain and infection subsided after one day and disappeared after one week. A new dentist said that I did not need a root canal…”\n\n• “…[A]lways had problems with my teeth and gums…led to lifelong chronic gum and tooth infections . . . has completely removed the plaque buildup and now my teeth and gums feel clean and healthy…my gums have stopped bleeding. …Dentist In A Bottle”\n\nOn the “Reasons You Should Switch to a Natural Mouthwash Today” blog post, dated September 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Freasons-you-should-switch-to-a-natural-mouthwash-today), which contains a hyperlink to purchase Dentist In A Bottle:\n\n• “Two main ingredients in our mouthwash, Dentist in a Bottle, are Fulvic and Silver. Both are known for their antibacterial properties and can be very effective at reducing harmful bacteria. Using these two together can help prevent gum disease and tooth decay.”\n\n• “…Effective on Bacteria”\n\n• “Assistance with the prevention of tooth decay”\n\n• “Most natural rinses, like ours, contain popular ingredients like peppermint, rosemary, thyme, cinnamon bark, eucalyptus, wintergreen, lemon, clove and birch oil. Research has proven their anti bacterial [sic], antimicrobial and anti-inflammatory properties’”\n\n• “‘Oral infections can result in inflammation in other parts of the body since our oral mucosa has a direct pathway to the bloodstream.’ …Our Dentist in a Bottle offers overall improvement in oral health...”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated September 5, 2022:\n\n• “Fulvic and Silver [ingredients in Dentist In A Bottle] are known for their antibacterial properties and can be very effective at reducing harmful bacteria.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 8, 2022:\n\n• “By reducing harmful bacteria growth and replacing essential mineral, Dentist in a Bottle, freshens the mouth…while assisting in the prevention and remediation of gum and tooth decay.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated July 12, 2021:\n\n• “Our effective mouthwash is a natural alternative to toxic mouthwashes…reduces harmful bacteria growth and replaces essential minerals!”\n\nFulvic Green product\n\nOn the “The Surprising Benefits of Chlorophyll” blog post, dated August 1, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-surprising-benefits-of-chlorophyll), which contains a hyperlink to purchase Fulvic Green:\n\n• Under the heading “10 Amazing Benefits of Chlorophyll” [an ingredient in Fulvic Green]:\n\n− “2. [R]epair small gut wounds.”\n\n− “5. It’s also an excellent blood purifier that helps prevent or even reverse dis-ease [sic] in your body.”\n\nOn the “Superfood Hawaiian Spirulina” blog post, dated June 27, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fsuperfood_hawaiian_spirulina), which contains a hyperlink to purchase Fulvic Green:\n\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\n\n− “[R]educes allergy symptoms”\n\n− “[G]reat anti-inflammation”\n\n− “[C]an reduce risk of cancer”\n\n− “[P]revents & helps with cardiovascular disease”\n\n• Under the heading “Why Take Hawaiian Spirulina [an ingredient in Fulvic Green] Supplements?”:\n\n− “Lowers Blood Pressure…A great way to lower your blood pressure is to add spirulina to your diet.”\n\n− “[S]pirulina …Foods high in antioxidants have been proven to lower inflammation and eliminate free radicals which can prevent degenerative brain diseases…spirulina helps with ADHD.”\n\n− “Lower Blood Sugar…Spirulina can lower blood sugar levels.”\n\n− “Can Reduce Risk of Cancer…Adding spirulina to your diet can reduce risk of cancer. Testing…showed the spirulina increased the production of antibodies as well as infection-fighting proteins and cells that help to protect against cancer…spirulina could have potential to prevent a number of other diseases”\n\n− “Protect Against Liver Disease…Protection against liver disease”\n\n− “Detox from Heavy Metals…Spirulina acts as a detox for your body, especially from heavy metals, like arsenic. …United States is one of the countries that are most affected by arsenic poisoning. Spirulina is a natural remedy for getting rid of that arsenic and other metals that have accumulated in the body.”\n\n− “Reduce Cholesterol…Spirulina can greatly reduce cholesterol as well. Cholesterol can be a problem that leads to heart disease…Anyone at risk for heart disease…should consider adding spirulina to their diet.”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated August 1, 2022:\n\n• Under the heading “CHLOROPHYLL [an ingredient in Fulvic Green] BENEFITS”:\n\n− “ANTI-CARCINOGENIC”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated June 27, 2022:\n\n• Under the heading “Benefits of Spirulina” [an ingredient in Fulvic Green]:\n\n− “[R]educes allergy symptoms”\n\n− “[G]reat anti-inflammation”\n\n− “[C]an reduce risk of cancer”\n\nSilver Solution product\n\nOn the Silver Solution product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-solutions):\n\n• On the image of your product label:\n\n− [W]ide-spectrum antibacterial solution minimizes risk of infections”\n\n• “Silver [an ingredient in Silver Solution] is considered a very powerful antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\n\nOn the “The Many Uses of Silver” blog post, dated December 27, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe-many-uses-of-silver), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\n\n• “Taking Silver [an ingredient in Silver Solution] orally can assist with symptoms of colds, sinus infections…can lessen the symptoms of allergies and arthritis.”\n\n• “Silver [an ingredient in Silver Solution] can fight hundreds of disease causing [sic] bacteria & viruses...”\n\n• “If you don't like taking antibiotics for urinary tract or bladder infections, silver [an ingredient in Silver Solution], a natural alternative can assist to clear up your system by taking 1\u002F2 teaspoon of our Silver orally…”\n\nOn the “What's the Difference Between Silver and Gold?” blog post, dated December 13, 2021, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fwhats-the-difference-between-silver-and-gold), which refers to your Silver Solution product available for purchase on your website (www.ambayagold.com):\n\n• “Silver [an ingredient in Silver Solution] ions cause inhibition of bacterial growth. Therefore they are naturally antibacterial. Silver ions, and their interaction with enzymes and proteins play an important role in antibacterial efficacy in the body.”\n\n• “…Silver [an ingredient in Silver Solution] can be used as a non-toxic, safe, and easy to use supplement as a natural antibiotic…”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated December 19, 2021:\n\n• “Silver [an ingredient in Silver Solution] is naturally antibacterial…”\n\nDetox Cleanse Renew\n\nOn the Essentials Kit webpage (https:\u002F\u002Fambayagold.com\u002Fpages\u002Fthe-essentials-kit), which contains a hyperlink to purchase Detox Cleanse Renew:\n\n• “RESTORE FULVIC [an ingredient in Detox Cleanse Renew] RESTORE HEALTH…Toxic build up and mineral deficiencies are two of the biggest health issues that people face today and can lead to symptoms like: …Blood Sugar Imbalances…Insomnia…”\n\n• “BENEFITS OF FULVIC… REDUCES INFLAMMATION …FIGHTS PATHOGENS...”\n\nOn the “The Best Detox For Environmental Toxins And Radiation” blog post, dated July 4, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fthe_best_detox_for_environmental_toxins_and_radiation), which contains a hyperlink to purchase Detox Cleanse Renew:\n\n• “[C]ancers, disease and birth defects are increasing in both humans and animals due to environmental pollutants full of heavy metals and other toxins. …The best way to remove toxic heavy metals from environmental pollution and radiation from the body is by chelating them out with a product…Clinoptilolite Zeolite [an ingredient in Detox Cleanse Renew] is by far the best way to combat these toxins.”\n\n• “The miracle toxin magnet, Zeolite [an ingredient in Detox Cleanse Renew] …draws heavy metals and toxins to the Zeolite…enabling the toxins to be safely eliminated…”\n\n• “As the heavy metals and toxins are eliminated the immune system can grow strong again to better fight off viruses, bacteria and deformed cells...”\n\n• “Routinely detoxifying with zeolite [an ingredient in Detox Cleanse Renew] is necessary because when you’re exposed to toxins, your body stores them in your cells. Over time, toxins and radiation can build up to dangerous levels—leading to disease, chronic fatigue, brain fog and even cancer.”\n\nSilver Spray product\n\nOn the Silver Spray product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fag-liquid-silver-spray):\n\n“AMBAYA GOLD . . . SILVER SPRAY . . . wide-spectrum antibacterial solution minimizes risk of infections” [from your product label for SILVER SPRAY]\n\n“Silver Spray . . . Natural antibacterial . . . Disinfects like hydrogen peroxide without the burn . . .” [https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmSADzUva93\u002F and https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002Fposts\u002Fpfbid02Hkd21pHbyrU5TL1MaAgRh1E9CJWtbKVenM5kyQaRtKtC4G9XL2ZMZZ58u7LApMGQl]\n\nMagnesium Oil Spray product\n\n“Our fast acting topical Magnesium Oil Spray offers the benefits of pure Magnesium Oil in a proprietary Fulvic base. . . .This convenient spray is designed is designed to provide relief from body tension and soreness quickly and effectively. . . .For muscle cramps or pains, spray directly on problem area.” [from your product website, https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fmagnesium-oil-spray]\n\nSpecifically, these products are intended for use as a first aid antiseptic, and an external analgesic, respectively1\n\nUnapproved New Drugs\n\nYour Brain Balance, Immune System Boost, Dentist In A Bottle, Essensiac, Fulvic Green, Silver Solution, and Detox Cleanse Renew products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nFurther, your “Silver Spray” product, containing silver, is a first aid antiseptic subject to section 505G of the FD&C Act, which governs nonprescription drugs marketed without an approved application. Specifically, your silver-containing product falls under section 505G(a)(5) of the FD&C Act, because FDA has determined that no silver containing OTC drugs are generally recognized as safe and effective under a final determination issued under 21 CFR part 330.2, 3 Therefore, Silver Spray is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for this drug product. Accordingly, “Silver Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nYour “Magnesium Oil Spray” is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).4\n\nHowever, “Magnesium Oil Spray” does not conform to the conditions specified in the final administrative order for the reasons described below. Your “Magnesium Oil Spray” is not formulated and labeled as an external analgesic counterirritant drug product that is consistent with the final administrative order. Specifically, your product is labeled to contain the ingredients magnesium chloride, fulvic, indium, aloe vera, pyridoxine HCl (B6), MSM, and plant based phytonutrients, all of which are outside of the final applicable administrative order. According to 21 CFR 201.66(b)(2), an “active ingredient” means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans. Although your firm does not specifically list these ingredients as active ingredients, your product website includes statements that claim this combination of ingredients is “designed to provide relief from body tension and soreness” as a treatment for symptoms related to magnesium deficiency that include “leg cramps and muscle soreness,” along with “migraines, insomnia, [and] fatigue.” Such statements demonstrate that those ingredients are considered “active ingredients” as defined by 21 CFR 201.66(b)(2) because this combination of ingredients is intended to furnish pharmacological activity. However, this combination of active ingredients is not permitted under the applicable final order nor are any of these ingredients permitted as a single active ingredient in an external analgesic product under the final administrative order.\n\nThus, as formulated and labeled, “Magnesium Oil Spray” does not comply with the final administrative order described above or any applicable proposed or final rule. FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Magnesium Oil Spray” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Therefore, “Magnesium Oil Spray” is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, “Magnesium Oil Spray” is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nIn addition, “Silver Spray” and “Magnesium Oil Spray” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nMisbranded Drugs\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Brain Balance, Silver Solution, Dentist In A Bottle, Essensiac, Fulvic Green, and Detox Cleanse Renew products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nUnapproved New Animal Drugs\n\nBased on our review of your website www.ambayagold.com and your social media website www.facebook.com\u002FAmbayaGoldHealth, your Pet Health+ product is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\n\nExamples of claims observed on your website and social media website that provide evidence that your product is intended for use as a drug include:\n\nPet Health+ product\n\nOn the Pet Health+ product webpage (https:\u002F\u002Fambayagold.com\u002Fproducts\u002Fpet-health):\n\n• “Detox of heavy metals, chemicals and other toxins* Protection from worms, parasites, and fungus* Natural anti-inflammatory agents*…Protection from infection*…Accelerated wound recovery*”\n\n• “In our Pet Health +, our clean sourced Clinoptilolite Zeolite is formulated and suspended in a freshwater Humic and Fulvic liquid solution. The Humic helps to penetrate deep into the cells, providing a cleansing action by safely binding harmful toxins.”\n\n• “Why Silver and Gold? Monatomic Silver is considered a powerful natural antibacterial element because its ions cause inhibition of bacterial growth. Silver ions' interaction with enzymes and proteins play an important and essential role in antibacterial efficacy in the body.”\n\n• A customer testimonial from 2\u002F18\u002F2022 states, “This product has help [sic] to support for our new dog’s… anxiety issues…”\n\nOn the “Natural Remedies for Pain Relief in Dogs” blog post, dated December 5, 2022, (https:\u002F\u002Fambayagold.com\u002Fblogs\u002Fnews\u002Fnatural-remedies-for-pain-relief-in-dogs), which contains a hyperlink to purchase Pet Health+:\n\n• “Holistic pet supplements and pain relievers can have a wide range of benefits like: …Assistance with detox of heavy metals, chemicals, and other toxins…Protection from worms, parasites, fungus, and infection…Natural anti-inflammatory agents…Accelerated wound recovery…All of the above benefits have been reported by users of our pet multivitamin, Pet Health+ [hyperlinks to the Pet Health+ product page].\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated May 15, 2022:\n\n• “Pet Health+ helps…Assist with detox of heavy metals, chemicals, and other toxins…Protect from worms, parasites, fungus, and infection”\n\nOn your Facebook account (https:\u002F\u002Fwww.facebook.com\u002FAmbayaGoldHealth\u002F) post, dated October 8, 2021, with three photos of a cat:\n\n• “…[H]er cat’s obsessive grooming…This caused her to form “hot spots” where the skin had become inflamed and formed open wounds. …When modern medicine didn’t help, she tried Pet Health+ and here are her results after ONLY a week and a half!”\n\nYour Pet Health+ product is a \"new animal drug\" under section 201(v) of the Act [21 U.S.C. § 321(v)] because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Pet Health+ is not approved, conditionally approved, or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the Act [21 U.S.C. § 360b(a)] and adulterated under section 501(a)(5) of the Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Carrie Jolly, Compliance Officer, via email at carrie.jolly@fda.hhs.gov or at 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado. You may reach Ms. Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –\n\nWest Division 4\n\n_____________________\n\n1 It is not clear whether you intend your “Silver Spray” and “Magnesium Oil Spray” products to be marketed as dietary supplements. Your firm lists these two products on your website under the heading “Supplements.” Under section 201(ff)(2)(A)(i) of the FD&C Act [21 U.S.C. § 321(ff)(2)(A)(i)], a dietary supplement is defined, among other things, as a product intended for ingestion. Topical products and other products that are not intended for ingestion cannot be dietary supplements.\n\n2 See 21 CFR 310.548(b): \"Any OTC drug product containing colloidal silver ingredients or silver salts that is labeled, represented, or promoted for the treatment and\u002For prevention of any disease is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the Act) for which an approved application or abbreviated application under section 505 of the Act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the Act.”\n\n3 FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(8)(i). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) are deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC000007, available at OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n\n4 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR. part 330 prior to enactment of the CARES Act. In the case of OTC anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).","Ambaya Gold Health Products, LLC","ambaya-gold-health-products-llc-648130-12052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambaya-gold-health-products-llc-648130-12052023","2026-10-26T08:07:54.362384+00:00","2024-04-02","648130","Food & Beverages","Division of Human and Animal Food Operations West IV","Pilar G. Martin","2026-08-20T00:12:07.904+00:00","VIA UPS","2023-12-05",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":23,"posted_date":91,"marcs_cms_no":92,"product_type":93,"closeout_date":19,"issuing_office":82,"recipient_name":94,"body_fetched_at":95,"delivery_method":96,"recipient_title":19,"reference_number":19,"action_taken_date":97,"medical_device_id":19,"response_letter_date":19},177,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-29T04:00:00Z\">04\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foptihealth-products-inc-704899-04292026\">OptiHealth Products, Inc.\u003C\u002Fa>","Human Foods Program","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Russell Dickson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>OptiHealth Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>275 River Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint James\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11780\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@optihealthstore.com\"> support@optihealthstore.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 29, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 704899\u003C\u002Fp>\u003Cp>Dear Mr. Dickson:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Foptihealthproducts.com in December 2025 and has determined that you take orders there for your product Super Antioxidant (OPCXtra). We also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002FOptiHealthProducts where you direct consumers to your website,\u003Cbr>https:\u002F\u002Foptihealthproducts.com\u002F to purchase your products. The claims on your website, https:\u002F\u002Foptihealthproducts.com\u002F establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\u003Cp>“\u003Cstrong>6 Remarkable Benefits of Bilberry Extract\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002F6-remarkable-benefits-of-bilberry-extract\u003C\u002Fp>\u003Cul>\u003Cli>Under the section, \u003Cstrong>“Heart Health Support”\u003C\u002Fstrong>\u003Cbr>o “The antioxidants in bilberries are believed to help reduce the risk of heart disease by improving blood vessel function, reducing blood pressure, and lowering cholesterol levels…”\u003C\u002Fli>\u003Cli>Under the section, \u003Cstrong>“Diabetes Management”\u003C\u002Fstrong>\u003Cbr>o “Bilberry extract has shown promise in helping regulate blood sugar levels, making it a potential ally for individuals with diabetes or those at risk of developing the condition…”\u003C\u002Fli>\u003Cli>Under the section, \u003Cstrong>“Anti- Inflammatory Properties”\u003C\u002Fstrong>\u003Cbr>o “Chronic inflammation is linked to a wide range of health issues, from arthritis to cancer. Bilberry's anti-inflammatory properties, may help alleviate inflammation and reduce the risk of chronic diseases associated with prolonged inflammation.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>“Antioxidants and Aging: The Key to a Youthful Glow and Enhance Health”\u003C\u002Fstrong> https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fantioxidants-and-aging-the-key-to-a-youthful-glow-and-enhanced-health\u003C\u002Fp>\u003Cul>\u003Cli>Under the section, \u003Cstrong>“Cognitive Function”\u003C\u002Fstrong>\u003Cbr>o “Antioxidants can help reduce oxidative damage in brain cells, potentially lowering the risk of age-related cognitive decline and diseases like Alzheimer's.”\u003C\u002Fli>\u003Cli>Under the section, \u003Cstrong>“Cardiovascular Health”\u003C\u002Fstrong>\u003Cbr>o “Antioxidants like flavonoids and vitamin E can improve heart health by reducing oxidation of cholesterol, lowering blood pressure, and improving arterial flexibility. This can decrease the risk of cardiovascular diseases, which are a major health concern for aging populations.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This post links to the following blog on the firm’s website “Seeing Clearly: Combating Oxidative Stress and Macular Degeneration – OptiHealth Products”\u003Cbr>o “[A]s we age, the risk of vision-related conditions such as macular degeneration becomes increasingly prevalent. Central to this degenerative process is oxidative stress, which wreaks havoc on the delicate structures of the eye. In this blog, we explore the intricate relationship between oxidative stress and macular degeneration, shedding light on how OPC antioxidants offer a beacon of hope in preserving vision and ocular health.”\u003C\u002Fp>\u003Cul>\u003Cli>Under the section \u003Cstrong>“Understanding Oxidative Stress and Macular Degeneration”\u003C\u002Fstrong>\u003Cbr>o “In the context of ocular health, oxidative stress plays a significant role in the development and progression of macular degeneration. The macula, a small but crucial part of the retina responsible for central vision, is particularly vulnerable to oxidative damage. Over time, this oxidative assault leads to the deterioration of macular tissues, resulting in blurred vision, distortion, and eventual vision loss—a condition known as age-related macular degeneration (AMD).”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>“The Neuroprotective Benefits of OPC Antioxidants” \u003C\u002Fstrong>https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fthe-neuroprotective-benefits-of-opc-antioxidants\u003Cbr>o “\u003Cstrong>Supporting Cognitive Function\u003C\u002Fstrong>: Cognitive decline is a hallmark feature of aging and neurodegenerative diseases such as Alzheimer's and Parkinson's. OPC antioxidants offer a ray of hope by promoting cognitive function and memory retention, potentially slowing the progression of age-related cognitive decline.”\u003C\u002Fp>\u003Cp>Your product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your Super Antioxidant (OPCXtra) product is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Super Antioxidant (OPCXtra) product fails to bear adequate directions for its intended use, and therefore the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be addressed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplement@fda.hhs.gov. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003Cstrong> Bilbery is an ingredient in the firm’s product “OPXtra” \u003C\u002Fstrong>https:\u002F\u002Foptihealthproducts.com\u002Fproducts\u002Fopcxtra-isotonic-opc-super-antioxidant-supplement\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Russell Dickson\n\nRecipient Title\n\nPresident\n\nOptiHealth Products, Inc.\n\n275 River Rd\n\nSaint James, NY 11780\n\nUnited States\n\nsupport@optihealthstore.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nApril 29, 2026\nWARNING LETTER\nCMS # 704899\nDear Mr. Dickson:\nThe U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Foptihealthproducts.com in December 2025 and has determined that you take orders there for your product Super Antioxidant (OPCXtra). We also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002FOptiHealthProducts where you direct consumers to your website,\nhttps:\u002F\u002Foptihealthproducts.com\u002F to purchase your products. The claims on your website, https:\u002F\u002Foptihealthproducts.com\u002F establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\nExamples of some of the claims that provide evidence that your product is intended for use as a drug include:\n“6 Remarkable Benefits of Bilberry Extract1” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002F6-remarkable-benefits-of-bilberry-extract\nUnder the section, “Heart Health Support”\no “The antioxidants in bilberries are believed to help reduce the risk of heart disease by improving blood vessel function, reducing blood pressure, and lowering cholesterol levels…”\nUnder the section, “Diabetes Management”\no “Bilberry extract has shown promise in helping regulate blood sugar levels, making it a potential ally for individuals with diabetes or those at risk of developing the condition…”\nUnder the section, “Anti- Inflammatory Properties”\no “Chronic inflammation is linked to a wide range of health issues, from arthritis to cancer. Bilberry's anti-inflammatory properties, may help alleviate inflammation and reduce the risk of chronic diseases associated with prolonged inflammation.”\n“Antioxidants and Aging: The Key to a Youthful Glow and Enhance Health” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fantioxidants-and-aging-the-key-to-a-youthful-glow-and-enhanced-health\nUnder the section, “Cognitive Function”\no “Antioxidants can help reduce oxidative damage in brain cells, potentially lowering the risk of age-related cognitive decline and diseases like Alzheimer's.”\nUnder the section, “Cardiovascular Health”\no “Antioxidants like flavonoids and vitamin E can improve heart health by reducing oxidation of cholesterol, lowering blood pressure, and improving arterial flexibility. This can decrease the risk of cardiovascular diseases, which are a major health concern for aging populations.”\nThis post links to the following blog on the firm’s website “Seeing Clearly: Combating Oxidative Stress and Macular Degeneration – OptiHealth Products”\no “[A]s we age, the risk of vision-related conditions such as macular degeneration becomes increasingly prevalent. Central to this degenerative process is oxidative stress, which wreaks havoc on the delicate structures of the eye. In this blog, we explore the intricate relationship between oxidative stress and macular degeneration, shedding light on how OPC antioxidants offer a beacon of hope in preserving vision and ocular health.”\nUnder the section “Understanding Oxidative Stress and Macular Degeneration”\no “In the context of ocular health, oxidative stress plays a significant role in the development and progression of macular degeneration. The macula, a small but crucial part of the retina responsible for central vision, is particularly vulnerable to oxidative damage. Over time, this oxidative assault leads to the deterioration of macular tissues, resulting in blurred vision, distortion, and eventual vision loss—a condition known as age-related macular degeneration (AMD).”\n“The Neuroprotective Benefits of OPC Antioxidants” https:\u002F\u002Foptihealthproducts.com\u002Fblogs\u002Fnews\u002Fthe-neuroprotective-benefits-of-opc-antioxidants\no “Supporting Cognitive Function: Cognitive decline is a hallmark feature of aging and neurodegenerative diseases such as Alzheimer's and Parkinson's. OPC antioxidants offer a ray of hope by promoting cognitive function and memory retention, potentially slowing the progression of age-related cognitive decline.”\nYour product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour Super Antioxidant (OPCXtra) product is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Super Antioxidant (OPCXtra) product fails to bear adequate directions for its intended use, and therefore the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be addressed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplement@fda.hhs.gov. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\n____________________\n1 Bilbery is an ingredient in the firm’s product “OPXtra” https:\u002F\u002Foptihealthproducts.com\u002Fproducts\u002Fopcxtra-isotonic-opc-super-antioxidant-supplement","OptiHealth Products, Inc.","optihealth-products-inc-704899-04292026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foptihealth-products-inc-704899-04292026","2026-10-26T08:09:38.562979+00:00","2026-05-12","704899","Dietary Supplements","Mr. Russell Dickson","2026-08-19T04:43:05.134+00:00","Via Email","2026-04-29",{"id":99,"raw":100,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":23,"posted_date":113,"marcs_cms_no":114,"product_type":115,"closeout_date":19,"issuing_office":104,"recipient_name":116,"body_fetched_at":117,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":118,"medical_device_id":19,"response_letter_date":19},2731,[101,102,103,104,105,13,13,13],"\u003Ctime datetime=\"2022-04-19T13:20:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-13T04:00:00Z\">04\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-earth-health-products-llc-628383-04132022\">True Earth Health Products, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jonathan Greenhut\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>True Earth Health Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>260 Smith St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Farmingdale\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11735\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:CustomerCare@SheerScience.com\"> CustomerCare@SheerScience.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 13, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Greenhut,\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. Plexaderm® Skincare DARK SPOT FADE GEL drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Plexaderm® Skincare DARK SPOT FADE GEL is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product label and labeling from your website Sheerscience.com, where the product is available for purchase, that provide evidence of the intended use (as defined in 21 CFR 201.128) of your product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Dark Spot Fade Gel\u003C\u002Fstrong> is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration and age spots. . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Active Ingredients\u003C\u002Fstrong> Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Lightener . . . \u003Cstrong>Uses\u003C\u002Fstrong> For the gradual fading of ■ dark spots ■ freckles ■ age spots ■ brownish skin discolorations” [from your Plexaderm® Skincare DARK SPOT FADE GEL label]\u003C\u002Fp>\n\n\u003Cp>“Dark Spot Fade Gel is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration, and age spots. It combines the proven benefits of Hydroquinone with a powerful blend of emollients, exfoliating and brightening ingredients to reveal a visibly softer, smoother, more balanced complexion. . . . This product will help balance uneven skin tone from sun damage, age spots, and hyperpigmentation that have formed on the skin’s surface over the years.” [from your website https:\u002F\u002Fwww.sheerscience.com\u002Fskincare\u002F]\u003C\u002Fp>\n\n\u003Cp>Plexaderm® Skincare DARK SPOT FADE GEL is a skin bleaching drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, Plexaderm® Skincare DARK SPOT FADE GEL is deemed to be a new drug under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for Plexaderm® Skincare DARK SPOT FADE GEL. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Moreover, Plexaderm® Skincare DARK SPOT FADE GEL is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is deemed as such under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor is the skin bleaching\u002Fskin lightening drug product named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On August 29, 2006 FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJonathan Greenhut\n\nRecipient Title\n\nChief Executive Officer\n\nTrue Earth Health Products, LLC\n\n260 Smith St\n\nFarmingdale, NY 11735\n\nUnited States\n\nCustomerCare@SheerScience.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: April 13, 2022\n\nDear Mr. Greenhut,\n\nThis letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. Plexaderm® Skincare DARK SPOT FADE GEL drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nPlexaderm® Skincare DARK SPOT FADE GEL is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\n\nExamples of the claims observed on your product label and labeling from your website Sheerscience.com, where the product is available for purchase, that provide evidence of the intended use (as defined in 21 CFR 201.128) of your product include, but may not be limited to, the following:\n\n“Dark Spot Fade Gel is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration and age spots. . . . Drug Facts . . . Active Ingredients Hydroquinone 2% . . . Purpose . . . Skin Lightener . . . Uses For the gradual fading of ■ dark spots ■ freckles ■ age spots ■ brownish skin discolorations” [from your Plexaderm® Skincare DARK SPOT FADE GEL label]\n\n“Dark Spot Fade Gel is the ultimate skin brightening treatment for hyperpigmentation, skin discoloration, and age spots. It combines the proven benefits of Hydroquinone with a powerful blend of emollients, exfoliating and brightening ingredients to reveal a visibly softer, smoother, more balanced complexion. . . . This product will help balance uneven skin tone from sun damage, age spots, and hyperpigmentation that have formed on the skin’s surface over the years.” [from your website https:\u002F\u002Fwww.sheerscience.com\u002Fskincare\u002F]\n\nPlexaderm® Skincare DARK SPOT FADE GEL is a skin bleaching drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, Plexaderm® Skincare DARK SPOT FADE GEL is deemed to be a new drug under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for Plexaderm® Skincare DARK SPOT FADE GEL. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMoreover, Plexaderm® Skincare DARK SPOT FADE GEL is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is deemed as such under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor is the skin bleaching\u002Fskin lightening drug product named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n________________________\n\n1 On August 29, 2006 FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\n\n2 Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.","True Earth Health Products, LLC","true-earth-health-products-llc-628383-04132022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-earth-health-products-llc-628383-04132022","2026-10-26T08:10:15.522721+00:00","2022-04-19","628383","Drugs","Jonathan Greenhut","2026-08-20T02:00:24.289+00:00","2022-04-13",{"id":120,"raw":121,"subject":125,"body_html":126,"body_text":127,"firm_name":128,"letter_id":129,"created_at":88,"fei_number":19,"letter_url":130,"updated_at":131,"action_type":22,"case_status":23,"posted_date":132,"marcs_cms_no":133,"product_type":134,"closeout_date":19,"issuing_office":124,"recipient_name":135,"body_fetched_at":136,"delivery_method":137,"recipient_title":19,"reference_number":138,"action_taken_date":132,"medical_device_id":19,"response_letter_date":19},345,[122,122,123,124,125,13,13,13],"\u003Ctime datetime=\"2026-02-10T05:00:00Z\">02\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodx-health-720762-02102026\">ProDx Health\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-720762\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andreas Kogelnik, MD, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder &amp; Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ProDx Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1190 O'Brien Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Menlo Park\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94025\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prodxhealth.com\"> support@prodxhealth.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 10, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-720762\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Andreas Kogelnik:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA or the Agency) has learned that your firm, ProDx Health, is offering for sale in the United States human immunodeficiency virus (HIV) serological diagnostic sample self-collection kits (hereinafter, your “sample self-collection kits”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003Ca id=\"footnoteref1_ygaot82\" href=\"#footnote1_ygaot82\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; &nbsp;Under section 201(h)(1) of the FD&amp;C Act, 21 U.S.C. 321(h)(1), your sample self-collection kits are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>FDA has reviewed your company’s website at https:\u002F\u002Fprodxhealth.com (last visited February 2026) and your firm’s February 3, 2026 response to previous FDA correspondence. &nbsp;Based on our review of these materials, your firm offers its sample self-collection kits for delivery to individuals and intends for these individuals to use the kits to self-collect serological samples and ship those samples to laboratories for HIV testing. FDA has determined that your sample self-collection kits are adulterated under section 501(f)(1)(B) of the FD&amp;C Act, 21 U.S.C. 351(f)(1)(B) because they do not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&amp;C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&amp;C Act, 21 U.S.C. 360j(g). &nbsp;Your sample self-collection kits are also misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the Agency, as required by section 510(k) of the FD&amp;C Act, 21 U.S.C. 360(k). &nbsp;\u003C\u002Fp>\u003Cp>FDA has not authorized your firm’s sample self-collection kits for use in HIV serological diagnostic testing. Notably, this letter focuses on your sample self-collection kits and is not intended to be a comprehensive list of potential issues with your firm’s products.\u003C\u002Fp>\u003Cp>Without appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your sample self-collection kits. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We note that there are FDA-approved over-the-counter HIV self-tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your sample self-collection kits. Your firm should take prompt action to address the violations identified in this letter. &nbsp;Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. &nbsp;If you believe that your firm’s sample self-collection kits are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. &nbsp;Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_ygaot82\">\u003Ca href=\"#footnoteref1_ygaot82\">1\u003C\u002Fa>The letter FDA issued you on January 8, 2026, erroneously referred to your device as a “dried blood\nspot (DBS) card” self-collection kit. We have removed that letter from our website and are issuing this\namended Warning Letter.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-720762\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nAndreas Kogelnik, MD, PhD\n\nRecipient Title\n\nFounder & Chief Executive Officer\n\nProDx Health\n\n1190 O'Brien Dr\n\nMenlo Park, CA 94025\n\nUnited States\n\nsupport@prodxhealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nFebruary 10, 2026\nCBER 26-720762\nDear Dr. Andreas Kogelnik:\nThe United States Food and Drug Administration (FDA or the Agency) has learned that your firm, ProDx Health, is offering for sale in the United States human immunodeficiency virus (HIV) serological diagnostic sample self-collection kits (hereinafter, your “sample self-collection kits”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).1 Under section 201(h)(1) of the FD&C Act, 21 U.S.C. 321(h)(1), your sample self-collection kits are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nFDA has reviewed your company’s website at https:\u002F\u002Fprodxhealth.com (last visited February 2026) and your firm’s February 3, 2026 response to previous FDA correspondence. Based on our review of these materials, your firm offers its sample self-collection kits for delivery to individuals and intends for these individuals to use the kits to self-collect serological samples and ship those samples to laboratories for HIV testing. FDA has determined that your sample self-collection kits are adulterated under section 501(f)(1)(B) of the FD&C Act, 21 U.S.C. 351(f)(1)(B) because they do not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C. 360j(g). Your sample self-collection kits are also misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the Agency, as required by section 510(k) of the FD&C Act, 21 U.S.C. 360(k).\nFDA has not authorized your firm’s sample self-collection kits for use in HIV serological diagnostic testing. Notably, this letter focuses on your sample self-collection kits and is not intended to be a comprehensive list of potential issues with your firm’s products.\nWithout appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your sample self-collection kits. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We note that there are FDA-approved over-the-counter HIV self-tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your sample self-collection kits. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your firm’s sample self-collection kits are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n\n1The letter FDA issued you on January 8, 2026, erroneously referred to your device as a “dried blood\nspot (DBS) card” self-collection kit. We have removed that letter from our website and are issuing this\namended Warning Letter.","ProDx Health","prodx-health-720762-02102026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodx-health-720762-02102026","2026-10-26T08:09:44.671953+00:00","2026-02-10","720762","Biologics","Andreas Kogelnik, MD, PhD","2026-08-19T05:07:15.753+00:00","Via UPS and EMAIL","CBER 26-720762",{"id":140,"raw":141,"subject":146,"body_html":147,"body_text":148,"firm_name":149,"letter_id":150,"created_at":88,"fei_number":19,"letter_url":151,"updated_at":152,"action_type":22,"case_status":23,"posted_date":153,"marcs_cms_no":154,"product_type":155,"closeout_date":19,"issuing_office":145,"recipient_name":156,"body_fetched_at":157,"delivery_method":158,"recipient_title":19,"reference_number":154,"action_taken_date":159,"medical_device_id":19,"response_letter_date":19},145,[142,143,144,145,146,13,13,13],"\u003Ctime datetime=\"2026-05-26T04:00:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026\">GSC Products, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>729653\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wayne Perry\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GSC Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1441 Van Patten Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Duanesburg\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12056-2522\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Wayne Perry:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 331(a).\u003C\u002Fp>\u003Cp>This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Based on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cstrong>Drug Facts . . . Purpose\u003C\u002Fstrong>…Relieves pain and nausea…Relieves pain &amp; inflammation…Increases circulation . . . \u003Cstrong>Uses\u003C\u002Fstrong>: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\u003C\u002Fp>\u003Cp>“Powerful &amp; Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\u003Cbr>https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\u003C\u002Fp>\u003Cp>Your SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\u003C\u002Fp>\u003Cp>In addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\u003C\u002Fp>\u003Cp>Furthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\u003C\u002Fp>\u003Cp>Thus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nReference #:\n\n729653\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nWayne Perry\n\nRecipient Title\n\nFounder and President\n\nGSC Products, LLC\n\n1441 Van Patten Rd\n\nDuanesburg, NY 12056-2522\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nMay 18, 2026\nWARNING LETTER\nTo Wayne Perry:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your websites. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of your websites, https:\u002F\u002Fsinusplumber.com and https:\u002F\u002Fwww.greensations.com, in March 2026. Your https:\u002F\u002Fsinusplumber.com website also directs consumers to your Amazon storefront to purchase your product. Based on our review, your SINUS PLUMBER Headache Nasal Spray product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&C Act, 21 U.S.C. 331(d) and 331(a).\nThis review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nUnapproved New Drug Violations\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nBased on a review of your websites, your SINUS PLUMBER Headache Nasal Spray is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your websites, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\n“Drug Facts . . . Purpose…Relieves pain and nausea…Relieves pain & inflammation…Increases circulation . . . Uses: For the temporary relief of: ■ General headache and migraine symptoms.” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin]\n“Powerful & Fast Headache Relief √ Tension √ Clusters √ Migraines” [from the product label on the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and\nhttps:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\n“Sinus Plumber Headache Nasal Spray targets a variety of headaches with the pain relief power of capsaicin, feverfew, peppermint and caffeine.”…“This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” [from the Sinus Plumber product website https:\u002F\u002Fsinusplumber.com\u002Fproducts\u002Fsinus-plumber-migraine-headache-nasal-spray-with-capsaicin and https:\u002F\u002Fwww.greensations.com\u002FCayenne-Pepper-Headache-Nasal-Spray-p\u002Fsp-4.htm]\nBased on the above labeling evidence, SINUS PLUMBER Headache Nasal Spray is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your SINUS PLUMBER Headache Nasal Spray, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).1 However, SINUS PLUMBER Headache Nasal Spray does not conform to the conditions specified in M013 for the reasons described below.\nYour SINUS PLUMBER Headache Nasal Spray is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\nIn addition, your SINUS PLUMBER Headache Nasal Spray labeling includes intended uses that are not permitted for OTC internal analgesic drug products in M013. Specifically, claims such as “This formula is commonly used for headaches that feel sinus-related or pressure-driven, including sinus headaches, tension headaches, migraines, and cluster headaches.” and “Purpose . . . Relieves . . . nausea . . . inflammation . . . increase circulation” that suggest SINUS PLUMBER Headache Nasal Spray is intended to treat sinuses, tension, clusters, and migraines, and is intended to relieve nausea, inflammation, and increase circulation go beyond the general intended uses for an OTC internal analgesic drug product and do not conform to the permitted uses set forth in M013.50(b).\nFurthermore, your SINUS PLUMBER Headache Nasal Spray is formulated with active ingredients that are not permitted for OTC internal analgesic drug products under M013.10. Specifically, feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous, and peppermint oil are not permitted as single active ingredients under M013.10, nor is this combination of active ingredients permitted under M013.20. Therefore, your SINSUS PLUMBER Headache Nasal Spray product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\nThus, your SINUS PLUMBER Headache Nasal Spray product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.2 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\nThe introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, SINUS PLUMBER Headache Nasal Spray is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729653” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________\n1 M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf]\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINUS PLUMBER Headache Nasal Spray is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","GSC Products, LLC","gsc-products-llc-729653-05182026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsc-products-llc-729653-05182026","2026-10-26T08:08:50.940349+00:00","2026-05-26","729653","Drugs Over-the-Counter Drugs","Wayne Perry","2026-08-19T04:39:54.735+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2026-05-18",{"id":161,"raw":162,"subject":167,"body_html":168,"body_text":169,"firm_name":170,"letter_id":171,"created_at":65,"fei_number":19,"letter_url":172,"updated_at":173,"action_type":22,"case_status":23,"posted_date":174,"marcs_cms_no":175,"product_type":115,"closeout_date":19,"issuing_office":104,"recipient_name":19,"body_fetched_at":176,"delivery_method":96,"recipient_title":19,"reference_number":19,"action_taken_date":177,"medical_device_id":19,"response_letter_date":19},1721,[163,164,165,104,166,13,13,13],"\u003Ctime datetime=\"2023-11-28T14:20:00Z\">11\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-22T05:00:00Z\">11\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-bernes-whole-health-products-665456-11222023\">Dr. Berne’s Whole Health Products\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Dr. Berne’s Whole Health Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>174 Tesuque Village Rd, Unit 458\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tesuque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87574\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@drsamberne.com\"> hello@drsamberne.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 665456\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Samuel Berne:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fshop.drsamberne.com\u002F in August 2023. The FDA has observed that your website offers the products “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\n\n\u003Cp>In addition, the results of the FDA laboratory testing of a batch of Dr. Berne's MSM Eye Drops 5% demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the FD&amp;C Act, 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance. Introducing or delivering this product for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Fshop.drsamberne.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From the Customer Sheet section on the product pages for “Dr. Berne’s MSM Eye Drops 5%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-drops, “Dr. Berne’s MSM Eye Drops 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002F15-msm, and “Dr. Berne’s MSM Eye Mist 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-eye-mist:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>Allergies\u003C\u002Fstrong>[,] MSM has strong anti-inflammatory activity in the body, which can greatly assist in reducing inflammation that is common with allergic reactions. Both environmental and food allergies can be reduced with MSM. Asthma and hay fever sufferers also have reported significant relief with MSM.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your March 16, 2018, YouTube video titled, “MSM Eye Massage (Eye Exercise)” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fmsm-eye-massage\u002F where you demonstrate an eye massage with one of your MSM eye drop products:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“This MSM eye massage is great for inflammatory eye conditions, blepharitis, dry-eye, improving the lymph system, and stimulation of tears.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your July 6, 2022, YouTube video titled, “Diagnosing Macular Degeneration” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fdiagnosing-macular-degeneration\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“. . . I’d start using my natural eyedrops called MSM drops, and I would get the 5%, MSM and the 5% MSM. MSM is a sulfur molecule is the third leading trace mineral found in the body. And it supports collagen in the eye. It’s an anti inflammatory agent. And it will lubricate and moisturize your eyes, which neutralizes drusen production because drusen likes to grow in a dry environment. And the other thing it will do is it will lubricate your macula. So when you’ve got dry macular degeneration, the macula is basically drying out. And that’s where you start getting these distortions.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your October 12, 2022, YouTube video titled, “I’m Answering Your Questions! Sulfa vs. Sulfur” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-sulfa-vs-sulfur\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[T]he difference between those two pharmaceuticals and MSM eyedrops, so MSM definitely is an anti inflammatory agent. It’s a natural sulfur product that is found in your body.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your October 31, 2022, YouTube video titled, “I’m Answering Your Questions” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-12\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“My MSM eyedrops are really great for corneal dystrophies, like fuks, and it’s really about hydrating, protecting your eyes from too much sunlight, and also blue light . . .”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are not generally recognized as safe and effective (GRASE) for their above-referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory testing of a batch of Dr. Berne's MSM DROPS 5% Solution drug product (lot 6786, “Best By 032025”) found that it contained microbial contamination. The sample results failed to meet USP &lt;71&gt;, sterility tests. Therefore, this drug product is adulterated under section 501(a)(1) of the FD&amp;C Act, in that it consists in whole or in part of any filthy, putrid, or decomposed substances.\u003C\u002Fp>\n\n\u003Cp>Fungal and bacterial microorganisms were identified from drug product samples analyzed for sterility, which included, but were not limited to Exophiala sp. and Bacillus spp. The presence of microorganisms in conjunction with the route of administration poses a high risk to patients. Using contaminated eye drops could result in a range of ocular infections, from minor to serious vision-threatening infections, which could progress in some cases to a life-threatening infection.\u003C\u002Fp>\n\n\u003Cp>During the FDA teleconference on August 21, 2023, you stated that your drug products are manufactured by a contract manufacturer, and you agreed to conduct a voluntary recall of the lot currently in U.S. distribution.\u003C\u002Fp>\n\n\u003Cp>On August 26, 2023, you voluntarily recalled lot 6786 of Dr. Berne’s MSM DROPS 5% Solution to the consumer level due to microbial contamination. In addition, you are voluntarily recalling all lots of Dr. Berne’s MSM DROPS 5% Solution, Dr. Berne’s MSM DROPS 15% Solution, Dr. Berne’s Organic Castor Oil Eye Drops, and Dr. Berne’s MSM MIST 15% Solution to the consumer level due to potential microbial contamination, as noted on the following FDA website:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdr-bernes-whole-health-products-issues-voluntary-nationwide-recall-dr-bernes-msm-drops-5-and-15\u003C\u002Fp>\n\n\u003Cp>On August 22, 2023, FDA issued the following drug alert warning to consumers not to purchase and to immediately stop using Dr. Berne’s MSM Drops 5% Solution due to bacterial contamination, fungal contamination, or both:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-methylsulfonylmethane-msm-eye-drops-due\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003Cbr>\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act. For additional information regarding contract manufacturing, please refer to FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address any violations may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nDr. Berne’s Whole Health Products\n\n174 Tesuque Village Rd, Unit 458\n\nTesuque, NM 87574\n\nUnited States\n\nhello@drsamberne.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nNovember 22, 2023\n\nRE: 665456\n\nDear Samuel Berne:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fshop.drsamberne.com\u002F in August 2023. The FDA has observed that your website offers the products “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nYour “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\n\nIn addition, the results of the FDA laboratory testing of a batch of Dr. Berne's MSM Eye Drops 5% demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the FD&C Act, 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance. Introducing or delivering this product for introduction into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nUnapproved New Drugs\n\nBased on a review of your website, your “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Fshop.drsamberne.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nFrom the Customer Sheet section on the product pages for “Dr. Berne’s MSM Eye Drops 5%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-drops, “Dr. Berne’s MSM Eye Drops 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002F15-msm, and “Dr. Berne’s MSM Eye Mist 15%” https:\u002F\u002Fshop.drsamberne.com\u002Fcollections\u002Fmsm-drops\u002Fproducts\u002Fmsm-eye-mist:\n\n“Allergies[,] MSM has strong anti-inflammatory activity in the body, which can greatly assist in reducing inflammation that is common with allergic reactions. Both environmental and food allergies can be reduced with MSM. Asthma and hay fever sufferers also have reported significant relief with MSM.”\n\nFrom your March 16, 2018, YouTube video titled, “MSM Eye Massage (Eye Exercise)” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fmsm-eye-massage\u002F where you demonstrate an eye massage with one of your MSM eye drop products:\n\n“This MSM eye massage is great for inflammatory eye conditions, blepharitis, dry-eye, improving the lymph system, and stimulation of tears.”\n\nFrom your July 6, 2022, YouTube video titled, “Diagnosing Macular Degeneration” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fdiagnosing-macular-degeneration\u002F:\n\n“. . . I’d start using my natural eyedrops called MSM drops, and I would get the 5%, MSM and the 5% MSM. MSM is a sulfur molecule is the third leading trace mineral found in the body. And it supports collagen in the eye. It’s an anti inflammatory agent. And it will lubricate and moisturize your eyes, which neutralizes drusen production because drusen likes to grow in a dry environment. And the other thing it will do is it will lubricate your macula. So when you’ve got dry macular degeneration, the macula is basically drying out. And that’s where you start getting these distortions.”\n\nFrom your October 12, 2022, YouTube video titled, “I’m Answering Your Questions! Sulfa vs. Sulfur” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-sulfa-vs-sulfur\u002F:\n\n“[T]he difference between those two pharmaceuticals and MSM eyedrops, so MSM definitely is an anti inflammatory agent. It’s a natural sulfur product that is found in your body.”\n\nFrom your October 31, 2022, YouTube video titled, “I’m Answering Your Questions” on your webpage https:\u002F\u002Fwww.drsamberne.com\u002Fim-answering-your-questions-12\u002F:\n\n“My MSM eyedrops are really great for corneal dystrophies, like fuks, and it’s really about hydrating, protecting your eyes from too much sunlight, and also blue light . . .”\n\nYour “Dr. Berne’s MSM Eye Drops 5%,” “Dr. Berne’s MSM Eye Drops 15%,” and “Dr. Berne’s MSM Eye Mist 15%” products are not generally recognized as safe and effective (GRASE) for their above-referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nAdulteration Violations\n\nFDA laboratory testing of a batch of Dr. Berne's MSM DROPS 5% Solution drug product (lot 6786, “Best By 032025”) found that it contained microbial contamination. The sample results failed to meet USP \u003C71>, sterility tests. Therefore, this drug product is adulterated under section 501(a)(1) of the FD&C Act, in that it consists in whole or in part of any filthy, putrid, or decomposed substances.\n\nFungal and bacterial microorganisms were identified from drug product samples analyzed for sterility, which included, but were not limited to Exophiala sp. and Bacillus spp. The presence of microorganisms in conjunction with the route of administration poses a high risk to patients. Using contaminated eye drops could result in a range of ocular infections, from minor to serious vision-threatening infections, which could progress in some cases to a life-threatening infection.\n\nDuring the FDA teleconference on August 21, 2023, you stated that your drug products are manufactured by a contract manufacturer, and you agreed to conduct a voluntary recall of the lot currently in U.S. distribution.\n\nOn August 26, 2023, you voluntarily recalled lot 6786 of Dr. Berne’s MSM DROPS 5% Solution to the consumer level due to microbial contamination. In addition, you are voluntarily recalling all lots of Dr. Berne’s MSM DROPS 5% Solution, Dr. Berne’s MSM DROPS 15% Solution, Dr. Berne’s Organic Castor Oil Eye Drops, and Dr. Berne’s MSM MIST 15% Solution to the consumer level due to potential microbial contamination, as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdr-bernes-whole-health-products-issues-voluntary-nationwide-recall-dr-bernes-msm-drops-5-and-15\n\nOn August 22, 2023, FDA issued the following drug alert warning to consumers not to purchase and to immediately stop using Dr. Berne’s MSM Drops 5% Solution due to bacterial contamination, fungal contamination, or both:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-warns-consumers-not-purchase-or-use-certain-methylsulfonylmethane-msm-eye-drops-due\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act. For additional information regarding contract manufacturing, please refer to FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address any violations may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","Dr. Berne’s Whole Health Products","dr-bernes-whole-health-products-665456-11222023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-bernes-whole-health-products-665456-11222023","2026-10-26T08:08:26.526839+00:00","2023-11-28","665456","2026-08-20T00:28:51.97+00:00","2023-11-22",{"id":179,"raw":180,"subject":83,"body_html":185,"body_text":186,"firm_name":187,"letter_id":188,"created_at":189,"fei_number":19,"letter_url":190,"updated_at":191,"action_type":22,"case_status":23,"posted_date":192,"marcs_cms_no":193,"product_type":93,"closeout_date":19,"issuing_office":184,"recipient_name":194,"body_fetched_at":195,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":196,"medical_device_id":19,"response_letter_date":19},3332,[181,182,183,184,83,13,13,13],"\u003Ctime datetime=\"2021-05-26T15:00:00Z\">05\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-20T04:00:00Z\">05\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021\">NS Products, Inc.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Wolfe Vaughn and Craig Sheralyn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>NS Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11721 State Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marysville\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98271\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 20, 2021\u003Cbr>\n\u003Cbr>\nRE: 605706\u003C\u002Fp>\n\n\u003Cp>Dear Wolfe Vaughn and Craig Sheralyn:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\u003C\u002Fp>\n\n\u003Cp>The claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On the home page:\u003Cbr>\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\u003C\u002Fp>\n\n\u003Cp>On the “ABOUT FERTILITY” page:\u003Cbr>\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\u003Cbr>\n\u003Cbr>\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\u003C\u002Fp>\n\n\u003Cp>On the “HOW IT WORKS” page:\u003Cbr>\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\u003Cbr>\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\u003Cbr>\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\u003Cbr>\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\u003Cbr>\no “Raspberry Fruit - Relieves impotence . . .”\u003C\u002Fp>\n\n\u003Cp>Your website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cp>On the “CUSTOMER REVIEWS” page:\u003Cbr>\n• “I had a miscarriage in June 2010 &amp; have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May &amp; I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\u003C\u002Fp>\n\n\u003Cp>Your product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003Cbr>\n\u003Cbr>\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. \u003Cem>POM Wonderful LLC\u003C\u002Fem>, 155 F.T.C. 1, 60-61, (2013),&nbsp;\u003Cem>aff’d in relevant part\u003C\u002Fem>, 777 F.3d 478 (D.C. Cir. 2015); \u003Cem>Daniel Chapter One\u003C\u002Fem>, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), \u003Cem>aff’d\u003C\u002Fem>, 405 Fed. Appx. 505 (D.C. Cir. 2010);&nbsp;\u003Cem>Removatron Int'l Corp\u003C\u002Fem>., 111 F.T.C. 206, 297-99 (1988), \u003Cem>aff’d\u003C\u002Fem>, 884 F.2d 1489, 1496 (1stCir. 1989); see also, \u003Cem>FTC v. Direct Mktg. Concepts\u003C\u002Fem>, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), \u003Cem>aff’d\u003C\u002Fem>, 624 F.3d 1 (1st Cir. 2010); \u003Cem>FTC v. Nat'l Urological Group, Inc\u003C\u002Fem>., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), \u003Cem>aff’d\u003C\u002Fem>, 356 Fed. Appx. 358 (11th Cir. 2009); \u003Cem>FTC v. Natural Solution, Inc\u003C\u002Fem>., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act.&nbsp;\u003Cem>See Daniel Chapter One\u003C\u002Fem>, WL 5160000 at *17-19.\u003C\u002Fp>\n\n\u003Cp>The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and\u003Cbr>\nApplied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nWolfe Vaughn and Craig Sheralyn\n\nNS Products, Inc.\n\n11721 State Ave\n\nMarysville, WA 98271\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nMay 20, 2021\n\nRE: 605706\n\nDear Wolfe Vaughn and Craig Sheralyn:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.naturacure.net in March 2021 and has determined that you take orders there for the product “NaturaCure.” You are also advised that the Federal Trade Commission reviewed your website in May 2021.\n\nThe claims on your website establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn the home page:\n\n• “You avoid expensive surgical procedures, injections and ineffective treatments. . . NaturaCure may replace conventional fertility treatments….”\n\nOn the “ABOUT FERTILITY” page:\n\n• “NaturaCure works with your body, eliminating the root cause of your specific infertility disorder (such as: ovarian cysts, uterine fibroids, endometriosis, high FSH, PCOS etc.)….”\n\n• “You will get pregnant very fast and give birth to healthy children regardless of . . . how severe or chronic your infertility disorder.”\n\nOn the “HOW IT WORKS” page:\n\n• “If you suffer from infertility, tried every prescription, patch and injection the doctors have prescribed but nothing works – and want a solution that really works – then you need to try . . . NaturaCure.”\n\n• “Depending on individual customers and the types of infertility treated, success rates ranged from about 50% up to 98%. Included in these statistics are cases of infertility involving: . . . Obstruction of the fallopian tubess [sic] [,] Amenorrhea[,] Absent ovulation[,] Endometriosis[,] Uterine fibroids[,] . . . None liquidification of semen [sic][,] Tubal blockage[,] . . . Previous tubal ligation”\n\n• “Discovery NaturaCure’s Award Winning Herbal Formulation”\n\no “Bee Propolis - is beneficial for autoimmune related fertility issues such as recurrent miscarriage due to immunological response (mother's body attacks and rejects the fetus), autoimmune related premature ovarian failure and antisperm antibody.”\n\no “Raspberry Fruit - Relieves impotence . . .”\n\nYour website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of NaturaCure for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn the “CUSTOMER REVIEWS” page:\n\n• “I had a miscarriage in June 2010 & have been trying to conceive ever since . . . In April 2011 I decided to order NaturaCure. Started taking it in May & I am now 7 weeks pregnant! . . . THIS REALLY WORKS!!!!”\n\nYour product “NaturaCure” is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product “NaturaCure” is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, “NaturaCure” fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions, you may also contact Aaron Dotson at aaron.dotson@fda.hhs.gov.\n\nIn addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60-61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx. 505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297-99 (1988), aff’d, 884 F.2d 1489, 1496 (1stCir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06- 6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17-19.\n\nThe FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. The FTC strongly urges you to review all claims for your products and ensure that those claims are supported by competent and reliable scientific evidence. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.govwithin fifteen (15) working days of receipt of this letter, of the specific actions you have taken to address FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nActing Director\n\nOffice of Compliance\n\nCenter for Food Safety and\n\nApplied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission","NS Products, Inc.","ns-products-inc-605706-05202021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fns-products-inc-605706-05202021","2026-10-26T08:09:35.524317+00:00","2021-05-26","605706","Wolfe Vaughn and Craig Sheralyn","2026-08-20T03:06:45.755+00:00","2021-05-20",{"id":198,"raw":199,"subject":203,"body_html":204,"body_text":205,"firm_name":206,"letter_id":207,"created_at":42,"fei_number":19,"letter_url":208,"updated_at":209,"action_type":22,"case_status":23,"posted_date":210,"marcs_cms_no":211,"product_type":155,"closeout_date":19,"issuing_office":145,"recipient_name":212,"body_fetched_at":213,"delivery_method":214,"recipient_title":19,"reference_number":215,"action_taken_date":216,"medical_device_id":19,"response_letter_date":19},21706,[200,201,202,145,203,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-21T04:00:00Z\">09\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbabikian-healthcare-products-cjsc-730513-09212026\">Babikian Healthcare Products CJSC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-128\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Dikran Babikian\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Babikian Healthcare Products CJSC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Gevorg Chaush Highway 90\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>2413\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Proshyan Community\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kotayk\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Armenia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 21, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-128\u003C\u002Fp>\u003Cp>To Dr. Dikran Babikian:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, Babikian Healthcare Products CJSC, FDA Establishment Identifier (FEI) 3027526825.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) &amp; 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, intended for the U.S. market. Your response to our request for records and information under section 704(a)(4) indicated that you do not test the identity of each incoming component, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your drug products prior to manufacturing. Your response also indicated that you accept your suppliers’ certificates of analyses without verifying the test results at appropriate intervals.\u003C\u002Fp>\u003Cp>You also did not provide evidence that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the active ingredients in your drug products, meet USP limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\">.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Without adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you adequately test your finished OTC drug products prior to release and distribution to the United States. For example, the finished product testing reports you provided did not include appropriate assay testing for the identity and strength of each active ingredient or for impurities prior to release. Additionally, the records you provided failed to demonstrate adequate microbiological testing for each batch of your drug product prior to release.\u003C\u002Fp>\u003Cp>Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all predetermined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that your quality unit (QU) adequately exercised its authority and responsibilities for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishing appropriate written procedures for production and process controls to qualify process performance and for qualification of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, which produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> used as a component in your drug products (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Maintaining complete manufacturing information relating to the production and control in batch records (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Providing appropriate stability data to support the labeled drug product expiration date (21 CFR 211.137(a)).\u003C\u002Fli>\u003Cli>Establishing adequate QU authority and procedures (21 CFR 211.22(a) &amp; 211.22(d)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA guidance documents \u003Cem>Quality Systems Approach to Pharmaceuticals CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Registration and Listing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that two separate establishments are referenced in this warning letter. Under section 510(i) of the FD&amp;C Act and 21 CFR 207.17(a) any establishment within any foreign country engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States must be registered with FDA. Under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), it is a prohibited act to fail to register an establishment as required by section 510 of the FD&amp;C Act. Additionally, a drug may be considered misbranded within the meaning of section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o) if it was manufactured in an establishment not duly registered under section 510 of the FD&amp;C Act. It is your responsibility to ensure that all drugs manufactured at your establishment(s) comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firms, FEI 3027526825 and FEI 3032638909, on Import Alert 66-40 on June 22, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Babikian Healthcare Products CJSC, Gevorg Chaush Highway 90, Proshyan Community, Kotayk 2413 Armenia into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3027526825 and ATTN: Christina Capacci-Daniel in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>U.S. Agent: Mr. Michael Sarian\u003Cbr>American Healthcare Systems Corp., Inc.\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that Babikian Healthcare Products, 8 North Ave, Apartment 22, Yerevan, FEI 3032638909 was also listed as the manufacturer of record for several shipments to the U.S. but was not a registered FDA manufacturing facility. See the Facility Registration section below for guidance.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-26-128\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nDr. Dikran Babikian\n\nRecipient Title\n\nChief Executive Officer\n\nBabikian Healthcare Products CJSC\n\nGevorg Chaush Highway 90\n\n2413\n\nProshyan Community\n\nKotayk\n\nArmenia\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 21, 2026\nWARNING LETTER\nReference number: 320-26-128\nTo Dr. Dikran Babikian:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, Babikian Healthcare Products CJSC, FDA Establishment Identifier (FEI) 3027526825.1 This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) & 211.84(d)(2)).\nYour firm manufactures OTC drug products, including (b)(4), intended for the U.S. market. Your response to our request for records and information under section 704(a)(4) indicated that you do not test the identity of each incoming component, (b)(4), used in the manufacture of your drug products prior to manufacturing. Your response also indicated that you accept your suppliers’ certificates of analyses without verifying the test results at appropriate intervals.\nYou also did not provide evidence that (b)(4), the active ingredients in your drug products, meet USP limits for (b)(4). See FDA’s guidance document (b)(4).\nWithout adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nBased on the records and information you provided, you did not demonstrate that you adequately test your finished OTC drug products prior to release and distribution to the United States. For example, the finished product testing reports you provided did not include appropriate assay testing for the identity and strength of each active ingredient or for impurities prior to release. Additionally, the records you provided failed to demonstrate adequate microbiological testing for each batch of your drug product prior to release.\nTesting is an essential part of CGMP to ensure that the drug products you manufacture conform to all predetermined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and information you provided, you did not demonstrate that your quality unit (QU) adequately exercised its authority and responsibilities for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\nEstablishing appropriate written procedures for production and process controls to qualify process performance and for qualification of your (b)(4) system, which produces (b)(4) used as a component in your drug products (21 CFR 211.100(a)).\nMaintaining complete manufacturing information relating to the production and control in batch records (21 CFR 211.188).\nProviding appropriate stability data to support the labeled drug product expiration date (21 CFR 211.137(a)).\nEstablishing adequate QU authority and procedures (21 CFR 211.22(a) & 211.22(d)).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA guidance documents Quality Systems Approach to Pharmaceuticals CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nDrug Registration and Listing\nWe note that two separate establishments are referenced in this warning letter. Under section 510(i) of the FD&C Act and 21 CFR 207.17(a) any establishment within any foreign country engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States must be registered with FDA. Under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), it is a prohibited act to fail to register an establishment as required by section 510 of the FD&C Act. Additionally, a drug may be considered misbranded within the meaning of section 502(o) of the FD&C Act, 21 U.S.C. 352(o) if it was manufactured in an establishment not duly registered under section 510 of the FD&C Act. It is your responsibility to ensure that all drugs manufactured at your establishment(s) comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations.\nCGMP Consultant\nBased upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firms, FEI 3027526825 and FEI 3032638909, on Import Alert 66-40 on June 22, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Babikian Healthcare Products CJSC, Gevorg Chaush Highway 90, Proshyan Community, Kotayk 2413 Armenia into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3027526825 and ATTN: Christina Capacci-Daniel in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\ncc:\nU.S. Agent: Mr. Michael Sarian\nAmerican Healthcare Systems Corp., Inc.\n(b)(4)\n______________________________\n1 We note that Babikian Healthcare Products, 8 North Ave, Apartment 22, Yerevan, FEI 3032638909 was also listed as the manufacturer of record for several shipments to the U.S. but was not a registered FDA manufacturing facility. See the Facility Registration section below for guidance.","Babikian Healthcare Products CJSC","babikian-healthcare-products-cjsc-730513-09212026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbabikian-healthcare-products-cjsc-730513-09212026","2026-11-10T01:02:16.121874+00:00","2026-09-29","730513","Dr. Dikran Babikian","2026-10-14T12:34:23.173+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-26-128","2026-09-21",{"id":218,"raw":219,"subject":203,"body_html":224,"body_text":225,"firm_name":226,"letter_id":227,"created_at":88,"fei_number":19,"letter_url":228,"updated_at":229,"action_type":22,"case_status":23,"posted_date":230,"marcs_cms_no":231,"product_type":232,"closeout_date":19,"issuing_office":223,"recipient_name":233,"body_fetched_at":234,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":235,"medical_device_id":19,"response_letter_date":19},8,[220,221,222,223,203,13,13,13],"\u003Ctime datetime=\"2026-07-28T04:00:00Z\">07\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-12T04:00:00Z\">06\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026\">AHC Products, Inc. \u003C\u002Fa>","Center for Veterinary Medicine","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Wolf\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Compliance Manager and Pharmacist in Charge \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AHC Products, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 W Broadway St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Winchester\u003C\u002Fspan>, \u003Cspan>KY\u003C\u002Fspan> \u003Cspan>40391-1915\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 12, 2026\u003C\u002Fp>\u003Cp>CMS Case: 728604\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Wolf:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B)].\u003C\u002Fp>\u003Cp>In addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act). The specific products include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, AniPrin P, and Rot-B-Gone.\u003C\u002Fp>\u003Cp>\u003Cstrong>Current Good Manufacturing Practice Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\u003C\u002Fp>\u003Cp>Our review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\u003C\u002Fp>\u003Cp>In your response, you stated that for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the methodology utilized for product release was color comparison to the original \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, and you referenced a scientific publication suggesting that \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a \u003Cstrong>(b)(4)\u003C\u002Fstrong> methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\u003C\u002Fp>\u003Cp>Regarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\u003C\u002Fp>\u003Cp>Your response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> method for determining \u003Cstrong>(b)(4)\u003C\u002Fstrong> values in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is an entirely different matrix, application, and analytical purpose than your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and cannot be relied upon to determine a quantitative value for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fp>\u003Cp>Related to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\u003C\u002Fp>\u003Cp>You are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\u003C\u002Fp>\u003Cp>Moreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\u003C\u002Fp>\u003Cp>Release testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Procedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure that components were suitable for use in the manufacturing of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> or the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Adequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\u003C\u002Fp>\u003Cp>Your response stated that you sent samples of the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\u003C\u002Fp>\u003Cp>Your response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>, providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality;\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data);\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to qualify the equipment and to validate the processes used to manufacture your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product batches, prior to their use in commercial production.\u003C\u002Fp>\u003Cp>Multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\u003C\u002Fp>\u003Cp>Process validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\u003C\u002Fp>\u003Cp>You responded that you are investigating the initiation of the manufacturing process of the finished product \u003Cstrong>(b)(4)\u003C\u002Fstrong> without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced since August were tested by ICP-MS to determine the concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material.\u003C\u002Fp>\u003Cp>Regarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (ID \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, you indicated that as part of the qualification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to measure the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was purchased to determine the rate of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and a certified thermistor to confirm the temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated that SOP PRO-0002.4 Process Change Control will be revised.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\u003C\u002Fp>\u003Cp>The equipment qualification plan included in the response is incomplete. While you state that you have purchased a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\u003C\u002Fp>\u003Cp>The response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\u003C\u002Fp>\u003Cp>The response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\u003C\u002Fp>\u003Cp>The ICP-MS results you provided show significant variability, with \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentrations ranging from \u003Cstrong>(b)(4)\u003C\u002Fstrong>% across the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots tested, representing more than \u003Cstrong>(b)(4) \u003C\u002Fstrong>fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (equivalent to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% available \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You manufactured and distributed multiple lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that did not bear an expiration date in the product label.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Furthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (2) AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufacture date \u003Cstrong>(b)(4)\u003C\u002Fstrong>, missed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing which was required on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\u003C\u002Fp>\u003Cp>Stability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\u003C\u002Fp>\u003Cp>Regarding the lack of stability testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your response states that at such time as you are able to establish appropriate testing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> months, depending on the testing).\u003C\u002Fp>\u003Cp>Regarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the date the missed \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample was required to be tested should be \u003Cstrong>(b)(4)\u003C\u002Fstrong>, not \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and that the stability samples for this lot were pulled prior to the previous FDA inspection.\u003C\u002Fp>\u003Cp>You indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\u003C\u002Fp>\u003Cp>Your response is inadequate. The response does not address the lack of expiration dates on distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\u003C\u002Fp>\u003Cp>The requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\u003C\u002Fp>\u003Cp>Expiration dating must be based on adequate stability data generated under appropriate storage.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>The current expiry date for your finished drug products.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Animal Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>\"\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\"\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>AniPrin P\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“Aids in relieving minor muscle and joint pain.”\u003C\u002Fli>\u003Cli>“…an aid in reducing fever”\u003C\u002Fli>\u003Cli>“…relief of minor muscle aches… pains in horses.”\u003C\u002Fli>\u003Cli>“…Reproductive Harm…”\u003C\u002Fli>\u003Cli>“...analgesic”\u003C\u002Fli>\u003Cli>“...antipyretic”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Rot-B-Gone\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>“...If redness, irritation,..swelling persist, discontinue use.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>You must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See also, 21 CFR 211.137.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Wolf\n\nRecipient Title\n\nCompliance Manager and Pharmacist in Charge\n\nAHC Products, Inc.\n\n301 W Broadway St\n\nWinchester, KY 40391-1915\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJune 12, 2026\nCMS Case: 728604\nWARNING LETTER\nDear Mr. Wolf:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025.\nThis warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)].\nIn addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act). The specific products include (b)(4), AniPrin P, and Rot-B-Gone.\nCurrent Good Manufacturing Practice Violations\nWe reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection.\nOur review of the evidence gathered during the inspection and your response revealed significant violations, including the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm manufactures drug products, including (b)(4) wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released (b)(4) lots of (b)(4) without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of (b)(4) properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches.\nIn your response, you stated that for (b)(4), the methodology utilized for product release was color comparison to the original (b)(4) product, and you referenced a scientific publication suggesting that (b)(4) concentration can be reliably estimated by color comparison. You indicated that as part of your investigation, you are investigating a (b)(4) methodology and have preliminarily confirmed through ICP-MS testing that the finished product was approximately (b)(4)% of the (b)(4) raw material. You stated that you are in contact with laboratories to conduct USP testing of the raw material and then validation of methodologies to determine conformance of the finished product to final specifications prior to release.\nRegarding the AniPrin products, you stated that the heavy metal specifications and microbiological specifications listed on your COAs are controlled using incoming raw material specifications with random verification. You indicated that COAs for aspirin products will be revised to remove these specifications, and COAs for other products will be modified to clarify that these specifications are controlled by incoming specifications with random verification.\nYour response is inadequate. Visual color comparison is a subjective, qualitative assessment that cannot provide quantitative measurement of active ingredient concentration, as color can be affected by many factors including observer subjectivity. The scientific publication you referenced in the response describes a (b)(4) method for determining (b)(4) values in (b)(4), which is an entirely different matrix, application, and analytical purpose than your (b)(4) product. You conducted preliminary ICP-MS testing, but the laboratory report you provided in the response explicitly states that \"the methodology employed was not validated for the matrix\" and that \"the variability of the results are likely from an inconsistent dissociation of the (b)(4) and cannot be relied upon to determine a quantitative value for (b)(4).\"\nRelated to the AniPrin products, your explanation that microbiological and heavy metal specifications are \"controlled using incoming raw material specifications with random verification\" is insufficient, and your proposed corrective action to simply remove these specifications from your Certificates of Analysis or add clarifying language does not address the underlying compliance issue.\nYou are required to establish appropriate and scientifically-sound specifications for your drug products and then to conduct appropriate laboratory testing for conformance to those specifications. See, e.g., 21 CFR 201.22, 211.160, and 211.165.\nMoreover, your response lacks a definitive timeline for implementing validated analytical methods, provides no plan for verifying the quality of the product lots already distributed to commerce, and does not include a risk assessment for animals that may have received this inadequately tested product.\nRelease testing is a critical safeguard that verifies the identity, strength, quality, and purity of drug product batches before they reach the end-user. Without appropriate testing protocols in place, defective products that could cause harm may fail to be identified and rejected.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nProcedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)).\nYour firm failed to ensure that components were suitable for use in the manufacturing of your (b)(4) product. For example, you did not perform identity testing on each lot of incoming components including the active ingredient (b)(4) or the inactive ingredients (b)(4).\nAdequate testing is essential for establishing that raw materials—including, but not limited to, active pharmaceutical ingredients—conform to the appropriate specifications prior to their use in drug product manufacturing, including identity testing to detect potential mix-ups that occurred before you received the components. As a manufacturer, you bear the responsibility of sampling, testing, and examining drug components before releasing them for use in production to ensure that adequate quality standards are met.\nYour response stated that you sent samples of the active ingredient (b)(4) along with final product lots for ICP-MS testing and were able to confirm through ICP-MS that the final product was approximately (b)(4)% of the (b)(4) raw material. You indicated that you are pursuing USP testing of the raw material with a GMP laboratory, which you expect to be completed within ninety (90) days. You further stated that once you are able to confirm the ability of a GMP laboratory to conduct testing of the (b)(4) raw material, it will fall under your existing SOP titled \"Quality Testing of Documented Raw Materials.\"\nYour response is inadequate. The ICP-MS testing you describe was conducted retrospectively, after the raw materials had already been incorporated into finished product that was released and distributed into commerce. You did not describe any interim controls or testing procedures that will be implemented immediately to verify component identity while you establish a relationship with a qualified laboratory. Your response also fails to address the inactive ingredients (b)(4), providing no information about whether identity testing will be performed on these components or whether they will continue to be accepted based solely on supplier COAs.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\no an assessment of all materials to determine whether they are consistently of acceptable quality;\no a review to ensure assigned expiration or retest dates are appropriate (supported by data);\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nThe firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to qualify the equipment and to validate the processes used to manufacture your (b)(4) product batches, prior to their use in commercial production.\nMultiple lots of (b)(4), a (b)(4) agent for wounds, cuts, ulcers, and similar conditions, were released to the market since August 2025 without performing process validation to demonstrate a reproducible commercial manufacturing process that yields a product consistently meeting predetermined specifications and quality attributes.\nProcess validation evaluates the design integrity and state of control of a manufacturing process throughout its lifecycle. Each significant manufacturing stage must be appropriately designed to ensure the quality of inputs, in-process materials, and finished products. Process qualification studies establish whether an initial state of control has been achieved and must be successfully completed before commercial distribution. Ongoing monitoring of process performance and product quality is then required to maintain a stable manufacturing operation over the product lifecycle.\nYou responded that you are investigating the initiation of the manufacturing process of the finished product (b)(4) without adequate validation as part of deviation PDP-769U. You indicated that validation was initiated, and the management team was retrained on the relevant SOP. Your response states that as part of the validation, (b)(4) lots of (b)(4) produced since August were tested by ICP-MS to determine the concentration of (b)(4). Further, you indicated that with ICP-MS testing, you were able to confirm that the final product was approximately (b)(4)% of the (b)(4) raw material.\nRegarding the equipment qualification, your response was that a deviation (PDP-769U) to SOP PRO-0002.4 Process Change Control has been initiated and that as part of this deviation, you will investigate the implementation of the (b)(4) (ID (b)(4)). Additionally, you indicated that as part of the qualification of the (b)(4), a (b)(4) to measure the rate of (b)(4) was purchased to determine the rate of (b)(4), and a certified thermistor to confirm the temperature of (b)(4). You stated that SOP PRO-0002.4 Process Change Control will be revised.\nYour response is inadequate because it fails to demonstrate an understanding of process and equipment validation requirements and does not provide a comprehensive plan to validate your manufacturing process or to verify the quality of products already distributed to commerce.\nThe equipment qualification plan included in the response is incomplete. While you state that you have purchased a (b)(4) and NIST-certified thermistor, merely purchasing measurement instruments does not constitute equipment qualification. You failed to provide a comprehensive qualification protocol to demonstrate that the equipment consistently performs as intended when manufacturing actual product batches.\nThe response did not include a validation protocol that defines for example, the number of validation batches to be manufactured, the sampling plans, the analytical methods to be used with appropriate validation, or the statistical approaches for evaluating process capability.\nThe response addresses only analytical testing of finished products — one component of validation — but fails to address validation of the manufacturing process itself. Using ICP-MS testing on finished product lots as evidence of process validation is scientifically flawed and unacceptable.\nThe ICP-MS results you provided show significant variability, with (b)(4) concentrations ranging from (b)(4)% across the (b)(4) lots tested, representing more than (b)(4) fold difference. This variability demonstrates that your manufacturing process is not in a state of control and raises questions about whether your products consistently meet the labeled claim of (b)(4) (equivalent to (b)(4)% available (b)(4)). Despite this data, your response provides no explanation for this variability, no investigation into the root causes, and no assessment of whether this variability represents actual differences in product composition or limitations of the analytical method.\nIn response to this letter, provide:\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\n4. Your firm failed to follow your written stability testing program (21 CFR 211.166 (a)).\nYour firm has not initiated stability testing to establish appropriate storage conditions and expiration dating for (b)(4). You manufactured and distributed multiple lots of (b)(4) that did not bear an expiration date in the product label.1\nFurthermore, stability samples for the following drug products were not tested at the required intervals, and no deviation investigation was initiated: (1) AniPrin P, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4); and (2) AniPrin LQ 12% Regular Gallon, Lot (b)(4), manufacture date (b)(4), missed the (b)(4) testing which was required on (b)(4). This is a repeated observation from the previous inspection conducted in March 2022, where similar deficiencies in your stability program were cited.\nStability testing is essential to establish scientifically justified expiration dates and appropriate storage conditions that ensure drug products remain safe and effective from the time of manufacture until the end of their labeled shelf life.\nRegarding the lack of stability testing for (b)(4), your response states that at such time as you are able to establish appropriate testing of the (b)(4) content of the product, you will add this to your ongoing stability program. You indicated that once you go forward with production, an expiration date will reflect what you find on stability testing the initial lots (e.g., (b)(4) months, depending on the testing).\nRegarding the missed stability testing intervals for AniPrin products, you stated that for AniPrin P, Lot (b)(4), the date the missed (b)(4) sample was required to be tested should be (b)(4), not (b)(4), and that the stability samples for this lot were pulled prior to the previous FDA inspection.\nYou indicated that in response to the previous inspection, SOP QUA 00019 was changed to pull an additional two samples so that an extra sample is available if one is damaged, and that a deviation has been initiated. For AniPrin LQ 12% Regular Gallon, Lot (b)(4), you stated that a (b)(4) stability sample for this lot was not sent and that a deviation was initiated. You stated that the SOP was updated to include a double check that all samples on the reminder system are included in the laboratory accession form and shipped and that the managers responsible were retrained.\nYour response is inadequate. The response does not address the lack of expiration dates on distributed (b)(4) products. It does not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Further, you did not include a comprehensive review of all stability samples to verify that no other missed time points exist and failed to describe how you will verify that your revised procedures are effective in preventing recurrence.\nThe requirement to establish a stability program is not contingent upon your ability to develop analytical methods; rather, you should not manufacture and distribute a drug product until you have the capability to conduct appropriate stability testing.\nExpiration dating must be based on adequate stability data generated under appropriate storage.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each (b)(4) to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program.\nThe current expiry date for your finished drug products.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\nUnapproved New Animal Drug Violations\nBased on our review of your product labeling, your products are drugs under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. For the reasons described below, these products are unapproved new animal drugs and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nExamples of claims FDA observed on your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\n(b)(4)\n\"(b)(4).\"\nAniPrin P\n“Aids in relieving minor muscle and joint pain.”\n“…an aid in reducing fever”\n“…relief of minor muscle aches… pains in horses.”\n“…Reproductive Harm…”\n“...analgesic”\n“...antipyretic”\nRot-B-Gone\n“...If redness, irritation,..swelling persist, discontinue use.”\nYour products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. These products are not approved or index listed by FDA, and therefore, the products are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nYou must correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CVM-483-Responses@fda.hhs.gov. Refer to the CMS Case number 728604 FEI 3002745172 and ATTN: Dayna I. Martínez when replying.\nSincerely,\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Director\nDivision of Drug Compliance\nOffice Surveillance and Compliance\nCenter for Veterinary Medicine\n___________________\n1 See also, 21 CFR 211.137.\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","AHC Products, Inc.","ahc-products-inc-728604-06122026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fahc-products-inc-728604-06122026","2026-10-26T08:07:51.4831+00:00","2026-07-28","728604","Animal & VeterinaryDrugs","Mr. Michael Wolf","2026-08-19T04:27:41.535+00:00","2026-06-12",{"id":237,"raw":238,"subject":243,"body_html":244,"body_text":245,"firm_name":246,"letter_id":247,"created_at":18,"fei_number":19,"letter_url":248,"updated_at":249,"action_type":22,"case_status":23,"posted_date":250,"marcs_cms_no":251,"product_type":252,"closeout_date":19,"issuing_office":242,"recipient_name":19,"body_fetched_at":253,"delivery_method":254,"recipient_title":19,"reference_number":255,"action_taken_date":256,"medical_device_id":19,"response_letter_date":19},546,[239,240,241,242,243,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025\">LBC Products Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501315\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>LBC Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6360 South Pecos Road, Suite 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lehab@lbcproducts.com\"> lehab@lbcproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501315, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501315\n\nProduct:\n\nTobacco\n\nRecipient:\n\nLBC Products Inc.\n\n6360 South Pecos Road, Suite 8\n\nLas Vegas, NV 89120\n\nUnited States\n\nlehab@lbcproducts.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 2, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that LBC PRODUCTS INC. sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: HUSTLER PREMIUM E-LIQUID STRAWBERRY BLONDE 60 ML 3MG\u002FML.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501315, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","LBC Products Inc.","lbc-products-inc-717608-10022025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flbc-products-inc-717608-10022025","2026-10-26T08:09:12.826898+00:00","2025-10-07","717608","Tobacco","2026-08-19T16:14:50.902+00:00","VIA UPS and Electronic Mail","ER2501315","2025-10-02",{"id":258,"raw":259,"subject":243,"body_html":263,"body_text":264,"firm_name":265,"letter_id":266,"created_at":110,"fei_number":19,"letter_url":267,"updated_at":268,"action_type":22,"case_status":23,"posted_date":269,"marcs_cms_no":270,"product_type":252,"closeout_date":19,"issuing_office":242,"recipient_name":19,"body_fetched_at":271,"delivery_method":254,"recipient_title":19,"reference_number":19,"action_taken_date":272,"medical_device_id":19,"response_letter_date":19},2514,[260,261,262,242,243,13,13,13],"\u003Ctime datetime=\"2022-08-16T13:20:00Z\">08\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-12T04:00:00Z\">08\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022\">Rev Products LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Rev Products LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1309 Coffeen Avenue, Suite 2579\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sheridan\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@revecig.com\"> info@revecig.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tobacco Products Manufactured in an Unregistered Establishment Are Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&amp;C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\u003C\u002Fp>\n\n\u003Cp>Because your establishment was not registered in accordance with section 905(c) of the FD&amp;C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Cloud Peak Law, LLC\u003Cbr>\nAttn: Andrew Pierce\u003Cbr>\n1095 Sugar View Dr., Ste. 500\u003Cbr>\nSheridan, WY 828801\u003Cbr>\nreports@cloudpeaklaw.com\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nabuse@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>InMotion Hosting, Inc.\u003Cbr>\nabuse@inmotionhosting.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRev Products LLC\n\n1309 Coffeen Avenue, Suite 2579\n\nSheridan, WY 82801\n\nUnited States\n\ninfo@revecig.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 12, 2022\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Frevecig.com and determined your ENDS products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Frevecig.com revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Banana Ice, Cola Ice, and Ice Grape.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nTobacco Products Manufactured in an Unregistered Establishment Are Misbranded\n\nOur review indicates that you did not register your manufacturing establishment, located at 1309 Coffeen Avenue Suite 2579 Sheridan, WY 82801, as required by section 905(c) of the FD&C Act (21 U.S.C. § 387e(c)). Specifically, section 905(c) states that “[e]very person upon first engaging in the manufacture, preparation, compounding, or processing of a tobacco product or tobacco products in any establishment owned or operated in any State by that person shall immediately register with the Secretary that person's name, place of business, and such establishment.”\n\nBecause your establishment was not registered in accordance with section 905(c) of the FD&C Act, your tobacco products that were manufactured, prepared, propagated, compounded, or processed at that establishment are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)). The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201806, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nCloud Peak Law, LLC\n\nAttn: Andrew Pierce\n\n1095 Sugar View Dr., Ste. 500\n\nSheridan, WY 828801\n\nreports@cloudpeaklaw.com\n\nDomains By Proxy, LLC\n\nabuse@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nInMotion Hosting, Inc.\n\nabuse@inmotionhosting.com","Rev Products LLC","rev-products-llc-639730-08122022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frev-products-llc-639730-08122022","2026-10-26T08:09:49.092354+00:00","2022-08-16","639730","2026-08-20T01:40:04.669+00:00","2022-08-12",{"id":274,"raw":275,"subject":83,"body_html":281,"body_text":282,"firm_name":283,"letter_id":284,"created_at":285,"fei_number":19,"letter_url":286,"updated_at":287,"action_type":22,"case_status":288,"posted_date":289,"marcs_cms_no":290,"product_type":291,"closeout_date":292,"issuing_office":279,"recipient_name":293,"body_fetched_at":294,"delivery_method":295,"recipient_title":19,"reference_number":19,"action_taken_date":296,"medical_device_id":19,"response_letter_date":19},3523,[276,277,278,279,83,13,280,13],"\u003Ctime datetime=\"2021-02-19T17:00:00Z\">02\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-18T05:00:00Z\">02\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprohealth-inc-612227-02182021\">ProHealth Inc.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprohealth-inc-612227-06252021\">\u003Ctime datetime=\"2021-07-21T04:00:00Z\">07\u002F21\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Carson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>ProHealth Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>555 Maple St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Carpinteria\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93013\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>RE: [CMS: \u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>36TU\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>612227\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>U36T\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Mr. Carson,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address \u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>36T\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>www.prohealth.com\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>36T\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>in December 2020 and has determined that you take orders there for your \u003C\u002Fspan>\u003Cspan>\u003Cspan>41T\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Full Spectrum™ St. John's Wort Extract\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>41T\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> product. The claims on your website establish that your \u003Cspan>product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>36T\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>www.fda.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>36T\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Examples of some of the\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>website claims that provide evidence that your\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> “\u003C\u002Fspan>\u003Cspan>\u003Cspan>41T\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Full Spectrum™ St. John's Wort Extract”\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>41T\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> is intended for use as a drug include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>On the webpage for “Full Spectrum™ St. John's Wort Extract”: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>41T\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Effective for mild to moderate depression\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>19T41T\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>41T\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Reduces\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>&nbsp;anxiety\"\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>19T41T\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Your Full Spectrum™ St. John's Wort Extract product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. \u003Cspan>§§ \u003C\u002Fspan>331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. \u003Cspan>§ \u003C\u002Fspan>201.5).&nbsp; Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your Full Spectrum™ St. John's Wort Extract product is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Full Spectrum™ St. John's Wort Extract product fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. \u003Cspan>§\u003C\u002Fspan> 331(a)]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take prompt action to address the violations cited in this letter.&nbsp; Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and injunction. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations.&nbsp; Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.&nbsp; If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fspan> \u003Cspan>Your reply should be sent via e-mail to \u003C\u002Fspan>\u003Cspan>\u003Ca href=\"mailto:FDAAdvisory@fda.hhs.gov\">FDAAdvisory@fda.hhs.gov\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>William A. Correll Jr.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRichard Carson\n\nProHealth Inc.\n\n555 Maple St\n\nCarpinteria, CA 93013\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nRE: [CMS: 36TU612227U36T]\n\nDear Mr. Carson,\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address 36Twww.prohealth.com36T in December 2020 and has determined that you take orders there for your 41TFull Spectrum™ St. John's Wort Extract41T product. The claims on your website establish that your product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at 36Twww.fda.gov36T.\n\nExamples of some of the website claims that provide evidence that your “41TFull Spectrum™ St. John's Wort Extract”41T is intended for use as a drug include:\n\nOn the webpage for “Full Spectrum™ St. John's Wort Extract”:\n\n41T\"Effective for mild to moderate depression\" 19T41T\n\n41T\"Reduces anxiety\"19T41T\n\nYour Full Spectrum™ St. John's Wort Extract product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Full Spectrum™ St. John's Wort Extract product is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Full Spectrum™ St. John's Wort Extract product fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violations cited in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam A. Correll Jr.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","ProHealth Inc.","prohealth-inc-612227-02182021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprohealth-inc-612227-02182021","2026-10-26T08:09:44.855042+00:00","Closed Out","2021-02-19","612227","DrugsFood & Beverages","2021-07-21","Richard Carson","2026-08-20T03:22:24.314+00:00","Via Overnight Delivery","2021-02-18",{"id":298,"raw":299,"subject":303,"body_html":304,"body_text":305,"firm_name":306,"letter_id":307,"created_at":110,"fei_number":19,"letter_url":308,"updated_at":309,"action_type":22,"case_status":23,"posted_date":310,"marcs_cms_no":311,"product_type":115,"closeout_date":19,"issuing_office":104,"recipient_name":312,"body_fetched_at":313,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":314,"medical_device_id":19,"response_letter_date":19},2786,[300,301,302,104,303,13,13,13],"\u003Ctime datetime=\"2022-03-29T14:00:00Z\">03\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-28T04:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreenway-herbal-products-llc-627042-03282022\">Greenway Herbal Products LLC\u003C\u002Fa>","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David B. Laroche\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Greenway Herbal Products LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>509 W. College Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Murfreesboro\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>37130\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@tanasi.com\"> support@tanasi.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 627042\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;March 28, 2022\u003C\u002Fp>\n\n\u003Cp>TO: &nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;support@tanasi.com – &nbsp;&nbsp; &nbsp;David B. Laroche\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;GreenWay Herbal Products, LLC (d\u002Fb\u002Fa Tanasi)\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;509 W. College Street\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Murfreesboro, TN 37130\u003C\u002Fp>\n\n\u003Cp>RE: &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Ftanasi.com\u002F on February 18, 2022, and March 22, 2022, respectively. &nbsp;We also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002Ftanasibotanicals\u002F, where you direct consumers to your website, https:\u002F\u002Ftanasi.com\u002F, to purchase your products. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Ca id=\"footnoteref1_7hwa07u\" href=\"#footnote1_7hwa07u\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa> &nbsp;in people. &nbsp;Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Ca id=\"footnoteref2_eh2oi9e\" href=\"#footnote2_eh2oi9e\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa> &nbsp;In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Ca id=\"footnoteref3_zepwaem\" href=\"#footnote3_zepwaem\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa> &nbsp;Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website and social media website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>“Does CBD Defend Against COVID? . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>At the University Of Chicago, a team led by Marsha Rosner discovered that CBD curbs COVID-19 cell infections in lab experiments. By using small doses of CBD (approximately what patients would receive in an oral drug), the team discovered that CBD didn’t stop the spread of COVID-19 in test tubes. Rather, it started acting as soon as the virus entered healthy cells, blocking it from making copies of itself, thanks to interferon (an inflammatory protein).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBD, COVID and Epilepsy\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>When the team studied adults with severe epilepsy, they realized that individuals on Epidiolex, a CBD-based medication, showed lower COVID-19 infection rates. . . . Another team from Oregon State University, led by Richard van Breeman, recently shared a report in the Journal of Natural Products. It stated that high doses of CBDA and CBG actually prevent coronavirus from breaking into cells.” [from the January 30, 2022 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fdoes-cbd-defend-against-covid\u002F]&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>“3 CBDA Studies To Know Right Now . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. COVID\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A lab study in the Journal of Nature Products shows that cannabis compounds inhibit the COVID 19 virus from easily penetrating healthy human cells. Specifically, CBDA, and CBGA possess the ability to combat coronavirus. . . .&nbsp;\u003C\u002Fp>\n\n\u003Cp>Even better? Researchers examined the compounds’ impact against the COVID’s alpha and beta variants in a laboratory. And they proved effective. . . . lead researcher Richard van Breemen said that these compounds could prevent and even treat SARS-CoV-2 infections. And he suggested taking them orally, thanks to their extended history of safe application in humans. . . .\u003C\u002Fp>\n\n\u003Cp>You can enjoy the better-together benefits of CBDa and CBD in Tanasi’s range of full-spectrum hemp extracts.” [from the January 27, 2022 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002F3-cbda-studies-to-know-right-now\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; \u003Cstrong>&nbsp;“Cannabis and Covid: New Hope For Preventing Infections and Speeding Recovery . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cannabis and COVID: Preventing Infection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In the new study, author Richard van Breemen reveals that cannabinoids can help prevent a Sars-Cov-2 infection., [sic] How does that work? It seems that they block Covid-19 from entering your healthy cells. And, while all cannabinoids may be useful, two offer the most protection: &nbsp;CBGA and CBDA. &nbsp;(Also known as cannabigerolic acid and cannabidiolic acid.)\u003C\u002Fp>\n\n\u003Cp>Now, if you’re familiar with our Tanasi products, you probably know that these two compounds have many potential therapeutic properties. But now, with this study, we’ve learned that they may fight COVID by binding to the virus’ spike proteins. In turn, this makes it harder for Covid to force its way into your body’s healthy cells, possibly preventing infection.\u003C\u002Fp>\n\n\u003Cp>Already, that’s pretty exciting news. And it keeps getting better, because the cannabinoids seem to work against several Covid variants.” . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cannabis and COVID: How Cannabinoids Fuel Recovery from Infection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>After announcing his new findings, van Breemen also said that cannabinoids ‘have the potential to prevent as well as treat infection by SARS-CoV-2.’” [from the January 14, 2022 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fcannabis-and-covid-how-cannabinoids-could-prevent-infection\u002F]&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>“The Latest Information On CBD Covid Implications\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As the COVID-19 outbreak affects countries across the globe, we’re all hoping and waiting for new disease treatments. Thankfully, the latest studies and research shows cannabis’ potential to treat coronavirus-related symptoms. . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. CBD May Prevent a Cytokine Storm, and stop the Havoc it Wreaks in the Body\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Early results of an ongoing study published in HealthEuropa suggest that a specific combination of cannabinoids and terpenes appears to be twice as effective as the corticosteroid dexamethasone at lowering COVID-19 inflammation. . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Ongoing Research Is Examining The Full Effects Of The Virus And How CBD Can Mitigate Long-Term Damage\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Research from the Rabin Medical Center holds another clue. Their findings suggest that 8 out of the 11 patients receiving cannabis treatments program saw improvements in virus-related infections.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBD Covid Treatment: Can Cannabis Help?\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Many researchers believe that CBD might help fight COVID-19. It’s classified as a contagious respiratory illness that causes fatigue, breathing problems, and fever. For some people, it’s proven to be fatal. So could CBD and cannabis offer assistance in the ongoing fight against Covid-19? . . .\u003C\u002Fp>\n\n\u003Cp>CBD shows significant potential in the fight against Covid-19, mainly due to its significant anti-inflammatory properties. The latest research shows that cannabis and CBD might drastically improve Covid-19 symptoms. It could do so by lowering cytokine storms and protecting lung tissue from inflammation.” [from the October 3, 2021 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fcbd-covid-treatment-option\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; \u003Cstrong>&nbsp;“5 Things You Need to Know About THCV . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Anti-Inflammatory Effects . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>More recently, THCV was highlighted in connection with cannabinoids’ anti-inflammatory impact on Covid-19- lung inflammation. The research, published in the Nature journal Scientific Reports, suggests that cannabigerol (CBG) and low-dose THCV reduces inflammation in Covid patients’ lung cells. But at this time, there are no approved cannabinoid COVID treatments. . . .\u003C\u002Fp>\n\n\u003Cp>3. Most cannabis plants produce low concentrations of THCV. Certain strains can offer higher concentrations. . . . your best bet may be from the entourage effect associated with our full-spectrum CBD products.” [from the June 4, 2021 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002F5-things-you-need-to-know-about-thcv\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>“The Effects of Hemp on Inflammation . . .&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Medical College of Georgia and Dental College of Georgia recently conducted a relevant study. It showed that CBD could help reduce cytokine storms . . . and unrestricted lung inflammation in patients with Covid-19.” [from the November 17, 2020 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Feffects-of-hemp-on-inflammation\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;\u003Cstrong>“What Is Dexamethasone?&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dexamethasone has recently emerged as the best drug to treat severe life-threatening cases of Coronavirus Disease 2019 (COVID-19). . . . Dexamethasone is a synthetic corticosteroid that is used as an anti-inflammatory or immunosuppressant agent. . . . &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>What Are the Anti-Inflammatory Effects of Cannabinoids? . . .&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>GreenWay Tanasi, LLC, and its brand, Tanasi, a subsidiary of GreenWay Herbal Products, LLC, sells a number of cannabidiol (CBD) products that feature a unique patent-pending blend of cannabinoids (CBD and Cannabidiolic-acid (CBDA)) extracted from Cannabis Sativa L. hemp plants. &nbsp;GreenWay Herbal Products, LLC developed this patent-pending technology with a university partner, which has demonstrated that cannabinoids are natural anti-inflammatory agents that can suppress cytokine storms. &nbsp;In direct comparison studies, the unique formulation of cannabinoids used in the Tanasi CBD product line was as effective as dexamethasone in reducing cytokine storms. &nbsp;Thus [sic] it is not surprising that customers using the Tanasi CBD\u002FCBDA products report that they are very effective at reducing a number of inflammatory conditions. &nbsp;See the customer reviews at www.tanasi.com. Tanasi is not recommending using its CBD\u002FCBDA patent-pending formula as a treatment for COVID-19.” [from the July 2, 2020 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fwhat-is-dexamethasone\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;“In the new study, author Richard van Breemen reveals that cannabinoids can help prevent a Sars-Cov-2 infection.\u003C\u002Fp>\n\n\u003Cp>It seems that they block Covid-19 from entering your healthy cells. And, while all cannabinoids may be useful, two offer the most protection: CBGA and CBDA. . . .\u003C\u002Fp>\n\n\u003Cp>Cannabis and Covid | CBDa prevents Covid-19 infection | Tanasi CBD with CBDa” [from the January 18, 2022 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Ftanasibotanicals\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;“It does matter to know. . . &nbsp;TANASI.COM&nbsp;\u003Cbr>\nCBD Covid Relief | Cannabis Treatment for COVID 19 . . .” [from the October 8, 2021 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Ftanasibotanicals\u002F]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. &nbsp;This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. &nbsp;It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. &nbsp;\u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. &nbsp;Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. &nbsp;Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> &nbsp;In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. &nbsp;For COVID-19, no such study is currently known to exist for the products identified above. &nbsp;Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. &nbsp;You must immediately cease making all such claims. &nbsp;Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). &nbsp;Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Sincerely,\u003Cbr>\n\u002FS\u002F&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;\u002FS\u002F\u003Cbr>\nDonald Ashley&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Serena Viswanathan&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;\u003Cbr>\nDirector&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Associate Director\u003Cbr>\nOffice of Compliance&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Division of Advertising Practices &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;\u003Cbr>\nCenter for Drug Evaluation and Research&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Federal Trade Commission&nbsp;&nbsp; &nbsp;\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_7hwa07u\">\u003Ca href=\"#footnoteref1_7hwa07u\">1\u003C\u002Fa>As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19). \u003C\u002Fli>\n                      \u003Cli id=\"footnote2_eh2oi9e\">\u003Ca href=\"#footnoteref2_eh2oi9e\">2\u003C\u002Fa>Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_zepwaem\">\u003Ca href=\"#footnoteref3_zepwaem\">3\u003C\u002Fa>Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDavid B. Laroche\n\nGreenway Herbal Products LLC\n\n509 W. College Street\n\nMurfreesboro, TN 37130\n\nUnited States\n\nsupport@tanasi.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRE: 627042\n\nDate: March 28, 2022\n\nTO: support@tanasi.com – David B. Laroche\n\nGreenWay Herbal Products, LLC (d\u002Fb\u002Fa Tanasi)\n\n509 W. College Street\n\nMurfreesboro, TN 37130\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Ftanasi.com\u002F on February 18, 2022, and March 22, 2022, respectively. We also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002Ftanasibotanicals\u002F, where you direct consumers to your website, https:\u002F\u002Ftanasi.com\u002F, to purchase your products. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website and social media website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n• “Does CBD Defend Against COVID? . . .\n\nAt the University Of Chicago, a team led by Marsha Rosner discovered that CBD curbs COVID-19 cell infections in lab experiments. By using small doses of CBD (approximately what patients would receive in an oral drug), the team discovered that CBD didn’t stop the spread of COVID-19 in test tubes. Rather, it started acting as soon as the virus entered healthy cells, blocking it from making copies of itself, thanks to interferon (an inflammatory protein).\n\nCBD, COVID and Epilepsy\n\nWhen the team studied adults with severe epilepsy, they realized that individuals on Epidiolex, a CBD-based medication, showed lower COVID-19 infection rates. . . . Another team from Oregon State University, led by Richard van Breeman, recently shared a report in the Journal of Natural Products. It stated that high doses of CBDA and CBG actually prevent coronavirus from breaking into cells.” [from the January 30, 2022 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fdoes-cbd-defend-against-covid\u002F]\n\n• “3 CBDA Studies To Know Right Now . . .\n\n3. COVID\n\nA lab study in the Journal of Nature Products shows that cannabis compounds inhibit the COVID 19 virus from easily penetrating healthy human cells. Specifically, CBDA, and CBGA possess the ability to combat coronavirus. . . .\n\nEven better? Researchers examined the compounds’ impact against the COVID’s alpha and beta variants in a laboratory. And they proved effective. . . . lead researcher Richard van Breemen said that these compounds could prevent and even treat SARS-CoV-2 infections. And he suggested taking them orally, thanks to their extended history of safe application in humans. . . .\n\nYou can enjoy the better-together benefits of CBDa and CBD in Tanasi’s range of full-spectrum hemp extracts.” [from the January 27, 2022 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002F3-cbda-studies-to-know-right-now\u002F]\n\n• “Cannabis and Covid: New Hope For Preventing Infections and Speeding Recovery . . .\n\nCannabis and COVID: Preventing Infection\n\nIn the new study, author Richard van Breemen reveals that cannabinoids can help prevent a Sars-Cov-2 infection., [sic] How does that work? It seems that they block Covid-19 from entering your healthy cells. And, while all cannabinoids may be useful, two offer the most protection: CBGA and CBDA. (Also known as cannabigerolic acid and cannabidiolic acid.)\n\nNow, if you’re familiar with our Tanasi products, you probably know that these two compounds have many potential therapeutic properties. But now, with this study, we’ve learned that they may fight COVID by binding to the virus’ spike proteins. In turn, this makes it harder for Covid to force its way into your body’s healthy cells, possibly preventing infection.\n\nAlready, that’s pretty exciting news. And it keeps getting better, because the cannabinoids seem to work against several Covid variants.” . . .\n\nCannabis and COVID: How Cannabinoids Fuel Recovery from Infection\n\nAfter announcing his new findings, van Breemen also said that cannabinoids ‘have the potential to prevent as well as treat infection by SARS-CoV-2.’” [from the January 14, 2022 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fcannabis-and-covid-how-cannabinoids-could-prevent-infection\u002F]\n\n• “The Latest Information On CBD Covid Implications\n\nAs the COVID-19 outbreak affects countries across the globe, we’re all hoping and waiting for new disease treatments. Thankfully, the latest studies and research shows cannabis’ potential to treat coronavirus-related symptoms. . . .\n\n2. CBD May Prevent a Cytokine Storm, and stop the Havoc it Wreaks in the Body\n\nEarly results of an ongoing study published in HealthEuropa suggest that a specific combination of cannabinoids and terpenes appears to be twice as effective as the corticosteroid dexamethasone at lowering COVID-19 inflammation. . . .\n\n3. Ongoing Research Is Examining The Full Effects Of The Virus And How CBD Can Mitigate Long-Term Damage\n\nResearch from the Rabin Medical Center holds another clue. Their findings suggest that 8 out of the 11 patients receiving cannabis treatments program saw improvements in virus-related infections.\n\nCBD Covid Treatment: Can Cannabis Help?\n\nMany researchers believe that CBD might help fight COVID-19. It’s classified as a contagious respiratory illness that causes fatigue, breathing problems, and fever. For some people, it’s proven to be fatal. So could CBD and cannabis offer assistance in the ongoing fight against Covid-19? . . .\n\nCBD shows significant potential in the fight against Covid-19, mainly due to its significant anti-inflammatory properties. The latest research shows that cannabis and CBD might drastically improve Covid-19 symptoms. It could do so by lowering cytokine storms and protecting lung tissue from inflammation.” [from the October 3, 2021 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fcbd-covid-treatment-option\u002F]\n\n• “5 Things You Need to Know About THCV . . .\n\nAnti-Inflammatory Effects . . .\n\nMore recently, THCV was highlighted in connection with cannabinoids’ anti-inflammatory impact on Covid-19- lung inflammation. The research, published in the Nature journal Scientific Reports, suggests that cannabigerol (CBG) and low-dose THCV reduces inflammation in Covid patients’ lung cells. But at this time, there are no approved cannabinoid COVID treatments. . . .\n\n3. Most cannabis plants produce low concentrations of THCV. Certain strains can offer higher concentrations. . . . your best bet may be from the entourage effect associated with our full-spectrum CBD products.” [from the June 4, 2021 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002F5-things-you-need-to-know-about-thcv\u002F]\n\n• “The Effects of Hemp on Inflammation . . .\n\nThe Medical College of Georgia and Dental College of Georgia recently conducted a relevant study. It showed that CBD could help reduce cytokine storms . . . and unrestricted lung inflammation in patients with Covid-19.” [from the November 17, 2020 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Feffects-of-hemp-on-inflammation\u002F]\n\n• “What Is Dexamethasone?\n\nDexamethasone has recently emerged as the best drug to treat severe life-threatening cases of Coronavirus Disease 2019 (COVID-19). . . . Dexamethasone is a synthetic corticosteroid that is used as an anti-inflammatory or immunosuppressant agent. . . .\n\nWhat Are the Anti-Inflammatory Effects of Cannabinoids? . . .\n\nGreenWay Tanasi, LLC, and its brand, Tanasi, a subsidiary of GreenWay Herbal Products, LLC, sells a number of cannabidiol (CBD) products that feature a unique patent-pending blend of cannabinoids (CBD and Cannabidiolic-acid (CBDA)) extracted from Cannabis Sativa L. hemp plants. GreenWay Herbal Products, LLC developed this patent-pending technology with a university partner, which has demonstrated that cannabinoids are natural anti-inflammatory agents that can suppress cytokine storms. In direct comparison studies, the unique formulation of cannabinoids used in the Tanasi CBD product line was as effective as dexamethasone in reducing cytokine storms. Thus [sic] it is not surprising that customers using the Tanasi CBD\u002FCBDA products report that they are very effective at reducing a number of inflammatory conditions. See the customer reviews at www.tanasi.com. Tanasi is not recommending using its CBD\u002FCBDA patent-pending formula as a treatment for COVID-19.” [from the July 2, 2020 blog post on your webpage https:\u002F\u002Ftanasi.com\u002Fblog\u002Fwhat-is-dexamethasone\u002F]\n\n• “In the new study, author Richard van Breemen reveals that cannabinoids can help prevent a Sars-Cov-2 infection.\n\nIt seems that they block Covid-19 from entering your healthy cells. And, while all cannabinoids may be useful, two offer the most protection: CBGA and CBDA. . . .\n\nCannabis and Covid | CBDa prevents Covid-19 infection | Tanasi CBD with CBDa” [from the January 18, 2022 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Ftanasibotanicals\u002F]\n\n• “It does matter to know. . . TANASI.COM\n\nCBD Covid Relief | Cannabis Treatment for COVID 19 . . .” [from the October 8, 2021 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Ftanasibotanicals\u002F]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088\n\nSincerely, Sincerely,\n\n\u002FS\u002F \u002FS\u002F\n\nDonald Ashley Serena Viswanathan\n\nDirector Associate Director\n\nOffice of Compliance Division of Advertising Practices\n\nCenter for Drug Evaluation and Research Federal Trade Commission\n\nFood and Drug Administration\n\n1As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\n\n3Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F","Greenway Herbal Products LLC","greenway-herbal-products-llc-627042-03282022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreenway-herbal-products-llc-627042-03282022","2026-10-26T08:08:50.426617+00:00","2022-03-29","627042","David B. Laroche","2026-08-20T02:04:17.287+00:00","2022-03-28",{"id":316,"raw":317,"subject":322,"body_html":323,"body_text":324,"firm_name":325,"letter_id":326,"created_at":110,"fei_number":19,"letter_url":327,"updated_at":328,"action_type":22,"case_status":23,"posted_date":329,"marcs_cms_no":330,"product_type":70,"closeout_date":19,"issuing_office":321,"recipient_name":331,"body_fetched_at":332,"delivery_method":333,"recipient_title":19,"reference_number":19,"action_taken_date":334,"medical_device_id":19,"response_letter_date":19},2949,[318,319,320,321,322,13,13,13],"\u003Ctime datetime=\"2021-12-28T14:20:00Z\">12\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-07T05:00:00Z\">12\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestern-herb-products-inc-615439-12072021\">Western Herb Products, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations – West Division 6","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Certified Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rhonda H. Summerland\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Western Herb Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 115\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Index\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98256\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations – West Division 6\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 7, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 615439\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Summerland:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility located at 21624 Sertz Road, Index, Washington, on May 3, 4, and 12, 2021. During the inspection, we identified serious violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the Wormwood\u002FAloes dietary supplement product that you manufacture is misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343]. You can find the Act and FDA regulations through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>We received an e-mail correspondence from you dated May 31, 2021, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your significant violations of CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the required specifications for points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.70(a). You do not have written specifications to ensure the consistent production of your finished dietary supplements. Specifically, for your Wormwood\u002FAloes dietary supplement capsules, lot #06821-6:\u003C\u002Fp>\n\n\u003Cp>a. For your components:\u003Cbr>\n&nbsp; i. You failed to establish an identity specification, as required in 21 CFR 111.70(b)(1).\u003Cbr>\n&nbsp; ii. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2).\u003Cbr>\n&nbsp; iii. You failed to establish limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required in 21 CFR 111.70(b)(3).\u003Cbr>\nb. You failed to establish in-process specifications for any point, step, or stage in the MMR where control is necessary to help ensure that specifications are met for the identity, purity, strength, and composition of the dietary supplement, as required by 21 CFR 111.70(c)(1). Included in the manufacture of the Wormwood\u002FAloes dietary supplement is the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the wormwood powder and aloe powder. A \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>inspection is performed on the herb(s) after \u003Cstrong>(b)(4)\u003C\u002Fstrong> the blend of wormwood powder and aloe powder; however, an acceptance criterion related to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> blend (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) does not ensure that specifications are met for the composition of the dietary supplement.\u003Cbr>\nc. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e).\u003C\u002Fp>\n\n\u003Cp>We received and reviewed your revised specification sheets for the dietary ingredients, wormwood and aloe, and for the Wormwood\u002FAloes dietary supplement submitted with your May 31, 2021, written response to the inspection and have the following comments:\u003C\u002Fp>\n\n\u003Cp>The specifications were revised to include identification by microscopic examination with an acceptance criterion of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and the purity strength specification states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The identity specification is inadequate in that the microscopic specification fails to include characteristics that will allow you to confirm the identity of the ingredient at issue, such as specific microscopic characteristics that should be observed for comparison to the standard. We are also unable to evaluate the sufficiency of your “Purity\u002FStrength” standard on your revised specification sheet, which states, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” as this specification does not provide the specific portion or percentage that is wormwood or aloe powder, nor does it provide the specific concentration that is expected for each of the powders. The documentation you provided fails to provide a specification for composition for the individual wormwood powder and aloe powder.\u003C\u002Fp>\n\n\u003Cp>Further, you included microscopic examination in your revised specification sheets in addition to organoleptic and macroscopic methods to identify the botanical powder and provided photos of two products showing a comparison of their physical structures under the microscope at different forms (whole leaf, rough cut, and finer cut). Microscopic analyses may be an appropriate identity test for whole or coarsely cut botanical parts, but it may not be an appropriate identity test for powdered or extracted botanicals because of decreased reliability, or in those instances where misidentification of botanicals is known to occur [Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 72 Fed. Reg. 34752, 34852 (June 25, 2007)]. The physical characteristic of a plant significantly decreases as the plant is cut into a finer size or powder, as evidenced in the photos you provided.\u003C\u002Fp>\n\n\u003Cp>Your component and finished product specifications regarding limits of contamination are inadequate because you did not specify which heavy metals are subject to the specification (component) or are not established (finished product).\u003C\u002Fp>\n\n\u003Cp>Your finished product specification is further inadequate in that identity cannot be determined by verification of input as it does not provide a specific physical or qualitative property that can be used to confirm identity, nor does it include a numeric or quantitative limit for comparison; purity as a function of no additives or flow agents does not provide the specific portion or percentage that is wormwood and aloe powders; strength as an amount of dietary ingredient cannot be adequately evaluated because the method by which the strength can be verified was not provided; and composition as a statement of a blend of OG Wormwood (Artemisia absinthium) leaf and cape aloes (Aloes ferox) leaf powders in “00” gelatin capsules does not provide the percent of wormwood and aloe powders comprised in the blend.\u003C\u002Fp>\n\n\u003Cp>Further, you have not established specifications for the empty hard-shell gelatin capsule #00 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) used in the manufacture of your dietary supplement capsules.\u003C\u002Fp>\n\n\u003Cp>Finally, you provided a label proof that includes specifications (e.g., die number, dimensions stock, and unwind directions). To the extent that you intend to use the label proof to satisfy the requirement for label specifications under 21 CFR 111.70(d), we note that it is unclear if this is the label used in all labeling operations or if the specifications provided are the official labels. Furthermore, the label proof does not have approval by your quality unit documented on the record.\u003C\u002Fp>\n\n\u003Cp>Moreover, your response dated May 31, 2021, did not include any interim corrective action to ensure that the dietary supplements that you manufacture and distribute are what they purport to be and are free from contamination. Although you stated during the inspection that it would take approximately six months to complete the majority of your product specifications, and longer than six months for those products that you order only once or twice a year, you did not provide additional information about this timeline in your response or explain why it would take six months, nor did you specify corrections that you would make in the meantime.\u003C\u002Fp>\n\n\u003Cp>Once you have established the specifications identified above, you must verify that the specifications are met in accordance with 21 CFR 111.73 and 21 CFR 111.75, and you must make and keep records of the specifications established in accordance with 21 CFR 111.95(b)(1). Your Quality Control Personnel must approve specifications, among other things, as required by 21 CFR 111.105(a).\u003C\u002Fp>\n\n\u003Cp>2. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, during the inspection, when the FDA investigator requested information about your MMRs, you provided a document titled “Master Manufacturing Record,” dated March 8, 2021, for the manufacture of the Wormwood\u002FAloes dietary supplement. The document lacked the following information that must be included in an MMR, as required in 21 CFR 111.210:\u003C\u002Fp>\n\n\u003Cp>a. The strength and concentration of each dietary ingredient for each batch size [21 CFR 111.210(a)];\u003Cbr>\nb. A complete list of components to be used [21 CFR 111.210(b)];\u003Cbr>\nc. An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\u003Cbr>\nd. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)];\u003Cbr>\ne. A statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\u003Cbr>\nf. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\u003Cbr>\ng. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)]; and\u003Cbr>\nh. The following written instructions:\u003Cbr>\n&nbsp; i. Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled, as specified in the MMR [21 CFR 111.210(h)(1)];\u003Cbr>\n&nbsp; ii. Procedures for sampling and a cross reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\u003Cbr>\n&nbsp; iii. Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(3)]; and\u003Cbr>\n&nbsp; iv. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\u003C\u002Fp>\n\n\u003Cp>We received your revised MMRs submitted with your May 31, 2021, written response to the inspection. Our review of these documents indicates they are inadequate because they continue to lack the required information for an MMR as listed above.\u003C\u002Fp>\n\n\u003Cp>3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, which includes all required information, as required by 21 CFR 111.255(a) and 21 CFR 111.260. Specifically, the BPR you provided for your Wormwood\u002FAloes dietary supplement lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\u003C\u002Fp>\n\n\u003Cp>a. The identity of equipment used in producing the batch [21 CFR 111.260(b)];\u003Cbr>\nb. The date and time of the maintenance, cleaning, and sanitizing of the equipment used in producing the batch, or a cross-reference to records, such as individual equipment logs where the information is retained [21 CFR 111.260(c)];\u003Cbr>\nc. The identity and weight or measure of each component used [21 CFR 111.260(e)];\u003Cbr>\nd. A statement of the actual yield and a statement of the percentage of theoretical yield at the appropriate phases of processing [21 CFR 111.260(f)];\u003Cbr>\ne. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003Cbr>\nf. Documentation that the finished dietary supplement meets specifications for identity, purity, strength, composition, and limits on contamination and for packaging and labeling [21 CFR 111.260(i)];\u003Cbr>\ng. Documentation, at the time of performance, of the manufacture of the batch, including the date on which each step of the master manufacturing record was performed and the initials of the persons performing each step [21 CFR 111.260(j)(1)];\u003Cbr>\nh. Documentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the person responsible for verifying the weight or measure, the person responsible for adding the component to the batch, and the person responsible for verifying the addition of components [21 CFR 111.260(j)(2)];\u003Cbr>\ni. Documentation, at the time of performance, of packaging and labeling operations, including the unique identifier you assigned to packaging and labels used, an actual or representative label of the finished product as specified in the master manufacturing record, and the results of any tests or examinations conducted on packaged and labeled dietary supplements [21 CFR 111.260(k)]; and\u003Cbr>\nj. Documentation, at the time of performance, that the quality control personnel reviewed the batch production record, approved, or rejected any reprocessing or repackaging, approved, and released the batch or rejected the batch for distribution, and approved and released or rejected the packaged and labeled dietary supplement [21 CFR 111.260(l)].\u003C\u002Fp>\n\n\u003Cp>We are unable to adequately assess your corrective action submitted in your May 31, 2021, response for this observation because you did not provide documentation for review that demonstrates you are preparing a BPR that includes all required information for every manufactured batch of dietary supplement.\u003C\u002Fp>\n\n\u003Cp>4. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing, as required by 21 CFR 111.103. Specifically, you have no written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing.\u003C\u002Fp>\n\n\u003Cp>Once you have established your quality control written procedures, you must implement quality control operations in your manufacturing, packaging, labeling, and holding operations, as required by 21 CFR 111.65.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your revised Standard Operating Procedures (SOPs) submitted with your May 31, 2021, written response. Section IV Quality Control\u002FQA of your SOP includes the duties of quality control, duties of quality assurance, and inspection of materials. However, it does not include written procedures documenting how you conduct a material review, make a disposition decision, and approve or reject any reprocessing related to ingredients, in-process material, finished products, and packaging and labeling components.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures to fulfill the requirements for product complaints, as required by 21 CFR 111.553. Specifically, you have no written procedures for product complaints.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your revised SOPs submitted with your May 31, 2021, written response. Section I Materials of your SOP includes a subsection on product returns which describes your complaint procedure. It states that complaints are addressed on an individual basis, and if a concern about a specific lot of herbs is warranted, customers who received the lot are notified as noted in your recall plan. Your written procedure is inadequate in that it does not provide sufficient information to determine whether a qualified person will review and investigate product complaints to determine whether the product complaint involves a possible failure of a dietary supplement to meet any of its specifications, including those specifications and other requirements that, if not met, may result in a risk of illness or injury; whether quality control personnel will review and approve decisions about whether to investigate a product complaint and review and approve the findings and follow-up action of any investigation performed; and whether the required review and investigation of the product complaint by a qualified person, and the review by quality control personnel about whether to investigate a product complaint, and the findings and follow-up action of any investigation performed, must extend to all relevant batches and records, as required by 21 CFR 111.553 and 21 CFR 111.560.\u003C\u002Fp>\n\n\u003Cp>Note that after you have established such procedures, you must make and keep a written record of every product complaint, as required by 21 CFR 111.570(b)(2).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>6. Your Wormwood\u002FAloes dietary supplement is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] in that the labels fails to identify the appropriate part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a. The label indicated that \u003Cem>Artemisia absinthium\u003C\u002Fem> is derived from the leaf part of the plant, however, the specification sheet indicated that the botanical ingredient is derived from the aerial parts, which include the entire plant parts that grow above the ground.\u003Cbr>\nb. The label indicated that \u003Cem>Aloe ferox\u003C\u002Fem> is derived from the leaf part of the plant, however, the supplier specification sheet indicated it is derived from the juice or resin from leaves.\u003C\u002Fp>\n\n\u003Cp>The plant part declared on the product label must be consistent with the actual plant part identity as indicated on the specification sheet.\u003C\u002Fp>\n\n\u003Cp>7. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>a. The title, \"Supplement Facts,\" is not larger than all other print in the panel [21 CFR 101.36(e)(1)];\u003Cbr>\nb. The title and all headings are not bolded to distinguish them from the other information [21 CFR 101.36(e)(1)];\u003Cbr>\nc. The Serving Size is not placed under the \"Supplement Facts\" heading and not aligned on the left side of the nutrition label [21 CFR 101.36(b)(1)]; and\u003Cbr>\nd. There are no spaces between text lines and the letters within the panel touch one another and, in general, the label is not offset from the remainder of the label in a box and does not have the bolding, heavy bars, etc. [21 CFR 101.36(e)].\u003C\u002Fp>\n\n\u003Cp>8. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, \u003Cem>Artemisia absinthium\u003C\u002Fem> and \u003Cem>Aloe ferox\u003C\u002Fem> are not the standardized common names for these dietary ingredients. Furthermore, the product specification sheet and master manufacturing records indicate the product’s dietary ingredients are powdered extracts, but the product label fails to state the dietary ingredients are extracts.\u003C\u002Fp>\n\n\u003Cp>9. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel, as required by 21 CFR 101.7. Specifically, your label states that “This package contains approximately” 300 “00” capsules. “Approximately” is not provided for in 21 CFR 101.7.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food\u003Cbr>\nOperations – West Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nCertified Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRhonda H. Summerland\n\nRecipient Title\n\nPresident\n\nWestern Herb Products, Inc.\n\nP.O. Box 115\n\nIndex, WA 98256\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations – West Division 6\n\nUnited States\n\nDecember 7, 2021\n\nIn reply, refer to CMS 615439\n\nWARNING LETTER\n\nDear Dr. Summerland:\n\nThe United States Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility located at 21624 Sertz Road, Index, Washington, on May 3, 4, and 12, 2021. During the inspection, we identified serious violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the Wormwood\u002FAloes dietary supplement product that you manufacture is misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343]. You can find the Act and FDA regulations through links in FDA's home page at www.fda.gov.\n\nWe received an e-mail correspondence from you dated May 31, 2021, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\n\nDietary Supplement CGMP Violations\n\nYour significant violations of CGMP requirements are as follows:\n\n1. You failed to establish the required specifications for points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.70(a). You do not have written specifications to ensure the consistent production of your finished dietary supplements. Specifically, for your Wormwood\u002FAloes dietary supplement capsules, lot #06821-6:\n\na. For your components:\n\ni. You failed to establish an identity specification, as required in 21 CFR 111.70(b)(1).\n\nii. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2).\n\niii. You failed to establish limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required in 21 CFR 111.70(b)(3).\n\nb. You failed to establish in-process specifications for any point, step, or stage in the MMR where control is necessary to help ensure that specifications are met for the identity, purity, strength, and composition of the dietary supplement, as required by 21 CFR 111.70(c)(1). Included in the manufacture of the Wormwood\u002FAloes dietary supplement is the (b)(4) and (b)(4) of the wormwood powder and aloe powder. A (b)(4) inspection is performed on the herb(s) after (b)(4) the blend of wormwood powder and aloe powder; however, an acceptance criterion related to the (b)(4) of the (b)(4) blend (e.g., (b)(4)) does not ensure that specifications are met for the composition of the dietary supplement.\n\nc. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e).\n\nWe received and reviewed your revised specification sheets for the dietary ingredients, wormwood and aloe, and for the Wormwood\u002FAloes dietary supplement submitted with your May 31, 2021, written response to the inspection and have the following comments:\n\nThe specifications were revised to include identification by microscopic examination with an acceptance criterion of “(b)(4),” and the purity strength specification states “(b)(4).” The identity specification is inadequate in that the microscopic specification fails to include characteristics that will allow you to confirm the identity of the ingredient at issue, such as specific microscopic characteristics that should be observed for comparison to the standard. We are also unable to evaluate the sufficiency of your “Purity\u002FStrength” standard on your revised specification sheet, which states, “(b)(4),” as this specification does not provide the specific portion or percentage that is wormwood or aloe powder, nor does it provide the specific concentration that is expected for each of the powders. The documentation you provided fails to provide a specification for composition for the individual wormwood powder and aloe powder.\n\nFurther, you included microscopic examination in your revised specification sheets in addition to organoleptic and macroscopic methods to identify the botanical powder and provided photos of two products showing a comparison of their physical structures under the microscope at different forms (whole leaf, rough cut, and finer cut). Microscopic analyses may be an appropriate identity test for whole or coarsely cut botanical parts, but it may not be an appropriate identity test for powdered or extracted botanicals because of decreased reliability, or in those instances where misidentification of botanicals is known to occur [Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 72 Fed. Reg. 34752, 34852 (June 25, 2007)]. The physical characteristic of a plant significantly decreases as the plant is cut into a finer size or powder, as evidenced in the photos you provided.\n\nYour component and finished product specifications regarding limits of contamination are inadequate because you did not specify which heavy metals are subject to the specification (component) or are not established (finished product).\n\nYour finished product specification is further inadequate in that identity cannot be determined by verification of input as it does not provide a specific physical or qualitative property that can be used to confirm identity, nor does it include a numeric or quantitative limit for comparison; purity as a function of no additives or flow agents does not provide the specific portion or percentage that is wormwood and aloe powders; strength as an amount of dietary ingredient cannot be adequately evaluated because the method by which the strength can be verified was not provided; and composition as a statement of a blend of OG Wormwood (Artemisia absinthium) leaf and cape aloes (Aloes ferox) leaf powders in “00” gelatin capsules does not provide the percent of wormwood and aloe powders comprised in the blend.\n\nFurther, you have not established specifications for the empty hard-shell gelatin capsule #00 ((b)(4)) used in the manufacture of your dietary supplement capsules.\n\nFinally, you provided a label proof that includes specifications (e.g., die number, dimensions stock, and unwind directions). To the extent that you intend to use the label proof to satisfy the requirement for label specifications under 21 CFR 111.70(d), we note that it is unclear if this is the label used in all labeling operations or if the specifications provided are the official labels. Furthermore, the label proof does not have approval by your quality unit documented on the record.\n\nMoreover, your response dated May 31, 2021, did not include any interim corrective action to ensure that the dietary supplements that you manufacture and distribute are what they purport to be and are free from contamination. Although you stated during the inspection that it would take approximately six months to complete the majority of your product specifications, and longer than six months for those products that you order only once or twice a year, you did not provide additional information about this timeline in your response or explain why it would take six months, nor did you specify corrections that you would make in the meantime.\n\nOnce you have established the specifications identified above, you must verify that the specifications are met in accordance with 21 CFR 111.73 and 21 CFR 111.75, and you must make and keep records of the specifications established in accordance with 21 CFR 111.95(b)(1). Your Quality Control Personnel must approve specifications, among other things, as required by 21 CFR 111.105(a).\n\n2. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, during the inspection, when the FDA investigator requested information about your MMRs, you provided a document titled “Master Manufacturing Record,” dated March 8, 2021, for the manufacture of the Wormwood\u002FAloes dietary supplement. The document lacked the following information that must be included in an MMR, as required in 21 CFR 111.210:\n\na. The strength and concentration of each dietary ingredient for each batch size [21 CFR 111.210(a)];\n\nb. A complete list of components to be used [21 CFR 111.210(b)];\n\nc. An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\n\nd. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)];\n\ne. A statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\n\nf. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\n\ng. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)]; and\n\nh. The following written instructions:\n\ni. Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled, as specified in the MMR [21 CFR 111.210(h)(1)];\n\nii. Procedures for sampling and a cross reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\n\niii. Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(3)]; and\n\niv. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\n\nWe received your revised MMRs submitted with your May 31, 2021, written response to the inspection. Our review of these documents indicates they are inadequate because they continue to lack the required information for an MMR as listed above.\n\n3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, which includes all required information, as required by 21 CFR 111.255(a) and 21 CFR 111.260. Specifically, the BPR you provided for your Wormwood\u002FAloes dietary supplement lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\n\na. The identity of equipment used in producing the batch [21 CFR 111.260(b)];\n\nb. The date and time of the maintenance, cleaning, and sanitizing of the equipment used in producing the batch, or a cross-reference to records, such as individual equipment logs where the information is retained [21 CFR 111.260(c)];\n\nc. The identity and weight or measure of each component used [21 CFR 111.260(e)];\n\nd. A statement of the actual yield and a statement of the percentage of theoretical yield at the appropriate phases of processing [21 CFR 111.260(f)];\n\ne. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\n\nf. Documentation that the finished dietary supplement meets specifications for identity, purity, strength, composition, and limits on contamination and for packaging and labeling [21 CFR 111.260(i)];\n\ng. Documentation, at the time of performance, of the manufacture of the batch, including the date on which each step of the master manufacturing record was performed and the initials of the persons performing each step [21 CFR 111.260(j)(1)];\n\nh. Documentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the person responsible for verifying the weight or measure, the person responsible for adding the component to the batch, and the person responsible for verifying the addition of components [21 CFR 111.260(j)(2)];\n\ni. Documentation, at the time of performance, of packaging and labeling operations, including the unique identifier you assigned to packaging and labels used, an actual or representative label of the finished product as specified in the master manufacturing record, and the results of any tests or examinations conducted on packaged and labeled dietary supplements [21 CFR 111.260(k)]; and\n\nj. Documentation, at the time of performance, that the quality control personnel reviewed the batch production record, approved, or rejected any reprocessing or repackaging, approved, and released the batch or rejected the batch for distribution, and approved and released or rejected the packaged and labeled dietary supplement [21 CFR 111.260(l)].\n\nWe are unable to adequately assess your corrective action submitted in your May 31, 2021, response for this observation because you did not provide documentation for review that demonstrates you are preparing a BPR that includes all required information for every manufactured batch of dietary supplement.\n\n4. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing, as required by 21 CFR 111.103. Specifically, you have no written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing.\n\nOnce you have established your quality control written procedures, you must implement quality control operations in your manufacturing, packaging, labeling, and holding operations, as required by 21 CFR 111.65.\n\nWe have reviewed your revised Standard Operating Procedures (SOPs) submitted with your May 31, 2021, written response. Section IV Quality Control\u002FQA of your SOP includes the duties of quality control, duties of quality assurance, and inspection of materials. However, it does not include written procedures documenting how you conduct a material review, make a disposition decision, and approve or reject any reprocessing related to ingredients, in-process material, finished products, and packaging and labeling components.\n\n5. You failed to establish and follow written procedures to fulfill the requirements for product complaints, as required by 21 CFR 111.553. Specifically, you have no written procedures for product complaints.\n\nWe have reviewed your revised SOPs submitted with your May 31, 2021, written response. Section I Materials of your SOP includes a subsection on product returns which describes your complaint procedure. It states that complaints are addressed on an individual basis, and if a concern about a specific lot of herbs is warranted, customers who received the lot are notified as noted in your recall plan. Your written procedure is inadequate in that it does not provide sufficient information to determine whether a qualified person will review and investigate product complaints to determine whether the product complaint involves a possible failure of a dietary supplement to meet any of its specifications, including those specifications and other requirements that, if not met, may result in a risk of illness or injury; whether quality control personnel will review and approve decisions about whether to investigate a product complaint and review and approve the findings and follow-up action of any investigation performed; and whether the required review and investigation of the product complaint by a qualified person, and the review by quality control personnel about whether to investigate a product complaint, and the findings and follow-up action of any investigation performed, must extend to all relevant batches and records, as required by 21 CFR 111.553 and 21 CFR 111.560.\n\nNote that after you have established such procedures, you must make and keep a written record of every product complaint, as required by 21 CFR 111.570(b)(2).\n\nMisbranded Dietary Supplements\n\n6. Your Wormwood\u002FAloes dietary supplement is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] in that the labels fails to identify the appropriate part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). For example:\n\na. The label indicated that Artemisia absinthium is derived from the leaf part of the plant, however, the specification sheet indicated that the botanical ingredient is derived from the aerial parts, which include the entire plant parts that grow above the ground.\n\nb. The label indicated that Aloe ferox is derived from the leaf part of the plant, however, the supplier specification sheet indicated it is derived from the juice or resin from leaves.\n\nThe plant part declared on the product label must be consistent with the actual plant part identity as indicated on the specification sheet.\n\n7. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example:\n\na. The title, \"Supplement Facts,\" is not larger than all other print in the panel [21 CFR 101.36(e)(1)];\n\nb. The title and all headings are not bolded to distinguish them from the other information [21 CFR 101.36(e)(1)];\n\nc. The Serving Size is not placed under the \"Supplement Facts\" heading and not aligned on the left side of the nutrition label [21 CFR 101.36(b)(1)]; and\n\nd. There are no spaces between text lines and the letters within the panel touch one another and, in general, the label is not offset from the remainder of the label in a box and does not have the bolding, heavy bars, etc. [21 CFR 101.36(e)].\n\n8. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, Artemisia absinthium and Aloe ferox are not the standardized common names for these dietary ingredients. Furthermore, the product specification sheet and master manufacturing records indicate the product’s dietary ingredients are powdered extracts, but the product label fails to state the dietary ingredients are extracts.\n\n9. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel, as required by 21 CFR 101.7. Specifically, your label states that “This package contains approximately” 300 “00” capsules. “Approximately” is not provided for in 21 CFR 101.7.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director\n\nOffice of Human and Animal Food\n\nOperations – West Division 6","Western Herb Products, Inc.","western-herb-products-inc-615439-12072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestern-herb-products-inc-615439-12072021","2026-10-26T08:10:31.194847+00:00","2021-12-28","615439","Rhonda H. Summerland","2026-08-20T02:18:14.398+00:00","Certified Mail","2021-12-07",{"id":336,"raw":337,"subject":203,"body_html":342,"body_text":343,"firm_name":344,"letter_id":345,"created_at":110,"fei_number":19,"letter_url":346,"updated_at":347,"action_type":22,"case_status":23,"posted_date":348,"marcs_cms_no":349,"product_type":115,"closeout_date":19,"issuing_office":341,"recipient_name":350,"body_fetched_at":351,"delivery_method":96,"recipient_title":19,"reference_number":19,"action_taken_date":352,"medical_device_id":19,"response_letter_date":19},2905,[338,339,340,341,203,13,13,13],"\u003Ctime datetime=\"2022-01-25T14:20:00Z\">01\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-29T05:00:00Z\">12\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealth-plus-inc-616877-12292021\">Health Plus Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Rita Mediratta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Health Plus Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13837 Magnolia Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chino\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91710\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ritam@healthplusinc.com\"> ritam@healthplusinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 29, 2021\u003Cbr>\n\u003Cbr>\nDear Ms. Mediratta:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Health Plus Inc., FEI 2027164, at 13837 Magnolia Avenue, Chino, California, from June 23 to July 1, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your July 20, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to ensure that returned drugs meet appropriate standards of safety, identity, strength, quality and purity prior to redistributing (21 CFR 211.204).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s handling of returned drug product before its redistribution is inadequate. For example, during the inspection, you were not able to provide documentation of adequate inspection and investigation of the returned product confirming the label conditions under which the returned drug product was held, stored, or shipped before its return and before redistributing. Furthermore, you failed to perform adequate testing to ensure the safety, identity, strength, quality, and purity of the returned product. Organoleptic examination alone is not sufficient to ensure that a product maintains its safety, identity, strength, purity, and quality after it has been in a situation where it may have been exposed to improper storage conditions.\u003C\u002Fp>\n\n\u003Cp>Before redistribution, you combined returned capsules from various lots into new batches with new lot numbers. These new lots did not have uniform character and quality, including capsules that would expire in less than three years. However, you then assigned these comingled batches new lot numbers and granted them an additional three-year shelf life. The new expiration dates are not supported by stability data and, in some instances, exceeded the expiration date of the returned product by up to 18 months. Your batch production records did not indicate you performed testing on these comingled batches before their redistribution.\u003C\u002Fp>\n\n\u003Cp>Your practices of conducting organoleptic examination on the returned product that was subjected to unknown conditions before return, making comingled batches by combining returned drug product with various lot numbers and expiration dates, and assigning a new product shelf life disregarding the expiration dates of the returned product are unacceptable.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and remediation plan to ensure the adequacy of your returned drug product handling and processing for redistribution. Provide a detailed action plan and associated procedures that should include, but not be limited to, the following:\u003Cbr>\n&nbsp; o Documentation of the conditions under which returned drug products have been held, stored, or shipped before, during and after return, reason for the return, quantity returned, date of disposition, and ultimate disposition, including procedures for destruction if doubt exists as to drug quality.\u003Cbr>\n&nbsp; o A procedure for ensuring the conditions under which returned drug products were held, stored, or shipped did not adversely affect the safety, identity, strength, quality or purity of the drug products.\u003C\u002Fp>\n\n\u003Cp>• Provide your action plan to address any product quality risks associated with the redistributed batches in the United States, including potential customer notifications and recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm did not adequately validate the process used to manufacture your over-the-counter drug product Super Colon Cleanse Stimulant Laxative. Your firm changed the formulation of your Super Colon Cleanse Stimulant Laxative in December 2017, including the removal of multiple components. You did not issue a process validation protocol and associated analytical testing report until November and December 2018, respectively, a year after your reformulation. Additionally, the only data supporting your November 2018 validation protocol, dated October 21, 2014, was from a test of the previous formulation and does not reflect the current drug product formulation. Since the December 2017 formulation change, your firm has manufactured and released at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of the drug product which you distributed to the U.S. market with inadequate process validation data.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you would create a new standard operating procedure (SOP) for process validation and would document and review the results of the process validation study. Additionally, you indicated that you would commence manufacturing the first process validation batch in August 2021.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because failure to conduct process validation studies can result in product quality attribute failures. You also failed to address your justification for continuing to manufacture the drug product when you have not adequately demonstrated that your manufacturing processes are reproducible and controlled to yield a drug product of uniform character and quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• A timeline for performing appropriate process performance qualification for your marketed drug product.\u003C\u002Fp>\n\n\u003Cp>• Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fp>\n\n\u003Cp>• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit (QU). Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately validate the method for assay used for your Super Colon Cleanse laxative drug product release specification. Specifically, per your specifications, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Spectrophotometer method for assay is to be conducted at the wavelength of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;as indicated in your finished drug product specifications. However, according to the data in the validation report you used the wavelength of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the method validation report did not include system suitability, nor did it demonstrate that your modified method is fit for purpose.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that the method validation for assay was conducted at the correct wavelength. Your response is inadequate as follows.\u003C\u002Fp>\n\n\u003Cp>• It lacked supporting documentation to support your claim that the method validation for assay was conducted at the correct wavelength.\u003C\u002Fp>\n\n\u003Cp>• It did not provide a risk assessment for the drug product released using the assay method that was not adequately validated nor a justification for continuation of the drug product currently on the market.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of all test methods to ensure that they are adequately validated and suitable for their intended purposes.\u003C\u002Fp>\n\n\u003Cp>• A retrospective assessment of reserve samples for all finished drug products that are currently on the market, using an adequately validated test method, to ensure that your drug products conform to the drug product specification.\u003C\u002Fp>\n\n\u003Cp>• A review of the completeness, consistency, accuracy of data from your use of uncontrolled documents (e.g., legal pads) to document the data.\u003C\u002Fp>\n\n\u003Cp>• A review of applicable compendial methods for your product.\u003C\u002Fp>\n\n\u003Cp>Refer to FDA’s guidance documents \u003Cem>Q2(R1) Validation of Analytical Procedures and Analytical Procedures and Methods Validation for Drugs and Biologics\u003C\u002Fem> for general principles and approaches for method validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq2r1-validation-analytical-procedures-text-and-methodology-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq2r1-validation-analytical-procedures-text-and-methodology-guidance-industry\u003C\u002Fa> and \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fanalytical-procedures-and-methods-validation-drugs-and-biologics\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fanalytical-procedures-and-methods-validation-drugs-and-biologics\u003C\u002Fa>, respectively.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>4. Your firm failed to follow a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s stability program is inadequate. Specifically, you only placed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;of your Super Colon Cleanse Stimulant Laxative drug product on stability and failed to perform any stability testing since at least September 2017. Furthermore, you did not have any stability data for drug product manufactured using the new formulation. Therefore, you lack sufficient stability data to substantiate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration of this drug product.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that the delay in conducting a stability study was because of restrained resources for the QU. You stated that you will initiate long-term stability testing for ongoing \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability testing and accelerated stability testing for the determination of the expiration dating period of the drug product.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your firm has been aware of the inadequacy of your stability program since the 2013 inspection. Subsequent inspections in 2015, 2018, and 2021, all had identical or similar observations in your stability program. Your response lacked information on what you did between 2013 and the current inspection to remediate your stability program.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your CAPA plan should include, but not be limited to:\u003Cbr>\n&nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf life claim remains valid\u003Cbr>\n&nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>• All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>Refer to FDA’s guidance document \u003Cem>Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\u002Fem> for general principles and approaches for stability testing at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq1ar2-stability-testing-new-drug-substances-and-products\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq1ar2-stability-testing-new-drug-substances-and-products\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to approve or reject all procedures or specifications impacting on the identity, strength, quality, and purity of the drug product (21 CFR 211.22(c)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to establish, review, and approve all procedures, including those which may impact the safety, identity, strength, quality, and purity of your drug product. Specifically, your QU failed to implement SOPs that are critical to ensure the quality of the drug product, such as the SOPs for operating the equipment used to manufacture the drug product.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you will create and revise corresponding SOPs. Your response is inadequate because you failed to provide supporting documentation (e.g., draft SOPs, training). Additionally, you provided similar responses to repeat or similar observations in the 2012, 2013, and 2018 inspections. Therefore, we have no assurance that your corrective actions will be implemented.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>• Your action plan to address any product quality or patient safety risks for your drug product in U.S. distribution, including potential customer notifications and recall.\u003C\u002Fp>\n\n\u003Cp>Refer to FDA’s guidance document: \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for general principles and approaches at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your inspectional history and significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection conducted in 2018, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier \u003Cstrong>616877\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any further questions, please contact Nayan Patel, Compliance Officer, by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven E. Porter, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Rita Mediratta\n\nRecipient Title\n\nPresident\n\nHealth Plus Inc.\n\n13837 Magnolia Avenue\n\nChino, CA 91710\n\nUnited States\n\nritam@healthplusinc.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nDecember 29, 2021\n\nDear Ms. Mediratta:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Health Plus Inc., FEI 2027164, at 13837 Magnolia Avenue, Chino, California, from June 23 to July 1, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your July 20, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to ensure that returned drugs meet appropriate standards of safety, identity, strength, quality and purity prior to redistributing (21 CFR 211.204).\n\nYour firm’s handling of returned drug product before its redistribution is inadequate. For example, during the inspection, you were not able to provide documentation of adequate inspection and investigation of the returned product confirming the label conditions under which the returned drug product was held, stored, or shipped before its return and before redistributing. Furthermore, you failed to perform adequate testing to ensure the safety, identity, strength, quality, and purity of the returned product. Organoleptic examination alone is not sufficient to ensure that a product maintains its safety, identity, strength, purity, and quality after it has been in a situation where it may have been exposed to improper storage conditions.\n\nBefore redistribution, you combined returned capsules from various lots into new batches with new lot numbers. These new lots did not have uniform character and quality, including capsules that would expire in less than three years. However, you then assigned these comingled batches new lot numbers and granted them an additional three-year shelf life. The new expiration dates are not supported by stability data and, in some instances, exceeded the expiration date of the returned product by up to 18 months. Your batch production records did not indicate you performed testing on these comingled batches before their redistribution.\n\nYour practices of conducting organoleptic examination on the returned product that was subjected to unknown conditions before return, making comingled batches by combining returned drug product with various lot numbers and expiration dates, and assigning a new product shelf life disregarding the expiration dates of the returned product are unacceptable.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment and remediation plan to ensure the adequacy of your returned drug product handling and processing for redistribution. Provide a detailed action plan and associated procedures that should include, but not be limited to, the following:\n\no Documentation of the conditions under which returned drug products have been held, stored, or shipped before, during and after return, reason for the return, quantity returned, date of disposition, and ultimate disposition, including procedures for destruction if doubt exists as to drug quality.\n\no A procedure for ensuring the conditions under which returned drug products were held, stored, or shipped did not adversely affect the safety, identity, strength, quality or purity of the drug products.\n\n• Provide your action plan to address any product quality risks associated with the redistributed batches in the United States, including potential customer notifications and recalls.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\n\nYour firm did not adequately validate the process used to manufacture your over-the-counter drug product Super Colon Cleanse Stimulant Laxative. Your firm changed the formulation of your Super Colon Cleanse Stimulant Laxative in December 2017, including the removal of multiple components. You did not issue a process validation protocol and associated analytical testing report until November and December 2018, respectively, a year after your reformulation. Additionally, the only data supporting your November 2018 validation protocol, dated October 21, 2014, was from a test of the previous formulation and does not reflect the current drug product formulation. Since the December 2017 formulation change, your firm has manufactured and released at least (b)(4) batches of the drug product which you distributed to the U.S. market with inadequate process validation data.\n\nIn your response, you stated that you would create a new standard operating procedure (SOP) for process validation and would document and review the results of the process validation study. Additionally, you indicated that you would commence manufacturing the first process validation batch in August 2021.\n\nYour response is inadequate because failure to conduct process validation studies can result in product quality attribute failures. You also failed to address your justification for continuing to manufacture the drug product when you have not adequately demonstrated that your manufacturing processes are reproducible and controlled to yield a drug product of uniform character and quality.\n\nIn response to this letter, provide the following:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing appropriate process performance qualification for your marketed drug product.\n\n• Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\n• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit (QU). Your change management program should also include provisions for determining change effectiveness.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices.\n\n3. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou did not adequately validate the method for assay used for your Super Colon Cleanse laxative drug product release specification. Specifically, per your specifications, the (b)(4) Spectrophotometer method for assay is to be conducted at the wavelength of (b)(4) as indicated in your finished drug product specifications. However, according to the data in the validation report you used the wavelength of (b)(4). In addition, the method validation report did not include system suitability, nor did it demonstrate that your modified method is fit for purpose.\n\nIn your response, you stated that the method validation for assay was conducted at the correct wavelength. Your response is inadequate as follows.\n\n• It lacked supporting documentation to support your claim that the method validation for assay was conducted at the correct wavelength.\n\n• It did not provide a risk assessment for the drug product released using the assay method that was not adequately validated nor a justification for continuation of the drug product currently on the market.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A comprehensive, independent assessment of all test methods to ensure that they are adequately validated and suitable for their intended purposes.\n\n• A retrospective assessment of reserve samples for all finished drug products that are currently on the market, using an adequately validated test method, to ensure that your drug products conform to the drug product specification.\n\n• A review of the completeness, consistency, accuracy of data from your use of uncontrolled documents (e.g., legal pads) to document the data.\n\n• A review of applicable compendial methods for your product.\n\nRefer to FDA’s guidance documents Q2(R1) Validation of Analytical Procedures and Analytical Procedures and Methods Validation for Drugs and Biologics for general principles and approaches for method validation at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq2r1-validation-analytical-procedures-text-and-methodology-guidance-industry and https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fanalytical-procedures-and-methods-validation-drugs-and-biologics, respectively.\n\n4. Your firm failed to follow a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYour firm’s stability program is inadequate. Specifically, you only placed (b)(4) of your Super Colon Cleanse Stimulant Laxative drug product on stability and failed to perform any stability testing since at least September 2017. Furthermore, you did not have any stability data for drug product manufactured using the new formulation. Therefore, you lack sufficient stability data to substantiate the (b)(4) expiration of this drug product.\n\nIn your response, you stated that the delay in conducting a stability study was because of restrained resources for the QU. You stated that you will initiate long-term stability testing for ongoing (b)(4) stability testing and accelerated stability testing for the determination of the expiration dating period of the drug product.\n\nYour response is inadequate because your firm has been aware of the inadequacy of your stability program since the 2013 inspection. Subsequent inspections in 2015, 2018, and 2021, all had identical or similar observations in your stability program. Your response lacked information on what you did between 2013 and the current inspection to remediate your stability program.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your CAPA plan should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\n• All procedures that describe these and other elements of your remediated stability program.\n\nRefer to FDA’s guidance document Q1A(R2) Stability Testing of New Drug Substances and Products for general principles and approaches for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq1ar2-stability-testing-new-drug-substances-and-products.\n\n5. Your firm’s quality control unit failed to approve or reject all procedures or specifications impacting on the identity, strength, quality, and purity of the drug product (21 CFR 211.22(c)).\n\nYou failed to establish, review, and approve all procedures, including those which may impact the safety, identity, strength, quality, and purity of your drug product. Specifically, your QU failed to implement SOPs that are critical to ensure the quality of the drug product, such as the SOPs for operating the equipment used to manufacture the drug product.\n\nIn your response, you stated that you will create and revise corresponding SOPs. Your response is inadequate because you failed to provide supporting documentation (e.g., draft SOPs, training). Additionally, you provided similar responses to repeat or similar observations in the 2012, 2013, and 2018 inspections. Therefore, we have no assurance that your corrective actions will be implemented.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• Your action plan to address any product quality or patient safety risks for your drug product in U.S. distribution, including potential customer notifications and recall.\n\nRefer to FDA’s guidance document: Quality Systems Approach to Pharmaceutical CGMP Regulations for general principles and approaches at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nQuality Unit Authority\n\nYour inspectional history and significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\n\nRepeat Observations at Facility\n\nIn a previous inspection conducted in 2018, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your response with unique identifier 616877.\n\nIf you have any further questions, please contact Nayan Patel, Compliance Officer, by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven E. Porter, Jr.\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations IV","Health Plus Inc.","health-plus-inc-616877-12292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealth-plus-inc-616877-12292021","2026-10-26T08:08:53.613916+00:00","2022-01-25","616877","Ms. Rita Mediratta","2026-08-20T02:14:46.143+00:00","2021-12-29",{"id":354,"raw":355,"subject":303,"body_html":359,"body_text":360,"firm_name":361,"letter_id":362,"created_at":110,"fei_number":19,"letter_url":363,"updated_at":364,"action_type":22,"case_status":23,"posted_date":314,"marcs_cms_no":365,"product_type":115,"closeout_date":19,"issuing_office":104,"recipient_name":366,"body_fetched_at":367,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":368,"medical_device_id":19,"response_letter_date":19},2794,[356,357,358,104,303,13,13,13],"\u003Ctime datetime=\"2022-03-28T14:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-25T04:00:00Z\">03\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiodine-products-inc-628296-03252022\">Iodine Products Inc\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gene Rosov\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Iodine Products Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8025 SW 63rd Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>So. Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33143\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:erosov@iodineproducts.com\"> erosov@iodineproducts.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: CMS# 628296\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 25, 2022\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.iodineproducts.com on March 2, 2022, and March 23, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos, https:\u002F\u002Fwww.facebook.com\u002FIodineProducts, and https:\u002F\u002Fwww.instagram.com\u002Fiodineproducts\u002F?hl=en, where you direct consumers to your website, http:\u002F\u002Fwww.iodineproducts.com\u002F, to purchase your products. The FDA has observed that your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Our new Anti-Viral Liquid Mask is a COVID KILLER. Once you use it, you’re protected. Doctors use it to prevent the transmission of COVID-19 between doctors, staff and patients worldwide. It works! . . . In your mouth. Spray 2-3 times in your mouth. Breathe inwards to pull the iodine aerosol into your throat . . . In your nose . . . make sure to get 1-2 sprays directly into your nose. Sniff to pull it upward.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-sprayanti-viral-large\u002F]\u003C\u002Fli>\n\t\u003Cli>“Lab and clinical studies show it kills ALL viruses, including the COVID-19 coronavirus, on contact in 15-30 seconds . . . A recent clinical study proves that the active ingredients in our 10 ml Liquid Mask CURE COVID-19 patients and simultaneously PREVENT transmission as they kill COVID-19 virus particles . . . Tags: anti-viral, COVID, COVID-19, Cure” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-spray-anti-viral-large\u002F]\u003C\u002Fli>\n\t\u003Cli>“The COVID-Killer 10 Ml Liquid Mask Anti-Viral Spray . . . Our 10-day 10 ml Liquid Mask is a COVID-19 virus killer. It sprays easily into nose and throat where it forms a protective coating that will last. Moreover, if you do come in to contact with a virus, such as . . . COVID . . . the iodine in the mask spray will kill is [sic] on contact within seconds . . . There are more studies that show that iodine kills COVID-19.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002F10-ml-liquidmask-anti-viral-nose-throat-spray-small\u002F]\u003C\u002Fli>\n\t\u003Cli>“Liquid Mask – only at iodineproducts.com – to Prevent COVID transmission . . . To truly prevent the transmission of this disease organism (the SARS-CoV-2 virus), you need Liquid Mask.” [from a January 8, 2021 post on your YouTube webpage https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos]\u003C\u002Fli>\n\t\u003Cli>“Our new free LIQUID MASK is a viral killer . . . This product in various forms is being used . . . to prevent the transmission of COVID-19 . . . PREVENT COVID! . . . Use our FREE Covid Killing Liquid Mask . . .” [from a January 11, 2021 post on your Facebook webpage https:\u002F\u002Fwww.facebook.com\u002FIodineProducts]\u003C\u002Fli>\n\t\u003Cli>“#11 of 19 Ways to Avoid Covid-19 . . . Tip #11 Get Liquid Mask . . . Liquid Mask kills the virus . . . #covid #covid_19 . . . #tipsforcovid19 #Covidtips #Covidfree . . . #covidrelief #covidliquidmasks” [from a February 28, 2021 post on your Instagram webpage https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCL1eUlCHIeM\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley&nbsp;\u003Cbr>\nDirector&nbsp;\u003Cbr>\nOffice of Compliance&nbsp;\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>_____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGene Rosov\n\nIodine Products Inc\n\n8025 SW 63rd Place\n\nSo. Miami, FL 33143\n\nUnited States\n\nerosov@iodineproducts.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRE: CMS# 628296\n\nDate: March 25, 2022\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.iodineproducts.com on March 2, 2022, and March 23, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos, https:\u002F\u002Fwww.facebook.com\u002FIodineProducts, and https:\u002F\u002Fwww.instagram.com\u002Fiodineproducts\u002F?hl=en, where you direct consumers to your website, http:\u002F\u002Fwww.iodineproducts.com\u002F, to purchase your products. The FDA has observed that your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Our new Anti-Viral Liquid Mask is a COVID KILLER. Once you use it, you’re protected. Doctors use it to prevent the transmission of COVID-19 between doctors, staff and patients worldwide. It works! . . . In your mouth. Spray 2-3 times in your mouth. Breathe inwards to pull the iodine aerosol into your throat . . . In your nose . . . make sure to get 1-2 sprays directly into your nose. Sniff to pull it upward.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-sprayanti-viral-large\u002F]\n\n“Lab and clinical studies show it kills ALL viruses, including the COVID-19 coronavirus, on contact in 15-30 seconds . . . A recent clinical study proves that the active ingredients in our 10 ml Liquid Mask CURE COVID-19 patients and simultaneously PREVENT transmission as they kill COVID-19 virus particles . . . Tags: anti-viral, COVID, COVID-19, Cure” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002Fliquid-mask-spray-anti-viral-large\u002F]\n\n“The COVID-Killer 10 Ml Liquid Mask Anti-Viral Spray . . . Our 10-day 10 ml Liquid Mask is a COVID-19 virus killer. It sprays easily into nose and throat where it forms a protective coating that will last. Moreover, if you do come in to contact with a virus, such as . . . COVID . . . the iodine in the mask spray will kill is [sic] on contact within seconds . . . There are more studies that show that iodine kills COVID-19.” [from your webpage https:\u002F\u002Fwww.iodineproducts.com\u002Fproduct\u002F10-ml-liquidmask-anti-viral-nose-throat-spray-small\u002F]\n\n“Liquid Mask – only at iodineproducts.com – to Prevent COVID transmission . . . To truly prevent the transmission of this disease organism (the SARS-CoV-2 virus), you need Liquid Mask.” [from a January 8, 2021 post on your YouTube webpage https:\u002F\u002Fwww.youtube.com\u002Fc\u002FIodineProducts\u002Fvideos]\n\n“Our new free LIQUID MASK is a viral killer . . . This product in various forms is being used . . . to prevent the transmission of COVID-19 . . . PREVENT COVID! . . . Use our FREE Covid Killing Liquid Mask . . .” [from a January 11, 2021 post on your Facebook webpage https:\u002F\u002Fwww.facebook.com\u002FIodineProducts]\n\n“#11 of 19 Ways to Avoid Covid-19 . . . Tip #11 Get Liquid Mask . . . Liquid Mask kills the virus . . . #covid #covid_19 . . . #tipsforcovid19 #Covidtips #Covidfree . . . #covidrelief #covidliquidmasks” [from a February 28, 2021 post on your Instagram webpage https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCL1eUlCHIeM\u002F]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n_____________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Iodine Products Inc","iodine-products-inc-628296-03252022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiodine-products-inc-628296-03252022","2026-10-26T08:09:00.755596+00:00","628296","Gene Rosov","2026-08-20T02:04:46.116+00:00","2022-03-25",{"id":370,"raw":371,"subject":376,"body_html":378,"body_text":379,"firm_name":380,"letter_id":381,"created_at":382,"fei_number":19,"letter_url":383,"updated_at":384,"action_type":22,"case_status":288,"posted_date":385,"marcs_cms_no":386,"product_type":70,"closeout_date":387,"issuing_office":375,"recipient_name":388,"body_fetched_at":389,"delivery_method":390,"recipient_title":19,"reference_number":19,"action_taken_date":391,"medical_device_id":19,"response_letter_date":19},1231,[372,373,374,375,376,13,377,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-11T04:00:00Z\">09\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthwest-minerals-inc-dba-mt-capra-products-685115-09112024\">Healthwest Minerals, Inc. dba Mt. Capra Products\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","Interstate Commerce\u002FFood\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthwest-minerals-inc-dba-mt-capra-products-685115-09032025\">\u003Ctime datetime=\"2025-09-08T04:00:00Z\">09\u002F08\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joseph C. Stout\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Healthwest Minerals, Inc. dba Mt. Capra Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>279 Southwest 9th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chehalis\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98532-3313\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 11, 2024\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 685115\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMENDED WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Stout:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address, https:\u002F\u002Fmtcapra.com and your social media website at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra in March and April 2024. Based on representations made on your websites at the time we reviewed them, your Goat Milk Formula Recipe Kit met the definition of an infant formula under section 201(z) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(z)] because it was a food which purported to be or was represented for special dietary use solely as a food for infants by reason of its simulation of human milk or its suitability as a complete or partial substitute for human milk. For example:\u003C\u002Fp>\n\n\u003Cp>• On your websites at https:\u002F\u002Fmtcapra.com\u002Fcategory\u002Fgoat-milk-formula\u002F:\u003C\u002Fp>\n\n\u003Cp>o “We have created a formula recipe that mimics breast milk and follows the guidelines created by the 1980 Infant Formula Act.”\u003C\u002Fp>\n\n\u003Cp>• On your website at https:\u002F\u002Fmtcapra.com\u002Fproduct\u002Fhomemade-goat-milk-formula-kit:\u003C\u002Fp>\n\n\u003Cp>o “The all-natural preferred alternative to commercial baby formula. This Goat Milk Recipe Kit supplies you with all of the wholesome, REAL FOOD ingredients your little one needs to thrive.”\u003C\u002Fp>\n\n\u003Cp>o “This goat milk formula recipe kit contains all the ingredients you need to get started making your own goat milk formula at home! The kit will produce 256 oz of formula before you need to purchase more milk and lactose. Some of the ingredients in the kit will last much longer. Note: This recipe kit is not a finished, ready-to-mix, infant formula but rather a combination of different REAL FOODS for those who cannot or choose not to breastfeed. If breastfeeding is not an option, this kit could be the answer you’ve been searching for: the perfect DIY alternative to commercial infant formula.”\u003C\u002Fp>\n\n\u003Cp>• On your Facebook page at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra:\u003C\u002Fp>\n\n\u003Cp>o Your February 12, 2024, post: “‘Infant formula is the number one regulated food in the U.S., and yet the allowable ingredients in off-the-shelf infant formula is often times very very poor. So there is a very good incentive to make your own formula.’ Get to know the creator, Joe Stout, and learn about the Goat Milk Formula Recipe on the GMF Livestream replay! . . . #DIYBabyFormula . . .”\u003C\u002Fp>\n\n\u003Cp>o Your October 18, 2023, post: “Our Goat Milk Formula was created nearly 10 years ago by our company President, Joe Stout. His newborn daughter, Liesl, was struggling with commercial formula. Since then, they have used the formula recipe with several of their 9 children, and provided a healthy solution for countless little ones and their parents. Swipe through to learn why our Goat Milk Formula is a standout. . . . Not only is goat milk the perfect substitute for cow milk, but its DNA is very similar to breast milk.”\u003C\u002Fp>\n\n\u003Cp>At the time we reviewed your websites, your Goat Milk Formula Recipe Kit product was a new infant formula under section 412(c)(2)(A) of the Act [21 U.S.C. § 350a(c)(2)(A)] because you had not previously manufactured an infant formula. See also 21 CFR 106.3 (defining “new infant formula,” in part, as a formula “which has not previously been the subject of a submission under section 412(c)” of the Act). A person who introduces a new infant formula into interstate commerce must make a submission that complies with section 412(d)(1) of the Act [21 U.S.C. § 350a(d)(1)].\u003C\u002Fp>\n\n\u003Cp>Under section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)], no person shall introduce or deliver for introduction into interstate commerce a new infant formula unless such person has at least 90 days prior to marketing the new infant formula, made the submission required by section 412(d)(1). The failure to make such a submission at least 90 days prior to marketing a new infant formula is a violation of section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)] and this is a prohibited act under section 301(s) of the Act [21 U.S.C. § 331(s)]. You may find the Act and FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that after a teleconference with you on May 7, 2024, you voluntarily recalled all Goat Milk Formula Recipe Kit product distributed between May 1, 2023, and May 1, 2024. We are aware that you contacted all customers who received product during that timeframe to inform them that the product should not be used as an infant formula. Additionally, you issued a press release on May 10, 2024, clarifying to the general public that you do not recommend using this product for infants from 0-12 months of age. We also acknowledge that you removed the ability to purchase the Goat Milk Formula Recipe Kit from your website, and that you made some changes to your website and social media websites, including but not limited to removing the above-mentioned statements regarding use as an infant formula. However, due to the serious public health concerns related to your unlawful marketing of a new infant formula, it is essential that this violation does not recur.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to prevent the recurrence of future violations. If you believe that your products were not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, 22215 26th Avenue SE, Suite 210, Bothell, Washington, 98021-4421, to the attention of Tracy K. Li, Compliance Officer. If you have any questions concerning this letter, you can contact Tracy K. Li at (425) 302-0428, or by email at Tracy.Li@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations West – Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJoseph C. Stout\n\nRecipient Title\n\nPresident\n\nHealthwest Minerals, Inc. dba Mt. Capra Products\n\n279 Southwest 9th Street\n\nChehalis, WA 98532-3313\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nSeptember 11, 2024\n\nIn reply, refer to CMS 685115\n\nAMENDED WARNING LETTER\n\nDear Mr. Stout:\n\nThe U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address, https:\u002F\u002Fmtcapra.com and your social media website at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra in March and April 2024. Based on representations made on your websites at the time we reviewed them, your Goat Milk Formula Recipe Kit met the definition of an infant formula under section 201(z) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(z)] because it was a food which purported to be or was represented for special dietary use solely as a food for infants by reason of its simulation of human milk or its suitability as a complete or partial substitute for human milk. For example:\n\n• On your websites at https:\u002F\u002Fmtcapra.com\u002Fcategory\u002Fgoat-milk-formula\u002F:\n\no “We have created a formula recipe that mimics breast milk and follows the guidelines created by the 1980 Infant Formula Act.”\n\n• On your website at https:\u002F\u002Fmtcapra.com\u002Fproduct\u002Fhomemade-goat-milk-formula-kit:\n\no “The all-natural preferred alternative to commercial baby formula. This Goat Milk Recipe Kit supplies you with all of the wholesome, REAL FOOD ingredients your little one needs to thrive.”\n\no “This goat milk formula recipe kit contains all the ingredients you need to get started making your own goat milk formula at home! The kit will produce 256 oz of formula before you need to purchase more milk and lactose. Some of the ingredients in the kit will last much longer. Note: This recipe kit is not a finished, ready-to-mix, infant formula but rather a combination of different REAL FOODS for those who cannot or choose not to breastfeed. If breastfeeding is not an option, this kit could be the answer you’ve been searching for: the perfect DIY alternative to commercial infant formula.”\n\n• On your Facebook page at https:\u002F\u002Fwww.facebook.com\u002Fmtcapra:\n\no Your February 12, 2024, post: “‘Infant formula is the number one regulated food in the U.S., and yet the allowable ingredients in off-the-shelf infant formula is often times very very poor. So there is a very good incentive to make your own formula.’ Get to know the creator, Joe Stout, and learn about the Goat Milk Formula Recipe on the GMF Livestream replay! . . . #DIYBabyFormula . . .”\n\no Your October 18, 2023, post: “Our Goat Milk Formula was created nearly 10 years ago by our company President, Joe Stout. His newborn daughter, Liesl, was struggling with commercial formula. Since then, they have used the formula recipe with several of their 9 children, and provided a healthy solution for countless little ones and their parents. Swipe through to learn why our Goat Milk Formula is a standout. . . . Not only is goat milk the perfect substitute for cow milk, but its DNA is very similar to breast milk.”\n\nAt the time we reviewed your websites, your Goat Milk Formula Recipe Kit product was a new infant formula under section 412(c)(2)(A) of the Act [21 U.S.C. § 350a(c)(2)(A)] because you had not previously manufactured an infant formula. See also 21 CFR 106.3 (defining “new infant formula,” in part, as a formula “which has not previously been the subject of a submission under section 412(c)” of the Act). A person who introduces a new infant formula into interstate commerce must make a submission that complies with section 412(d)(1) of the Act [21 U.S.C. § 350a(d)(1)].\n\nUnder section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)], no person shall introduce or deliver for introduction into interstate commerce a new infant formula unless such person has at least 90 days prior to marketing the new infant formula, made the submission required by section 412(d)(1). The failure to make such a submission at least 90 days prior to marketing a new infant formula is a violation of section 412(c)(1)(B) of the Act [21 U.S.C. § 350a(c)(1)(B)] and this is a prohibited act under section 301(s) of the Act [21 U.S.C. § 331(s)]. You may find the Act and FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nWe acknowledge that after a teleconference with you on May 7, 2024, you voluntarily recalled all Goat Milk Formula Recipe Kit product distributed between May 1, 2023, and May 1, 2024. We are aware that you contacted all customers who received product during that timeframe to inform them that the product should not be used as an infant formula. Additionally, you issued a press release on May 10, 2024, clarifying to the general public that you do not recommend using this product for infants from 0-12 months of age. We also acknowledge that you removed the ability to purchase the Goat Milk Formula Recipe Kit from your website, and that you made some changes to your website and social media websites, including but not limited to removing the above-mentioned statements regarding use as an infant formula. However, due to the serious public health concerns related to your unlawful marketing of a new infant formula, it is essential that this violation does not recur.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to prevent the recurrence of future violations. If you believe that your products were not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, 22215 26th Avenue SE, Suite 210, Bothell, Washington, 98021-4421, to the attention of Tracy K. Li, Compliance Officer. If you have any questions concerning this letter, you can contact Tracy K. Li at (425) 302-0428, or by email at Tracy.Li@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations West – Division 6","Healthwest Minerals, Inc. dba Mt. Capra Products","healthwest-minerals-inc-dba-mt-capra-products-685115-09112024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthwest-minerals-inc-dba-mt-capra-products-685115-09112024","2026-10-26T08:08:53.840094+00:00","2024-10-01","685115","2025-09-08","Joseph C. Stout","2026-08-19T22:57:24.092+00:00","Overnight Delivery","2024-09-11",{"id":393,"raw":394,"subject":203,"body_html":398,"body_text":399,"firm_name":400,"letter_id":401,"created_at":88,"fei_number":19,"letter_url":402,"updated_at":403,"action_type":22,"case_status":23,"posted_date":404,"marcs_cms_no":405,"product_type":155,"closeout_date":19,"issuing_office":145,"recipient_name":406,"body_fetched_at":407,"delivery_method":74,"recipient_title":19,"reference_number":408,"action_taken_date":409,"medical_device_id":19,"response_letter_date":19},4,[395,396,397,145,203,13,13,13],"\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-27T04:00:00Z\">07\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwoodbine-products-company-inc-729345-07272026\">Woodbine Products Company Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-107\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Stephen A. Kuzyk Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Secretary Treasurer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Woodbine Products Company Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>915 W. Smith Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Medina\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44256-2446\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-107\u003C\u002Fp>\u003Cp>July 27, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Kuzyk:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Woodbine Products Company Inc., FEI 1519202, at 915 W. Smith Road, Medina, from February 9 to 13, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 5, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> and ethanol-\u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., glycerin, propylene glycol, ethanol) used in the manufacture of your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Moreover, you used nonpharmaceutical-grade propylene glycol to manufacture your drug products.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of DEG or EG contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity before using it in manufacturing your OTC topical drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components includes a limit test in the United States Pharmacopoeia (USP) to ensure that the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ethanol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You manufacture multiple drugs that contain ethanol. You failed to adequately test your incoming component ethanol for methanol. Additionally, you failed to demonstrate that the component alcohol, used to manufacture your drug products, met USP monograph specifications including those for impurities (e.g., acetaldehyde, benzene). The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you tested retain samples of nine propylene glycol lots for DEG\u002FEG contamination and that samples of three lots were not available. You also state that in the future, you will conduct all USP identity and impurity tests for propylene glycol and glycerin. Your response is inadequate because you do not provide procedural controls to demonstrate adequate identification testing of your components. Also, your response does not investigate the use of nonpharmaceutical-grade components, nor does it evaluate the impact of improperly tested components to drug products on the market.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to the appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before their use in production to ensure that acceptable quality parameters are met.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of the adequacy of your supplier qualification program and its selection, qualification, and disqualification provisions. The review should include a corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol (ethanol), glycerin, propylene glycol, and certain additional high-risk components, we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains of all implicated finished drug product batches in which a retain of a high-risk drug component lot is unavailable for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination including, but not limited to, glycerin. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>For manufactured drug products within expiry, a commitment to provide, no later than 30 calendar days from the date of this letter, results from testing retains for all lots of alcohol components, including organic impurities. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately validate the processes used to manufacture your OTC drug products. You have not performed process performance qualification (PPQ) studies, nor do you have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality. Your firm also failed to validate your cleaning processes for non-dedicated equipment used to manufacture your OTC drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you will conduct cleaning validation on shared equipment and process validation on three batches of each drug formulation. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact of manufacturing with unvalidated processes, nor did you provide an action plan to address any drug product quality or safety risk for batches already distributed to the U.S. market.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>Furthermore, upon review of the inspectional records collected, it appears your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not suitable for its intended use. \u003Cstrong>(b)(4)\u003C\u002Fstrong> for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of microbiological contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for use in manufacturing operations.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for PPQ and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure that proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fli>\u003Cli>A risk assessment for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make their manufacturing equipment difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003C\u002Fli>\u003Cli>A description of the steps that will be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design, control, and maintenance to ensure the system design consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits. If gaps are identified, perform a risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to perform adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of adequate written responsibilities and procedures applicable to the QU and to follow such written procedures (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Establishment of laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>For each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fli>\u003Cli>Establishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you will implement QU procedures. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact to batches already distributed to the U.S. market without adequate QU oversight.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fli>\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1519202 and ATTN: Sena G. Dissmeyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-107\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Stephen A. Kuzyk Jr.\n\nRecipient Title\n\nSecretary Treasurer\n\nWoodbine Products Company Inc.\n\n915 W. Smith Road\n\nMedina, OH 44256-2446\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-107\nJuly 27, 2026\nDear Mr. Kuzyk:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Woodbine Products Company Inc., FEI 1519202, at 915 W. Smith Road, Medina, from February 9 to 13, 2026.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 5, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\nYour firm manufactures over-the-counter (OTC) (b)(4) drug products such as (b)(4) and ethanol-(b)(4). You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., glycerin, propylene glycol, ethanol) used in the manufacture of your OTC (b)(4) drug products. Moreover, you used nonpharmaceutical-grade propylene glycol to manufacture your drug products.\nProducts Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\nYou also failed to adequately test your incoming components at high risk of DEG or EG contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity before using it in manufacturing your OTC topical drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIdentity testing for glycerin and certain other high-risk drug components includes a limit test in the United States Pharmacopoeia (USP) to ensure that the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\nProducts Containing Ethanol\nYou manufacture multiple drugs that contain ethanol. You failed to adequately test your incoming component ethanol for methanol. Additionally, you failed to demonstrate that the component alcohol, used to manufacture your drug products, met USP monograph specifications including those for impurities (e.g., acetaldehyde, benzene). The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nIn your response, you state that you tested retain samples of nine propylene glycol lots for DEG\u002FEG contamination and that samples of three lots were not available. You also state that in the future, you will conduct all USP identity and impurity tests for propylene glycol and glycerin. Your response is inadequate because you do not provide procedural controls to demonstrate adequate identification testing of your components. Also, your response does not investigate the use of nonpharmaceutical-grade components, nor does it evaluate the impact of improperly tested components to drug products on the market.\nWithout adequate testing, you do not have scientific evidence that the components conform to the appropriate specifications before their use in the manufacture of your drug products. You are responsible for sampling, testing, and examining drug components before their use in production to ensure that acceptable quality parameters are met.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of the adequacy of your supplier qualification program and its selection, qualification, and disqualification provisions. The review should include a corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of alcohol (ethanol), glycerin, propylene glycol, and certain additional high-risk components, we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains of all implicated finished drug product batches in which a retain of a high-risk drug component lot is unavailable for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination including, but not limited to, glycerin. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nFor manufactured drug products within expiry, a commitment to provide, no later than 30 calendar days from the date of this letter, results from testing retains for all lots of alcohol components, including organic impurities. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to adequately validate the processes used to manufacture your OTC drug products. You have not performed process performance qualification (PPQ) studies, nor do you have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality. Your firm also failed to validate your cleaning processes for non-dedicated equipment used to manufacture your OTC drug products.\nIn your response, you state that you will conduct cleaning validation on shared equipment and process validation on three batches of each drug formulation. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact of manufacturing with unvalidated processes, nor did you provide an action plan to address any drug product quality or safety risk for batches already distributed to the U.S. market.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nFurthermore, upon review of the inspectional records collected, it appears your (b)(4) is not suitable for its intended use. (b)(4) for pharmaceutical use must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of microbiological contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of (b)(4) for use in manufacturing operations.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for PPQ and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\nA timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure that proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\nA risk assessment for the distributed drug products produced without performing any process validation studies.\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make their manufacturing equipment difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nA description of the steps that will be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nA comprehensive, independent assessment of your (b)(4) system design, control, and maintenance to ensure the system design consistently produces (b)(4) adhering to (b)(4) USP monograph specifications and appropriate microbial limits. If gaps are identified, perform a risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) failed to perform adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\nEstablishment of adequate written responsibilities and procedures applicable to the QU and to follow such written procedures (21 CFR 211.22(d)).\nEstablishment of laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nFor each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nEstablishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nEstablishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn your response, you state that you will implement QU procedures. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact to batches already distributed to the U.S. market without adequate QU oversight.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate.\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\nA complete and final review of each batch and its related information before the QU disposition decision.\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1519202 and ATTN: Sena G. Dissmeyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Woodbine Products Company Inc.","woodbine-products-company-inc-729345-07272026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwoodbine-products-company-inc-729345-07272026","2026-10-26T08:10:33.170942+00:00","2026-08-04","729345","Mr. Stephen A. Kuzyk Jr.","2026-08-19T04:27:37.449+00:00","320-26-107","2026-07-27",32,{"510k":412,"classification":413,"enforcement":414,"event":415,"event_backfill":416,"pma":417,"warning_letter":418},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]